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List of abbreviations 
Activated partial thromboplastin time   aPTT 
(Activated) protein C     (A)PC 
Alfa-two-macroglobulin    α2M 
α2M-thrombin-complex    α2M-IIa or α2M-T 
7-amino-4-methylcoumarin    AMC 
Antithrombin      AT 
Anti-vitamin K     AVK 
Bovine serum albumine    BSA 
Calibrated automated thrombogram   CAT 
Calibration factor      CF 
Calibrator      CAL 
Coefficient of variation    CV 
Corn trypsin inhibitor     CTI 
Desamino-D-arginine-vasopressine (desmopressine)  DDAVP 
Dimethylsulphoxide     DMSO 
Electro-cardiogram     ECG 
Endogenous thrombin potential    ETP 
Ethylenediamine-tetra-acetic acid   EDTA 
Factor eight inhibitor bypassing therapy   FEIBA 
Fluorescence intensity    F 
Mixture of fluorogenic substrate and calcium  FluCa 
High Molecular weight kininogen   HMWK 
Hirudin      H 
Innovin      Inn 
Lupus anticoagulant     LAC 
Melagatran     M 
Optical density     OD 
Penta-saccharide     Penta-S 
Phosphatidyl choline      PhC 
Phosphatidyl ethanolamine     PhE 
Phosphatidyl serine      PhS 
Phospholipids     PL 
Platelet poor plasma     PPP 
Platelet rich plasma     PRP 
Pool of normal platelet poor plasma   NPPP 
Prekallikrein     PK 
Protein S      PS 
Protease activated receptor    PAR 
Prothrombin     FII 
Prothrombinase     FII-ase or XaVa 
Prothrombin-time     PT 
(Recombinant) tissue factor    (r)TF 
Standard deviation     SD 
Tenase      IXaVIIIa 
Tissue Factor Pathway Inhibitor    TFPI 
Thrombin      FIIa or T 
Thrombin activated fibrinolysis inhibitor   TAFI 
Thrombin-antithrombin-complex    TAT 
Thrombin generation      TG  
Thromboelastography     TEG  
Thrombomodulin     TM  
Unfractionated heparin    UFH  
Venous thromboembolism    VTE   
Von Willebrand factor    vWF 
Whole blood clotting time    WBCT 
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Medical importance of haemostasis and thrombosis 
Fortunately, a plug is formed at the site of a lesion when we cut ourselves; oth-
erwise the slightest injury would make us bleed to death. The haemostatic sys-
tem responsible for this is an extremely intricate physiological mechanism that 
ensures that haemostasis (normal blood coagulation) occurs promptly at the site 
of a wound but does not spread unduly outside the wound area and stops as 
soon as haemostasis is completed [1, 2]. When haemostasis overreacts e.g. if an 
occlusive plug forms in a vessel (thrombosis), blood flow is hampered and fi-
nally stops. In case of arterial thrombosis, the organ fed by that vessel becomes 
ischemic and ultimately necrotic, while in the case of venous thrombosis the 
surrounding tissue becomes congested and inflamed. During evolution it was 
more important to favor adequate haemostasis than to prevent the possibility of 
thrombosis because bloodshed is a more important issue in the struggle for fer-
tile life than thrombosis is. Without haemostasis there is no chance to survive in 
nature. Also, life expectancy under primitive conditions must have been such 
that thrombotic disease hardly occurred. However, nowadays thrombosis being 
the cause behind common diseases as stroke and myocardial infarction, it has 
become the second cause of death and disease in the western world. In Western 
Europe and the USA ~3500 people per day die from thrombotic disease [3] 
mainly through myocardial infarction and stroke (arterial thrombosis ~90%), or 
pulmonary embolism (venous thrombosis ~10%). The burden of non-fatal dis-
ease is more than twice as high e.g. disability after ischemic stroke and post-
thrombotic syndrome after deep venous thrombosis. It is obvious that the medi-
cal importance of thrombosis can hardly be exaggerated.  
Current tests for clinicians nowadays 
Unfortunately, despite decades of investigation in the field of haemostasis and 
thrombosis, clinicians do still not have one universal test to determine blood 
coagulation capacity. Clinicians in the old days made their decisions based on 
clotting-times. Several clotting-time tests were (and are still) available (PT, 
aPTT, bleeding time, WBCT) each one giving information about another detail 
of the complicated web that blood clotting is. The Prothrombin-Time (PT) was 
used to check the extrinsic system, the activated Partial Thromboplastin Time 
(aPTT) for the intrinsic system. For defects in platelets there was the bleeding-
time while the Whole Blood Clotting Time (WBCT) and aPTT were used in 
haemophiliacs. Depending on which disease or which drug-treatment one 
wanted to monitor, a different test had to be chosen. None of them could be 
used as an integral function-test of the haemostatic-thrombotic mechanism. 
Haemophiliacs show a normal bleeding time and PT but prolonged aPTT or 
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WBCT. It is possible to monitor heparin-treatment with the aPTT but not with 
the PT. People treated with oral anticoagulants can be followed-up by PT or 
aPTT but not with bleeding-time. Thrombasthenias and the action of platelet-
drugs are reflected in platelet aggregation and in the bleeding-time. For throm-
bophilia (hypercoagulability) none of these tests give an indication. The prob-
lem with clotting times probably is that they only give a snapshot of the haemo-
static process, i.e. the moment that bulk thrombin formation starts.  
Therefore, during the last decades new techniques were developed. Attempts 
have been made to use the developing fibrin as an indicator of further stages in 
the process. In these methods the development of turbidity is measured or alter-
natively the mechanical properties are used (thromboelastography). Such fi-
brinogen-based methods show some important drawbacks which will be dis-
cussed later. In general, even though they are certainly useful for the determina-
tion of the clotting time, they do not give a full picture of the haemostatic-
thrombotic function because all fibrin is converted long before all thrombin has 
been formed. 
Other recently developed techniques used by clinicians nowadays are the ‘plate-
let function analyzer 100’ (PFA 100), the ‘Verify Now P2Y12 assay’ and the 
‘D-dimer test’. PFA 100 is used to detect defects in the platelets. It is a good 
screening test for platelet-related diseases as von Willebrand Factor disease and 
Glanzman and Bernard-Soulier thrombasthenias. Verify Now is designed to 
measure platelet P2Y12 receptor blockade as induced by clopidogrel. The D-
dimer test measures a fragment of fibrin (D-dimer) and is used to detect an ab-
normal high level of fibrin degradation products in the body. It detects signifi-
cant clot-formation and breakdown in the body but it says nothing about the 
location or the cause. It is a good test for excluding venous thromboembolism 
due to its high sensitivity; however its specificity is very low. In summary, none 
of these tests give an overall view on the haemostatic-thrombotic function and 
can serve as universal test to determine blood coagulation capacity. 
Therefore, despite the fact that blood is a very important fluid organ, there does 
not exist yet an adequate function test like e.g. the electro-cardiogram (ECG) for 
heart rhythm problems. A clotting time is like feeling the pulse. The quest is for 
the equivalent of the ECG. 
TG, a universal function test for the blood coagulation 
capacity ? 
For two reasons we do not have yet such an overall function test available. In 
the first place because it was not recognized that thrombin generation might 
fulfill this function. In the second place because it was not yet possible to meas-
ure thrombin generation in such an easy and accurate way that it could be used 
in clinical labs. It was very laborious to perform a thrombin generation experi-
CHAPTER 1 
 
 
 
14 
ment with the methods available in the early eighties. However, during the last 
decade, thrombin generation measurement was automated further resulting fi-
nally in the Calibrated Automated Thrombogram (CAT-method) as developed 
by Hemker et al. (see chapter 2). This method makes it possible to measure 
thrombin generation at high throughput and with an acceptable experimental 
error (<5%) which makes it a promising tool for the clinical routine-labs. 
As to the suitability of thrombin generation to serve as a function test; during 
the last years new insights challenged the old paradigm in which a thrombin-
independent platelet reaction assures primary haemostasis and thrombin-
dependent clotting was responsible for a secondary phase. It appears that 
thrombin plays a role right from the beginning. Furthermore, thrombin seems to 
play a pivotal role not only in venous thrombosis but also in arterial thrombosis. 
These insights, which will be discussed further in this chapter, allow us to make 
the proposition that the blood coagulation capacity can better be assessed via the 
thrombin generating capacity of the blood. 
The classical clotting-scheme 
Blood clotting is a very complicated web of interactions between several clot-
ting factors leading to a burst of thrombin-formation. A few molecules in the 
beginning of the series create an explosion of the final active enzyme: thrombin. 
One can compare it with a command that goes from the general to the officers, 
then to the sergeants and then to the men: in this way it takes little time to acti-
vate the whole army. This cascade sequence only explains the explosive forma-
tion of thrombin; however, clotting is not as simple as that. In fact, it is a web of 
positive and negative feedback reactions that finely tunes the output of thrombin 
and restricts it in time and place to the occurrence of a wound [1, 2] (figure 1). 
Coagulation starts at a damaged site in the vessel-wall. The vessel-wall is cov-
ered by cells that contain tissue factor (TF). After injury this TF is exposed to 
blood, which contains a whole series of non-activated clotting factors. TF acti-
vates one of these factors (FVII) into FVIIa and binds to it to form the first en-
zyme: VIIa-TF [4-6]. This activates factor X into FXa, which in turn activates 
prothrombin (FII) into thrombin (FIIa). This we call the Production Dimension. 
FXa is not a very efficient enzyme (kcat = 2-4 min-1); it needs the help of factor 
Va, which is activated by thrombin itself, to speed up FII activation a thousand 
fold [7, 8]. Both factors (FXa and FVa) bind to a procoagulant surface and form 
the prothrombinase complex (XaVaPL) [9]. This procoagulant surface binds 
also FII and thus favors the meeting of substrate and enzyme [10-12]. The 
enormous increase in FII activation by the contribution of factor Va and the 
procoagulant surface explains the burst of thrombin-production once traces of 
thrombin are formed. This offers also the possibility to regulate the activity of 
FXa, and hence thrombin production in space and time. This pathway (VIIa-TF 
Æ XaVaPL) is known as the extrinsic system. 
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VIIa-TF activates not only FX but also FIX. FIXa in its turn activates FX. Once 
a trace of thrombin is formed by FXa, this activates factor V but also factor 
VIII. FVIIIa forms a complex with factor IXa and this complex VIIIa-IXa 
(called “tenase”) produces more FXa [13]. Tenase is a very active complex and 
this reinforcement of FXa production is called the ‘Josso Loop’ [14]. This 
mechanism will not play a role when the TF-concentration is very high, as in 
the PT-test but it will start to play a role as soon as the TF-concentration is low 
(~ 5 pM in vitro). The fact that haemophiliacs bleed, illustrates that in vivo 
thrombin production is dependent upon factors VIII and IX, so that we can as-
sume that in vivo TF concentrations are low enough for the Josso Loop to work. 
At still lower TF concentrations (< ~ 1 pM) a second loop comes in action; that 
via FXI, that is directly activated by thrombin [15, 16]. FXIa activates in this 
case FIX which in turn activates FX. FXI is not only activated by thrombin, it is 
also the target of the contact activation pathway i.e. the interaction of FXII, high 
Vi
IIa
Protein C
APC
TM
IXa-VIIIa
XIa VIIa-TF
Platelet
Protein S
V XaVa
VIIIiVIII
XI
Xa-TFPI
XII
Figure 1: Scheme of the coagulation web. 
Thrombin-production is a complicated web of positive (blue) and negative (red) feedback 
loops that allows a controlled explosion of thrombin in time. The elliptical o  shapes 
represent platelet-derived procoagulant surfaces that are responsible for limitation in 
space. The activation of protein C via TM-IIa is located on the endothelial cells of the 
vessel wall. 
range
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molecular weight kininogen (HMWK) and prekallikrein (PK) on a negatively 
charged surface. The physiological role of this pathway is still a matter of de-
bate. Contact-activation appears often as an artifact during thrombin generation 
in vitro but recent work [17, 18] challenges the view that it is irrelevant for 
thrombus formation in vivo. It thus appears that, although the role of contact 
activated thrombin generation (the old ‘intrinsic system’) in physiologyical 
haemostasis remains uncertain, it may nevertheless play a role in thrombus for-
mation. 
Thrombin promotes its own formation by the activation of the helper proteins 
factor V and factor VIII, but it also inhibits its own formation. The activation of 
FV and FVIII is direct but its inactivation involves an intermediate step. 
Thrombin binds to thrombomodulin and this complex converts protein C into its 
activated form (APC). APC in turn, inactivates FVa and FVIIIa in a process in 
which also protein S plays a role [1, 19]. This creates a “time-window” in which 
the complexes prothrombinase (XaVa) and tenase (IXa-VIIIa) are active. This 
we call the Regulation Dimension. 
Also, FXa regulates its own formation by forming a complex with Tissue Factor 
Pathway Inhibitor (TFPI). This complex prevents further activation of FX and 
FIX by VIIa-TF and creates as such a second “time-window”. 
It is clear that thrombin has a large number of actions. It regulates its own for-
mation by activating and inactivating other proteins (FV, FVIII, FXI). Moreover 
thrombin is the main activator of platelets [20] and is responsible for the con-
version of fibrinogen into fibrin. It also activates FXIII which in turn is respon-
sible for the covalent binding between fibrin fibers, necessary to form a stable 
plug at the site of a wound. 
Activation of platelets is very important for the localization of thrombin genera-
tion. Clotting should not only occur at the desired time but also be restricted to 
the site of injury so as to avoid thrombosis. This is realized by sticking and sub-
sequent activation of the platelets to collagen exposed at the site of injury or by 
thrombin-mediated activation (see also below). Activation of platelets causes 
loss of the natural asymmetry of their plasma membrane and enriches the out-
side of the platelets with the procoagulant phospholipids phosphatidyl serine 
and phosphastidyl ethanolamine by a transbilayer movement from the inner 
leaflet to the outer leaflet of the membrane [21]. Activated clotting factors bind 
to the membranes of these activated platelets, so as to form the complexes 
prothrombinase (XaVa) and tenase (IXa-VIIIa). In figure 1 these activated 
platelets are represented by elliptical brown shapes. These procoagulant sur-
faces serve as a two-dimensional space where the substrates (FII and FX) are 
funneled to the enzyme complexes causing an enormous increase of reaction 
rate [10-12]. Thrombin formation increases by about a thousand fold [7, 8, 22], 
so without such a surface, no significant thrombin generation will occur. This 
provides the Localization Dimension: platelets stick in the wound and to fibrin 
threads and thus clotting only occurs where it is needed and remains restricted 
to the wounded area.  
INTRODUCTION 
 
 
 
17 
Thrombin in the blood does not live long; otherwise the slightest wound could 
make all the blood clot. Its half-life in plasma is less than a minute, due to the 
fact that antithrombins inactivate thrombin irreversibly. The haemostatic activ-
ity that develops in a wound or thrombus is essentially dependent upon the 
number of “man-hours” of thrombin that can develop in blood. This means that 
both the amount of thrombin generated and the length of time that it is active 
count. During haemostasis there is a non-equilibrium situation, comparable to 
emptying a bucket of water in a sink without a stopper (figure 2). Prothrombi-
nase activates prothrombin into thrombin and thrombin disappears through the 
action of antithrombins. 
 
New insights challenge some classical paradigms of haemostasis and 
thrombosis 
1) Primary versus secondary haemostasis 
It is a classical paradigm of haemostasis that in a first stage plate-
lets plug the wounded vessel and in a second stage thrombin is 
formed that cements together this platelet plug. The bleeding time 
reflects the first phase and the clotting time the second one. 
(Plasma)
(Serum)
Sink kinetics
Prothrombinase
Antithrombin
Out
In
Figure 2: Thrombin formation and disappearance (haemostasis) 
The dynamics of thrombin appearance and disappearance are like filling a sink without 
a stopper with a large bucket of water. The level of water will increase and then de-
crease again depending on how large the opening in the sewer is and how fast water is 
poured in. Suppose the bucket size is the amount of prothrombin, prothrombinase activ-
ity determines how fast it is poured in, and the drain size is the action of antithrombin. 
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There have always been observations that challenge this ‘textbook view’. Pro-
longed bleeding times have been detected in cases of severe over-dosage of oral 
anticoagulants [23] or heparin [24], both drugs acting on blood coagulation 
rather than on the platelets. Factors Va and VIIIa, products of thrombin action, 
appear within seconds in the blood flowing from a wound and diminish when 
heparin is administered [25]. This means that thrombin is formed before a 
wound stops bleeding. The activity of thrombin in such blood must be depend-
ent upon platelet function because it is inhibited by aspirin intake [26-28]. Early 
thrombin formation was most convincingly demonstrated in the elegant experi-
ments of the Furie group [29]. They visualized exposed tissue factor, aggregated 
platelets and fibrin at the site of a micro-trauma in a small vessel in the mouse 
and saw fibrin appear about 10 – 15 s after the lesion. Plasma clots at the fastest 
in ~12 seconds when an optimum concentration of TF is added, hence in these 
experiments thrombin must have appeared almost simultaneously with the 
platelet activation!  
Many experiments that supports the classical two-step view were done in ex-
perimental setups in which the interaction between platelets and clotting factors 
was a priori impossible (washed platelets or plasma without platelets). As soon 
as platelets and plasmatic coagulation factors are allowed to cooperate, they 
invariably show early and strong mutual interaction. Thrombin is the most po-
tent platelet activator [20] and the platelet membrane provides procoagulant 
phospholipids [21] that allow explosive TG [30]. This platelet-clotting-factor 
interaction is probably the most important positive feedback mechanism in 
haemostasis and responsible for the sudden arrest of blood flow from a wound. 
Therefore, it may be clear that thrombin is not only important during clotting, 
but it also plays a pivotal role for the platelet reaction to injury. 
2) Arterial versus venous thrombosis 
It is another classical paradigm of thrombosis that arterial throm-
bosis is a platelet dependent disease that should be treated with 
anti-platelet-drugs whereas venous thrombosis is a clotting disease 
that should be treated with anticoagulants. 
Classically thrombosis is divided into arterial and venous thrombosis based on 
the type of vessel that is affected. In venous thrombosis, the role of (genetic) 
defects in anticoagulant pathways (deficiency of antithrombin (AT) [31], pro-
teins C and S) as well as increased concentrations of coagulation proteins (e.g. 
prothrombin in association with the 20210 prothrombin gene variant [32]) is 
well established. Abundant literature data relate increased coagulation activity 
to a greater risk of venous thrombosis [33]. Several studies demonstrated that 
individuals with a congenital risk of venous thrombosis, such as factor VLeiden 
mutation show hypercoagulable plasma, indicated by an increased level of 
thrombin generation. This is directly reflected in medical practice: treatment 
and prevention of venous thrombosis require drugs that diminish thrombin ac-
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tivity in one way or another: by impeding carboxylation of vitamin K dependent 
proteins (vitamin K antagonists), by increasing antithrombin activity (heparins) 
or by inhibiting thrombin directly (hirudin and others). 
 
For arterial thrombosis the role of blood coagulation proteins is much less rec-
ognized. An important reason is the absence of strong risk associations between 
genetic thrombophilic traits such as the factor VLeiden mutation and atherothrom-
botic complications [34]. The origin of almost all arterial thrombotic diseases is 
searched in atherosclerotic changes in the vessel wall [35]. It is well known that 
diet (unsaturated fatty acids, low cholesterol), non-smoking and medication 
(statins), in short, the way of living, play a crucial role in the development of 
atherosclerosis which starts at an early age (<30) and continues over the course 
of decades. It is much less recognized that blood-clotting, more correctly the 
haemostatic-thrombotic system, pulls the trigger at the moment that the chronic 
condition of atherosclerosis converts to overt disease.  
 
However, the thrombogenicity of atherosclerotic plaques seems to be related to 
their TF content [36], which is primarily associated with infiltrating macropha-
ges. TF is exposed to the circulating blood when these plaques are ruptured, 
thereby initiating thrombus formation and related complications such as acute 
myocardial infarction [37]. It is being more and more recognized that thrombin 
plays its part in arterial thrombosis [35, 38]. Excess amounts of FII have been 
found to correlate with the occurrence of myocardial infarction [39]. Also 
higher than normal levels of von Willebrand factor (vWF) increase TG and are 
a risk factor for arterial thrombosis [39-41]. In a sub-population of young stroke 
patients (~30%) both TG in platelet rich plasma (PRP) and vWF have been 
shown to be significantly higher than normal [42]. Clinical trials have shown 
that vitamin K antagonists [43] as well as heparins [44, 45] decrease the reoc-
currence rate of myocardial infarction. “Antiplatelet” drugs achieve at least part 
of their effect by inhibiting TG in PRP [26, 27] and, inversely, aspirin has been 
shown to be beneficial also in venous thrombosis [46]. 
The classical paradigm of haemostasis that arterial thrombosis is 
due to the platelets and venous thrombosis to clotting thus seems to 
lose ground. 
This paradigm was also supported by the old observation that in venous throm-
bosis the thrombus really looks like a clot while in arterial thrombosis the 
thrombus doesn’t seem to contain much coagulated blood but rather appears as 
an aggregate of platelets. This however can be explained by the differences in 
sheer rates in veins and arteries (see below). 
Nevertheless, the precise role of the plasmatic thrombin generating system in 
arterial thrombotic disease remains enigmatic. 
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Thrombin is also needed for thrombus growth 
Not only haemostasis and thrombosis but also thrombus growth requires throm-
bin generation. As soon as experiments are carried out under conditions where 
thrombin can form, tissue factor and thrombin appear to play an important role, 
especially at low (venous) and intermediate (large artery) shear rates [20, 47-
49]. At high shear rates an effect of thrombin inhibition is not seen on initial 
thrombus formation but becomes obvious when the experiment is prolonged 
[48]. One of the functions of the aggregate must be to serve as a niche in which 
a sufficient local concentration of thrombin can build up. Where the concentra-
tion of thrombin is high enough, new platelets will be recruited through interac-
tion of thrombin with platelet-receptors GPIbα, PAR 1, PAR 3 and PAR 4 [50-
51] and more thrombin will form [52, 53]. This activation of the platelets indu-
ces a conformational change in their receptors GPIIb/IIIa making them appro-
priate for interaction with vWF-fibrinogen which induces on its turn aggrega-
tion of more platelets. 
But thrombin is not the only platelet-activator; several mechanisms of platelet-
aggregation or thrombus-growth exist in parallel. Collagen, which as TF is also 
present in the subendothelial layers of the vessel wall and is exposed at the site 
of injury, activates the platelets via the platelet-receptor GPVI (directly) and via 
GP1b with modified vWF. When the collagen-surface is completely covered by 
platelets the role of collagen is taken over by fibrin, formed in the aggregate, 
that activates the platelets via the same mechanism (GP1b with modified vWF) 
[54, 55]. Apparently the fibrin-clot is not only the final product of haemostasis 
but it also participates as a clotting-factor itself [56, 57]. This explains why 
thrombin becomes increasingly important when less collagen is exposed. The 
relative importance of thrombin- and collagen-dependent mechanisms has in-
deed been shown to be influenced by the type of injury to a vessel wall [58]. 
 
The differences in shear rates in veins and arteries and the need of a sufficient 
concentration of thrombin for thrombus growth also explains the old observa-
tion that in venous thrombosis the thrombus really looks like a clot while in ar-
terial thrombosis the thrombus looks like an aggregate of platelets. At low shear 
rates (veins) a sufficient concentration of thrombin can build up in the aggregate 
and diffuse into the surroundings converting a lot of fibrinogen. A thrombus in 
the veins therefore consists of a platelet-rich head of a few millimeters and a 
long tail of coagulated blood (that can reach over 10 centimeters). In the arteries 
however thrombin is washed away by the high flow before it is able to convert 
much fibrinogen. This results in a thrombus consisting mainly of the platelet-
rich head. 
Thrombin generation and bleeding 
Thrombin generation not only plays a pivotal role in thrombosis (venous and 
arterial) but also in bleeding diseases. It has been demonstrated in haemophili-
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acs (deficiency of factor VIII, IX or XI) as well as in all rare clotting factor de-
ficiencies (factor II, V, VII, X) that thrombin generation is diminished and that a 
clinical bleeding tendency is seen as soon as thrombin generation is below 20% 
of normal [59, 60]. The objective in antithrombotic therapy is to diminish 
thrombin activity by the use of vitamin K antagonists, heparins or hirudin, 
which carries of course a risk of bleeding when thrombin generation is dimin-
ished too much. Also in severe thrombocytopenia, as well as in Glanzmann [61] 
and Bernard-Soulier [56] disorder, thrombin generation is diminished. In von 
Willebrand’s-disease, thrombin generation in PRP is significantly impaired. The 
defect is more pronounced in PRP than in platelet poor plasma (PPP) [62], 
which indicates that it can not be explained by the concomitant deficiency of 
factor VIII. 
One of the reasons that low thrombin generation causes a bleeding tendency is 
likely to be found in the fact that the amount of thrombin formed determines the 
amount of Thrombin Activated Fibrinolysis Inhibitor (TAFI) that is generated 
[63]. Low thrombin generation therefore causes increased fibrinolysis. This is 
likely to be the explanation for the fibrinolytic character of much of the bleed-
ing in haemophiliacs and would explain the beneficial effect of antifibrinolytic 
agents. 
The function of the haemostatic-thrombotic system is better expressed by 
thrombin generating capacity than by fibrinogen-based methods as e.g. 
clotting times, thrombelastography. 
From the above it may be clear that thrombin plays not only a pivotal role in 
normal haemostasis but also in thrombosis and bleeding. Thrombin generation 
is the physiological function that governs thrombosis and it is this function that 
is pharmacologically manipulated to prevent and cure thrombosis. Since there is 
not always a close correlation between the thrombin generating capacity of 
blood and clotting-times (95% of thrombin is formed after clotting [64]), the 
coagulability of blood is better quantified by its thrombin-generating capacity 
than by measuring clotting times. Heparins e.g. strongly diminish the amount of 
thrombin that appears while the PT (TF-induced clotting-time) is not affected. A 
modified clotting time (the aPTT) has to be used. For anti-Vitamin K treatment 
a close correlation can be seen between TF induced clotting times as the PT and 
the amount of FIIa formed while other antithrombotics (e.g. dermatan sulphate) 
do not affect any clotting time measurement. There are no antithrombotics, 
however, that do not decrease the thrombin generation curve. 
On the other hand, thrombotic tendencies, such as those caused by a congenital 
defect of protein S (PS) or protein C (PC) or AT, or by an acquired resistance to 
activated protein C (APC) (e.g. oral contraceptives) [65-68] hardly affect any 
clotting time but always are accompanied by excessive thrombin formation. 
Also, bleeding-diseases do not always affect clotting-time tests. Haemophiliacs 
for example show a prolonged clotting-time in the aPTT but not in the PT. 
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Glanzmann thrombastenia only show a prolonged bleeding time but no pro-
longed PT or aPTT. Thrombin generation however still is affected because no 
good procoagulant surface is available [61]. 
One can only conclude that the thrombin forming capacity of blood can not un-
equivocally be determined with the aid of a clotting-time test only. Clotting 
times and the amount of thrombin formed are different things but both merit to 
be estimated. Measuring a thrombogram has the advantage that one obtains both 
parameters (lag-time and ETP) at the same time. The lag-time in a thrombogram 
is the time needed to reach a certain (low) level of thrombin (e.g. 10 nM) which 
corresponds with the time at which fibrinogen starts to be converted into fibrin, 
just like a clotting time. It depends on the chosen conditions (e.g. TF-
concentration, FIIa-concentration) whether the lag-time will have the character 
of a PT, a PT with diluted thromboplastin or an aPTT. Therefore measurement 
of a thrombogram produces more information than the clotting time can give. 
Measuring a clotting time can be seen as a way to obtain one parameter of the 
thrombogram, i.e. the lag-time of thrombin formation. 
Thrombin generation also yields information that can’t be deduced from deter-
mination of a (number of) single component(s) of the blood clotting mechanism. 
Thrombin generation is such a complicated web of interactions between such a 
large number of factors that there is no simple relation between a single factor 
concentration and the final outcome of thrombin generation. This is clearly the 
case in e.g. haemophiliacs: the bleeding tendency of these patients is not neces-
sarily related to the level of the missing factor [69]. The remainder of the clot-
ting system - including the platelets [70] - determines whether or not a given 
haemophiliac can make sufficient use of the small residual amount of FVIII or 
FIX. 
Particularly interesting is the lupus anticoagulant (LAC). This antibody causes 
an increase of the clotting time and thus is deemed “anticoagulant” but it also 
brings about a thrombotic tendency. This is called the ‘LAC paradox’. This 
paradox disappears as soon as one resorts to thrombin generation where it is 
seen that indeed the lag-time (=clotting time) is prolonged but also that throm-
bin generation is not inhibited by the activated protein C system [71]. 
 
As mentioned before, beside clotting-time tests there are also fibrinogen-based 
methods that attempt to go beyond the clotting time by measuring the turbidity 
[72] or mechanical properties of the clot [73]. These are useful for the precise 
determination of the clotting time but have the important disadvantage that the 
measured variable (mechanical properties, turbidity) is not unambiguously re-
lated to thrombin-concentration. It is a covariable of one of the effects of 
thrombin formation i.e. fibrin polymerization. This polymerization is related to 
thrombin formation, or even to the formation of fibrin monomers, in a compli-
cated and as yet incompletely understood manner. Therefore, the fundamental 
problem with fibrinogen-based methods is that an effect is studied that is de-
pendant in an unknown way on known and unknown variables. No relation is 
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known between mechanical properties or turbidity and the activity of thrombin, 
so the information can not be quantified in terms of thrombin concentrations. 
Further, fibrinogen is consumed long before thrombin formation is over mean-
ing that no information can be obtained on the stages of thrombin generation 
beyond the very beginning of the production phase.  
Sometimes curves are constructed as a result of mathematical transformations 
that can easily be mistaken for real thrombin generation curves [74, 75], but that 
do not improve the content of information in any way. In fact, a multitude of 
different methods allow scores of measurable properties of blood that change as 
a result of the formation of thrombin and/or fibrin. Often it will be possible to 
correlate such changes to a clinical picture [76]. Nevertheless, they must be 
considered surrogate variables that can better be abandoned now that exact 
quantification of thrombin generation has become available. 
How can the thrombin forming capacity of the blood be 
assessed ? 
The thrombogram and the ‘Endogenous Thrombin Potential’ (ETP) 
The general form of any thrombogram is independent of the measuring system 
and the experimental conditions (figure 3). The thrombogram starts with a lag-
phase or initiation phase in which hardly any observable traces of thrombin ap-
pears [77], followed by a production or propagation phase marked by a sudden 
burst of thrombin. Clotting occurs at the start of the explosive burst, i.e. at the 
end of the lag-time [64]. As mentioned before, the clotting-time is therefore a 
good estimate of the duration of the lag-phase and vice versa. The small traces 
of thrombin formed during the lag-time activate the clotting factors V, VIII, XI 
and platelets. As such they prepare the scene for the full blown TG during the 
production phase. The reaction mechanisms in the lag-phase and the production 
phase are different, that is why the lag-(=clotting) time does not automatically 
contain information on the amount of thrombin formed in the following peak. 
There is no sharp distinction between the production phase and the inactivation 
phase. The antithrombins present in plasma react with thrombin as soon as it 
appears. The velocity of inactivation is proportional with the thrombin concen-
tration and the antithrombin concentration. At the peak, thrombin generation 
and decay are equally fast. Once past the peak, decay gains on prothrombin 
conversion and somewhere in the down slope the latter will stop [78, 79]. 
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Thrombin is an enzyme and acts by converting substrate molecules. The number 
of molecules that can be converted by thrombin is proportional to both the con-
centration of this enzyme and the time that it can act i.e. to the area under the 
thrombin time curve. This area thus reflects the amount of natural substrates 
that could have been converted under in vivo conditions by the thrombin gener-
ated in the sample. It is called the endogenous thrombin potential (ETP) [80] 
and is a measure of the thrombin forming capacity of the blood. 
Timed subsampling on fibrinogen 
From the fifties until the early eighties, thrombograms were obtained by timed 
subsampling of aliquots of clotting blood or plasma onto a solution of fibrino-
gen, often diluted bovine plasma (without added calcium). By measuring the 
clotting time in each subsample the thrombin concentration was assessed for 
each time-point and a thrombin generation curve was constructed. This was 
very laborious work. 
Timed subsampling on a chromogenic substrate 
Subsampling onto a chromogenic substrate is the first method in which throm-
bin is measured directly. The thrombogram is obtained via determination of the 
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Figure 3: The general shape of a thrombogram. 
The most important parameters are indicated. The ETP (nM x min) is a good 
measure of the thrombin forming capacity of the blood. 
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thrombin content in small subsamples taken at short intervals from clotting 
blood or plasma. Automatic recording of the sampling time and semi-automatic 
measurement of the thrombin activities became possible, which also allowed 
executing several parallel experiments [79]. However, it remained laborious: it 
took about half a day to make six thrombograms with three people requiring 
great dexterity if parallel curves were to be measured. 
Because of the use of low MW-substrates, the total amidolytic activity meas-
ured during thrombin generation is the sum of free thrombin and the α2-
macroglobulin-thrombin-complex (α2M-IIa). Thrombin bound to α2M is 
stericly impeded to react with any physiological substrate because it is bound in 
a niche of this big molecule. The small chromogenic substrate however can still 
be attacked. This means that one has to correct for the contribution of this α2M-
IIa complex to the total amidolytic activity if one wants to know the concentra-
tion of free FIIa alone. The velocity of the formation of the complex is in good 
approximation proportional to the concentration of free thrombin. Therefore the 
amount of α2M-IIa in serum is proportional to the integral of the thrombogram 
i.e. to the ETP. This makes it easy to correct for this contribution of α2M-IIa by 
using a simple algorithm [80]. 
Adding a chromogenic substrate directly to the clotting plasma 
In an attempt to further automate the TG-measurement a chromogenic substrate 
was added directly to the clotting plasma. This cannot be done with high affinity 
substrates because they interfere with all thrombin driven feedback reactions 
and the clotting mechanism during the lag-phase is seriously disturbed. They 
bind thrombin so tightly that they act as potent thrombin-inhibitors. The decay 
phase seen in these thrombogram-like curves when using such substrates is due 
to substrate exhaustion and not to thrombin-disappearance because also the in-
activation of thrombin by antithrombin is strongly inhibited. 
However, suitable slow reacting thrombin substrates were found with such ki-
netic properties (high Km and low kcat) that the velocity of product formation is 
in good approximation proportional to the prevailing concentration of FIIa [81]. 
Of course, the presence of a chromogenic substrate implies that the physiologi-
cal reactions of thrombin are interfered with. Even a slow reacting substrate will 
compete with the antithrombins of the plasma for the active site of thrombin. 
This results in an artificially increased ETP because the thrombin decay will be 
slowed down. The magnitude of this effect can be easily calculated and cor-
rected for. 
This method was restricted to defibrinated plasma. Clot formation had to be 
avoided when using a chromogenic substrate because the light-scattering caused 
by the developing clot would disturb the OD-measurement. Defibrination of the 
plasma was carried out with suitable snake venom enzymes like Arvin which 
convert fibrinogen into fibrin without affecting any clotting factor of the coagu-
lation system. However, when removing this fibrin-clot out of the plasma, plate-
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lets were removed as well. This means that this method could only be used in 
defibrinated, platelet poor plasma. 
Adding a fluorogenic substrate directly to clotting plasma. 
To solve the drawback of defibrination, the logical next step was the use of a 
fluorogenic substrate since fluorescence can be measured in turbid media. This 
makes it possible to measure thrombin generation in PRP as well as in PPP [82]. 
However, other drawbacks appeared notably substrate-depletion and the inner-
filter effect. As a result of these effects, the same amount of thrombin activity 
causes a far greater increase of signal at the beginning of the experiment than 
towards the end. This means that the calibration factor is not constant but in-
creases during the experiment which makes it necessary to measure the calibra-
tion factor continuously. Another problem is the varying color of the plasma-
samples which introduces serious differences in the absorption of light. There-
fore, the reaction velocities measured in one plasma-sample can not be stan-
dardized by comparison to another plasma-sample. This would introduce seri-
ous experimental errors. 
Outline of this thesis 
The three drawbacks of fluorogenic methods mentioned above can be dealt with 
by the use of continuous individual calibration as in the Calibrated Automated 
Thrombogram (CAT-method). This method is presented in chapter II. A de-
scription is given of the standard conditions as well in PPP as in PRP and also 
the influence of added APC and TM is shown. Further the normal values and 
variability – experimental variation, intra-individual variation and inter-
individual variation – are presented. 
The mathematical procedure required to convert raw data (fluorescent signal 
versus time) into TG curves is explained in chapter III. 
In chapter IV it is shown how the time-course of prothrombinase-activity dur-
ing thrombin generation can be calculated starting from the TG curve if the ini-
tial concentration of AT is known. 
What happens if the effect of plasma-color, inner-filter effect and substrate-
consumption are neglected is seen in chapter V. Certain commercialized meth-
ods use a fixed calibration factor measured in buffer instead of continuous indi-
vidual calibration. We investigated the effect of both calibration methods on the 
reproducibility and compared the experimental and intra-individual variation of 
both methods. 
Measuring a system always means disturbing it. The addition of an artificial 
substrate that binds to thrombin, although it is a slow reacting substrate, will 
interfere with the physiological reactions of thrombin and as such influence 
thrombin generation. In chapter VI we show what this disturbance amounts to. 
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We discussed already two classical paradigms. A third current paradigm is that 
thrombin formation is the result of chemical interactions only [1]. In accordance 
with this view the velocity of thrombin generation is uniquely determined by the 
initial concentrations and reaction constants of the partaking components [83]. 
In chapter VII we show evidence that as clotting takes place thrombin genera-
tion velocity is co-determined by diffusion. 
It is impossible to measure thrombin generation in plasma without diluting it. 
Several methods are available using different dilutions of plasma. This poses the 
question what the influence of dilution is on thrombin generation. This is the 
subject of chapter VIII. 
In chapter IX, finally, protocols are presented for measuring thrombin genera-
tion. Not only of the most advanced method up to now, the CAT-method, but 
also of the ones preceding the CAT-method. As such an overview is given of 
measuring thrombin generation during half a century. However, nostalgia is not 
the reason why these ‘old’ techniques are raked up. As will be discussed in the 
preface of this chapter, each technique has its benefits and its specific use in 
specific situations. 
A general discussion of this thesis with a summary of the conclusions is given 
in Chapter X. 
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Abstract 
Calibrated automated thrombography displays the concentration of thrombin in 
clotting plasma with or without platelets (PRP / PPP) in up to 48 samples by 
monitoring the splitting of a fluorogenic substrate and comparing it to a constant 
known thrombin activity in a parallel, non-clotting sample. Thus, the non-
linearity of the reaction rate with thrombin concentration is compensated for, 
and adding an excess of substrate can be avoided. Standard conditions were es-
tablished at which acceptable experimental variation accompanies sensitivity to 
pathological changes. The coefficients of variation of the surface under the 
curve (ETP) are: within experiment ~3%; intra-individual: <5% in PPP, <8% in 
PRP; interindividual 15% in PPP and 19% in PRP. In PPP, calibrated automated 
thrombography shows all clotting factor deficiencies (except factor XIII) and 
the effect of all anticoagulants (AVK, heparin(-likes), direct inhibitors). In PRP, 
it is diminished in von Willebrand’s disease, but it also shows the effect of 
platelet inhibitors (e.g. aspirin and abciximab). Addition of APC or thrombo-
modulin inhibits thrombin generation and reflects disorders of the APC system 
(congenital and acquired resistance, deficiencies and lupus antibodies) inde-
pendent of concomitant inhibition of the procoagulant pathway as for example 
by anticoagulants. 
Introduction 
The thrombin generation curve (thrombogram) is an old and established tool in 
blood coagulation research [1– 4]. It reflects much, if not all, of the overall 
function of the blood clotting system [5]. In PPP, it shows all clotting factor 
deficiencies with the exception of factor XIII [6–8], and it is sensitive to the 
action of oral anticoagulation, heparins of all types [9], direct thrombin inhibi-
tors [10] and in fact all anticoagulant drugs tested. Hyperprothrombinaemia [11] 
and lack of AT [12], PS or PC as well as APC resistance increase thrombin gen-
eration. Thrombin generation and a derivative test, the end level of α2M-T in 
the ‘serum’ of defibrinated plasma, have been shown to be sensitive indicators 
of congenital [13] and acquired [14–16] defects in the APC pathway. 
In platelet-rich plasma, the thrombogram also reveals the part played by plate-
lets and hence the effect of von Willebrand factor [17], hypofibrinogenaemia 
[17], thrombo(cyto)penia [18] and Glanzmann’s [17] and Bernard-Soulier’s 
thrombopathies [19] as well as the effect of anti-platelet drugs [20, 21], 
GPIIb/IIIa antagonists included [22]. Agents that increase platelet reactivity 
(e.g. arachidonic acid, epinephrine and collagen [23]) accelerate thrombin gen-
eration in PRP. 
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Despite its potential value for clinical diagnosis, drug monitoring and epidemi-
ology, thrombin generation has not found universal application, primarily be-
cause of technical reasons: with the established subsampling techniques it takes 
about 1 h for a skilled laboratory worker to acquire one to four curves. The use 
of a slow-reacting fluorogenic substrate enables continuous measurement of 
thrombin generation in fibrin(ogen)-containing media which makes it possible 
to use PRP and to test the influence of platelets on thrombin generation [24, 25]. 
However, it raises the question of how to convert the velocity of fluorescence 
change (dF/dt) into thrombin concentration [26]. For various reasons, during the 
course of the experiment, the relationship between dF/dt and thrombin concen-
tration varies as fluorescence increases. We calculate thrombin activity as a 
function of time by comparing the fluorescent signal from the thrombin-
generating sample to that from a known stable concentration of thrombin activ-
ity measured simultaneously in a parallel sample. We developed software to 
combine the data from the two experiments and display the concentration of 
thrombin in the coagulating sample in real time during the experiment. Using a 
96-well plate fluorescence reader, up to 48 samples can thus be run. 
Materials and Methods 
Chemicals 
Recombinant relipidated tissue factor not containing polybrene or Ca2+ was a 
kind gift from Dade Behring (Marburg, Germany). Phospholipid vesicles con-
sisted of 20 mol% phosphatidylserine, 20 mol% phosphatidylethanolamine and 
60 mol% phosphatidylcholine. Hepes-buffered saline comprised 20 mM Hepes, 
140 mM NaCl, pH 7.35 (prepared as described [12]). 
Fluorogenic substrate, Z-Gly-Gly-Arg-AMC, was obtained from Bachem 
(Bubendorf, Switzerland). Upon splitting by thrombin, it releases the fluoro-
phore AMC, which is measured using a 390-nm-excitation and a 460-nm-
emission filter set. 
A fresh mixture of fluorogenic substrate and CaCl2 was prepared for each ex-
periment as follows: to 875 μl of buffer (Hepes 20 mM, pH 7.35) containing 60 
g/l BSA (Sigma, A-7030), 100 μl of 1 M CaCl2 was added. At 37 °C, 25 μl of a 
100 mM DMSO solution of the fluorogenic substrate was squirted in and im-
mediately vigorously mixed. The resulting clear solution, referred to as FluCa, 
thus is 2.5 mM in fluorogenic substrate and 100 mM in CaCl2. 
The chromogenic thrombin substrate was S2238 (Chromogenics, Mölndal, 
Sweden). Heparin was unfractionated heparin from LEO (Copenhagen, Den-
mark). 
APC was purified according to Regnault et al. [27]. As a TM-preparation we 
used recombinant human TM, a kind gift of Asahi (Japan). 
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Blood and Plasma 
Blood was obtained through antecubital venipuncture (1 volume trisodium cit-
rate 0.13 M to 9 volumes blood) from healthy individuals who consented to par-
ticipate in this study. Free flow or minimal suction was employed; vacuum con-
tainers were avoided. PRP was collected from the upper 3/4 volume of plasma 
supernatant, after centrifugation at 265 g for 10 min at room temperature. The 
platelets were counted (Beckman Coulter counter) and PRP was adjusted to 150 
x 109 platelets/l with its own PPP, prepared by centrifuging twice at 2900 g for 
10 min at room temperature. PRP was always used within 1 h after venipunc-
ture. In order to avoid contamination with procoagulant microparticles from 
aging platelets, PPP is preferably prepared within 30 min after venipuncture. 
Preparation of the Calibrator 
In order to obtain a stable thrombin-like activity in plasma, we used α2M-T. A 
crude α2M-containing fraction was isolated from citrated bovine plasma by pre-
cipitation with 12% (w/v) PEG-20000; the pellet was dissolved in 100 mM 
NaCl, 20 mM Hepes, pH 7.9 (1/10 of the original plasma volume) (modified 
from Barrett [28]). To this solution we added 12 μM bovine prothrombin, 6 mM 
CaCl2, 50 μM phospholipid vesicles (20% brain phosphatidylserine, 80% egg 
yolk phosphatidylcholine), 5 nM bovine factor Xa and 0.78 nM bovine factor 
Va. The mixture was stirred for 30 min at room temperature and then kept over-
night at 4 °C. The formed fibrin was removed and the preparation was applied 
to a Sephacryl column equilibrated with 100 mM sodium citrate, 20 mM Hepes 
(pH 7.4) and 0.02% NaN3. The α2M-T that had formed eluted as a sharp peak 
before contaminating proteins. 
The concentration of α2M-T is measured by its activity towards S2238 and ad-
justed to the activity of 600 nM human thrombin; 100 nM bovine AT and 2 
U/ml heparin are added in order to prevent coagulation of the plasma sample 
upon use. The material is lyophilized and used as a calibrator after reconstitu-
tion with sterile water. 
Automated Fluorogenic Measurement of Thrombin Generation under 
Standard Conditions 
The thrombograms are measured in a 96-well plate fluorometer (Ascent reader, 
Thermolabsystems OY, Helsinki Finland) equipped with a 390/460 filter set 
(excitation/emission) and a dispenser. Immulon 2HB, round-bottom 96-well 
plates (Dynex) are used. 
Each experiment needs two sets of readings, one from a well in which thrombin 
generation takes place (TG well) and a second one from a well to which the 
calibrator has been added (CAL well). The color of the plasma can influence the 
fluorescence intensity and therefore each plasma needs to be compared to its 
own calibrator measurement. If the same plasma is used under different condi-
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tions (different triggers, addition of APC or TM, addition of substances to be 
tested), the experiments can share the same calibrator. PPP and PRP from the 
same individual can also share the same calibrator. Usually experiments are car-
ried out in quadruplicate, i.e. a set of 4 TG wells is compared to a set of 4 CAL 
wells. A dedicated software program (Thrombinoscope, Synapse BV, Maas-
tricht, The Netherlands) enables the identification of the (sets of) wells and de-
termines the duration of the experiment and the sampling rate (usually 4 wells / 
minute). 
To each well, 80 μl of plasma is added. The TG wells receive 20 μl of buffer, 
containing the trigger but no Ca2+, and the CAL wells 20 μl of the α2M-T-
solution. For PPP, the trigger is 30 pM of rTF and 24 μM phosphatidylser-
ine/posphatidylcholine/phosphatidylethanolamine vesicles in Hepes-buffered 
saline. For PRP the trigger is 20 μl of 3 pM of rTF without added PL. 
The plate is placed in the fluorometer and allowed to warm to 37 °C (minimally 
5 min). The dispenser of the fluorometer is flushed with warm 100 mM CaCl2 
solution, emptied, and then flushed with warm FluCa. At the start of the ex-
periment, the instrument dispenses 20 μl of FluCa to all the wells to be meas-
ured, registers this as zero time, shakes them for 10 s and starts reading. During 
the measurement, the program uses a default calibrator to calculate tentative 
thrombin concentrations and displays the course of thrombin concentration in 
time for each group. Once the measurement is finished the program recalculates 
the TG-curves using for each group the readings of the relevant CAL wells. 
Experimental Results 
From Fluorescence Intensity to Thrombin Activity 
Free thrombin activity rapidly decays in plasma, so, in order to investigate the 
effect of constant thrombin activity on substrate consumption in plasma we used 
the α2M-T complex that splits the signalling substrate like thrombin does but 
that is not affected by plasma inhibitors. Under test conditions, its amidolytic 
activity in plasma, as tested by subsampling on S2238, remained constant for 
over 3 h (results not shown). The kinetic constants of α2M-T were compared to 
those of thrombin (table 1). The Km of thrombin and α2M-T is identical within 
the limits of experimental error. Therefore, the variation in the reaction velocity 
with decreasing substrate concentration will be practically identical. The turn-
over velocity of α2M-T (kcat) is half that of thrombin. To compensate for this 
difference, we express henceforward the concentration of α2M-T in ‘thrombin 
equivalents’, i.e. as the concentration of free thrombin that gives the same reac-
tion velocity (i.e. at half the actual concentration). 
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Figure 1A demonstrates that constant α2M-T activities do not cause a constant 
rate of fluorescence increase. The initial rates, measured as the tangents to the 
curves at t = 0, are proportional to the enzymatic activity added (figure 1B). The 
curvature is due to substrate consumption and to the non-linearity of fluores-
cence intensity (F) with increasing concentration of fluorogenic molecules (the 
‘inner filter effect’) [29]. Both effects increase with the amount of product 
formed and hence with the level of fluorescence. We calculated the difference 
between the ideal fluorescence intensity (Fi), i.e. the value that would have been 
obtained experimentally if the initial velocity would have been maintained and 
the experimentally measured fluorescence (Fe), i.e. the vertical distance be-
tween the bold and the thin lines in figure 1A. In the plot of Fi-Fe against Fe 
(figure 1C) the lines obtained at the six different thrombin activities superim-
pose, demonstrating that the deviation from the initial velocity is indeed only 
dependent on the level of fluorescence. Therefore, every fluorescence level re-
quires a different calibration factor to convert the velocity of the fluorescence 
increase (dF/dt) into thrombin activity (in nM). This calibration factor can be 
read from the graph obtained with a known calibrator concentration. 
The calibration factor is not only a function of the fluorescence level attained, it 
also depends upon the instrument used, the age of lamp and filters, and the color 
of the plasma; therefore, each group of experiments that is carried out with the 
same plasma requires its own calibration experiment. 
Influence of the Fluorogenic Substrate on the Course of Thrombin 
Generation 
The more substrate is present, the more thrombin molecules are occupied by the 
substrate and the less are they available for interaction with the natural anti-
thrombins [30]. This effect is not corrected for by calibration, because the cali-
brator does not react with antithrombins. Therefore, the measured thrombogram 
increases with increasing concentrations of the fluorogenic substrate (figure 
2A). When the amount of free thrombin is calculated (= [total thrombin] x Km / 
(Km + [substrate])), the influence of the substrate concentration becomes negli-
gible (figure 2B), showing that the fluorogenic substrate has little or no influ-
ence on the mechanism of prothrombin conversion. 
 
Km (µM) 292 ± 44 310 ± 34 305 ± 46 280 ± 57 
kcat (M-1s-1) 0.95 ± 0.1 0.89 ± 0.1 1.86 ± 0.26 ND 
 
       Table 1. Kinetic constants of thrombin and α2M-T 
        n=12. The Km of thrombin in plasma was measured indirectly as the Ki of the inhibition 
        of  thrombin decay. (ND = not done) 
 
Kinetic con-
stants 
α2M-T in 
buffer 
α2M-T in 
plasma 
Thrombin 
(buffer) 
Thrombin 
(plasma) 
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Figure 1. The effect of constant thrombin activity on the fluorescent 
signal production in plasma. 
A. The fluorescent traces of a range of α2M-T concentrations with the tan-
gents at t=0 (initial velocity). B. Relation between initial velocity and α2M-
T concentration. C. Difference between tangents and curves of the top 
frame plotted as a function of the measured fluorescence. 
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The Effect of Fibrinogen 
Previous techniques for automatic determination of the thrombogram used 
chromogenic substrates and required defibrination with coagulating snake 
venom enzymes in order to prevent turbidity changes [30]. We observed that the 
removal of fibrinogen has a profound influence on the thrombogram: in the ab-
sence of fibrinogen, the fluorogenic technique shows a lower thrombin peak and 
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Figure 2. Thrombograms obtained at different substrate concentra-
tions (PPP, standard conditions).  
A. Total thrombin. B. Free thrombin.  
Substrate concentrations (from top to bottom): 0.4; 0.3; 0.2 and 0.1 mM. 
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a higher α2M-T end level than in its presence (figure 3A). By adding increasing 
concentrations of fibrinogen to afibrinoginemic plasma, fibrinogen dose-
dependently decreases the amount of thrombin found in a sub-sampling experi-
ment and increases the amount of thrombin in a fluorometer experiment (figure 
3B). 
 
 
Standard Conditions 
In PPP we chose a final concentration of 5 pM of rTF together with 4 μM of 
procoagulant phospholipids. At this concentration of rTF, thrombin generation 
is dependent upon factors VIII and IX (figure 4) but not on factor XI, the influ-
ence of which is only seen at TF concentrations below 1 pM [8, and results not 
shown]. In the 3-pM range and above, thrombin generation in PPP is not criti-
cally dependent on the rTF concentration, whereas around 1pM it is. rTF does 
not normally carry enough procoagulant phospholipids to ensure optimal 
prothrombin conversion. Thrombin generation is phospholipid dependent in the 
range of 0 μM to 2 μM and reaches a plateau at ~3 μM. At ~10 μM, the contact 
activation properties of negatively charged PL start to play a role [8], we there-
fore used 4 μM PL. 
In the absence of traces of rTF, the lag phase of thrombin generation in PRP is 
long and variable, probably influenced by endogenous TF and contact activa-
tion. Adding 0.5 pM (final concentration) of rTF largely abolishes this variabil-
ity. It is essential that no PL are added to make the test critically dependent 
upon the PL coming from the activated platelets. Under these conditions, 
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Figure 3. The influence of fibrinogen on the thrombogram.  
A. Course of amidolytic activity (expressed as thrombin equivalents) in normal pooled 
plasma before (A) and after (B) defibrination. Means ± 2 SD, n = 24.  
B. ETP of the plasma from an afibrinoginemic patient with increasing amounts of fi-
brinogen added. ● = Fluorogenic method; ○ = subsampling method.
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thrombin generation is dependent upon the platelet number in the range of 0–
100 x 109/l; at a platelet-number >200 x 109/l dependence is minimal. In our 
experience, at 150 x 109/l a useful equilibrium establishes between the inde-
pendence of small fluctuations in the platelet count and the sensitivity to platelet 
inhibitors. 
 
 
In PRP, under these conditions, thrombin generation is dependent upon platelet 
function (and hence on the level of von Willebrand factor [7]) as well as upon 
the concentration of factors VIII, IX and XI; the effect of activated factor VII is 
readily seen (results not shown). The thrombogram reflects the action of all an-
ticoagulants tested, alone or in combination. In the case of heparin, release of 
platelet factor 4 causes the inhibitory effect to be significantly smaller in the 
presence of platelets than in PPP (figure 5). In the case of oral anticoagulation, 
the concomitant inhibition of the protein C system is readily seen. 
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Figure 5. Influence of heparin 
administration on thrombin 
generation in PPP and PRP.  
At t=0, 7000 aXa units of enoxa-
parin were injected subcutane-
ously.  
Thin line = PPP, t = 0h 
Bold line = PPP, t = 4h 
++ = PRP, t = 0h 
○○ = PRP, t = 4 h. 
Time axis truncated at t =30 min. 
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Figure 4. Influence of TF  
concentration on thrombin 
generation in normal and 
haemophilia A and B plasma.  
a. Normal plasma.  
b. Haemophilia A plasma.  
c. Haemophilia B plasma.  
rTF concentrations in decreasing 
peak height: 15, 10 and 5 pM 
rTF. 
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Normal Values and Variability 
The experimental variability in the main parameters of the thrombogram is 
shown in table 2. (The lag time is arbitrarily defined as the moment that 10 nM 
thrombin is formed.) The variation measured in identical parallel experiments in 
one 96-well plate is low (3–5%) and even lower when an occasional apparently 
aberrant curve, usually due to the presence of a floating bubble or accidental 
miss-pipetting, is left out. 
 
Table 2. Normal values and variability 
The intra-individual day-to-day variation was measured on 9 different days in 4 individuals. 
Experimental CV was determined on 36 identical samples measured simultaneously. 
 
 
The intra-individual CV was measured by making thrombograms of 4 healthy 
subjects once in 9 consecutive weeks. The CV of the ETP in PRP for each indi-
vidual was around 8% (7.4, range 6–11). The interindividual variability deter-
mined based on the means of the 9 individual experiments was 17.5%. The 
combination of relatively stable day-to-day values and large interindividual 
variation is further illustrated in figure 6 (a representative selection is shown so 
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Figure 6. Intra- and inter-
individual variability in the 
PRP thrombogram.  
From the experiments used to 
establish the intra- and inter-
individual variability, the curves 
are given of three subjects, de-
termined four times at 2-week 
intervals. The line type is varied 
per indi-vidual. ○ = Mild von 
Willebrand factor deficiency. 
10 
 
  Average (n=36) 
SD 
 
CV Inter-
individual 
CV Intra-
individual 
CV expe-
rimental 
PPP  ETP (nM.min) 1879 284 15 4.5 2.5 
  Peak (nM) 458 60 13 5.5 4.5 
  Lag-time (min) 3.1 1.4 47 8.1 5 
PRP  ETP (nM.min) 1648 315 19 7.4 3 
  Peak (nM) 118 41 34 10.3 3.5 
  Lag-time (min) 8.1 1.9 24 9.4 7 
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as not to overload the figure). Part of the variation in PRP must be due to the 
variation in von Willebrand factor. The lower curve in figure 6, for example, is 
from an individual with a mild von Willebrand factor deficiency (ristocetine 
cofactor activity 49%, factor VIII:c 72%). 
Influence of Added APC and TM 
Figure 7 demonstrates that thrombin generation is considerably decreased by the 
addition of APC or TM. PRP is significantly less sensitive to APC than PPP. 
The sensitivity to TM does not show this large difference between PPP and 
PRP. The degree of inhibition observed is dependent upon both the TF concen-
tration and the concentration of APC and TM. Under our standard conditions 
the inhibitions shown in table 3 are observed. Because the effect of APC or TM 
is compared to the same plasma to which no activator of the PC system is 
added, its effects can be observed independent of concomitant inhibition of 
thrombin generation as for example under antithrombotic treatment or in the 
presence of lupus anticoagulants [16]. 
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Figure 7. Effect of the protein C system on normal plasma. 
A. PPP. B. PRP. Drawn line = Control; ++ = TM added (10 nM); ○○= APC added (10 nM in PPP, 
6 nM in PRP). Inhibition of the ETP: PRP-TM: 64%; PRP-APC: 29%; PPP-TM: 76%; PPP-APC: 
87%. 
       
Plasma Addition Concentration (nM) Inhibition (%) SD (%) 
PPP TM 3 34.4 4.9 
 APC 6.5 47.5 5.1 
PRP TM 10 69.7 5.8 
 APC 25 71.8 5.5 
            Table 3. Effect of TM and APC supplementation 
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Discussion 
Measuring the haemostatic function of the blood is important both in bleeding 
and thrombotic disorders. Nevertheless, there is no universal test of this func-
tion available to the clinician. Clotting times of different types do not indicate a 
thrombotic tendency of unknown origin or mild haemostatic disorders. Different 
clotting assays are needed for different types of anticoagulants (oral anticoagu-
lation/heparin). And for some types of antithrombotic therapy no adequate func-
tion test is available (e.g. heparin likes). 
The thrombin generation test is a time-honored tool in coagulation research [1–
4], and its wide scope is easily understood from the focal place of thrombin in 
the haemostatic-thrombotic mechanism [5]. On the one hand, scores of factors 
influence its formation, and on the other hand, it has numerous actions on blood 
and vessel components. The ensemble of pro- and anticoagulant factors deter-
mines thrombin generation in PPP, where a standard amount of procoagulant 
phospholipids is normally added. In PRP, thrombin generation is also dependent 
upon platelet function because platelets provide the necessary phospholipids, 
clotting factor V and, presumptively, clotting factor receptors. 
Thrombin generation in PRP thus reflects the major part of the physiological 
clotting system. Ideally, the contribution of white and red cells and the vessel 
wall should be included, and flow conditions created. To date, this is not yet 
technically possible. In PRP, the vessel wall can be partly represented by adding 
TF and TM. 
In the older literature thrombin generation is used both as a diagnostic test and 
as a tool in basic research [1–4, 18]. Its use in modern, large-scale, clinical, epi-
demiological or pharmacological studies is hampered by its extreme labor-
intensiveness. With the conventional subsampling techniques, even when opti-
mally streamlined [31], it takes about 1 h of a skilled technician to obtain one to 
four thrombograms. Therefore, we developed the test presented here, which al-
lows a throughput of up to 48 single thrombin-time graphs per hour in an auto-
mated procedure. 
In this test, the thrombin concentration in the sample is calculated from the con-
version velocity of a slow-reacting fluorogenic thrombin substrate. The princi-
ple of this approach has been developed with chromogenic substrates [30]. 
Unlike optical density measurements, the fluorescent signal is not influenced by 
the turbidity of the emerging clot, so fibrinogen-containing plasma and PRP can 
be used. 
With fluorogenic substrates, however, constant thrombin activity does not cause 
a constant increase in the output signal, and thus the first derivative of the signal 
produced does not directly reflect thrombin concentrations. As seen in figure 1, 
the velocity of the fluorescence increase diminishes as the level of fluorescence 
increases. It is also seen that (i) the initial velocities are proportional to the 
amount of enzyme added (figure 1B) and (ii) that the decrease in signal produc-
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tion is a function of the level of fluorescence but not of time or of the thrombin 
activity per se (figure 1C). The two phenomena that cause this non-linearity are 
(i) non-linearity of fluorescence with the concentration of fluorogenic molecules 
[29] and (ii) substrate consumption. 
In practice, the effect of substrate consumption – with any substrate – cannot be 
overcome by adding the substrate in excess. The more substrate is added, the 
more thrombin molecules are bound to it and thus protected from the action of 
plasmatic antithrombins. This not only prolongs the experiment beyond reason-
able limits but also increases substrate consumption and consequently the inner 
filter effect. 
Moreover, the substrate is a competitive inhibitor of physiological feedback re-
actions and thus may interfere with the development of prothrombinase: figure 
2 shows that at the concentration of substrate used in our standard procedure, no 
significant inhibition of thrombin formation is observed. 
The effect of non-linearity cannot be solved by comparing thrombin generation 
in an experimental sample to that in standard plasma. In an inhibited sample less 
product is formed than in the standard so substrate consumption and the inner 
filter effect are low and more signal will be obtained per unit of thrombin activ-
ity than in the control. Thus inhibition is underestimated. Inversely, in samples 
where the activity is higher than normal, the signal is more reduced by sub-
strate-consumption and by the inner filter effect than in standard plasma so that 
higher activity is also underestimated. From the data in figure 1 we calculated 
the magnitude of such under-estimations, both as a percentage of the standard 
plasma and as a percentage of the actual value and found that they transgress 
acceptable limits as soon as the activity deviates significantly from that in the 
standard plasma (figure 8). 
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duced by comparison with a 
standard plasma 
Underestimation induced by calcu-
lating inhibition or activation by 
comparison of the uncorrected ETP 
to that in a standard plasma. The 
thin line gives the deviation in per-
cent of the standard plasma, the 
bold line gives the deviation in 
percent of the measured value. 
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Fibrinogen 
In subsampling experiments, where the thrombin concentration in the fluid 
phase is determined, 30–50% more thrombin is found in defibrinated plasma 
than in plasma from which the fibrin has not been removed [32]. In fluorogenic 
experiments, significantly more thrombin activity is found in the presence of 
fibrin than in its absence (figure 3). Therefore, thrombin bound to fibrin must be 
co-estimated in the fluorogenic experiment. This is not without importance be-
cause it has been shown that thrombin bound to fibrin can activate factors V, 
VIII and XI as well as platelets [32]. Also, antithrombin (and hence heparins) is 
reported not to inhibit fibrin-bound thrombin, whereas heparin cofactor II (and 
thus dermatan sulfate) and direct thrombin inhibitors do [33–35]. Our previ-
ously reported study showing that in PRP the presence of fibrinogen is essential 
for normal thrombin generation [17] has been confirmed with the fluorogenic 
technique presented here (results not shown). 
Another important effect of fibrin(ogen) is that it diminishes the amount of 
α2M-T formed during the experiment (figure 3). The high end level attained in 
defibrinated plasma (or in the presence of polymerization inhibitors, results not 
shown) suggests that polymerizing fibrin prevents the interaction between 
thrombin and α2M. Therefore, in the presence of fibrin(ogen), correction for the 
α2M-T end level is minimal, and the traces of amidolytic activity obtained dur-
ing the experiment practically represent the course of free thrombin. This im-
plies that the use of the α2M-T end level as a means to estimate ETP [30, 15] is 
not only dependent on the level of α2M in the plasma but also on the level of 
fibrinogen. For unknown reasons, the experimental error in defibrinated plasma 
is higher than in non-defibrinated plasma (figure 3A). 
Standard Conditions 
The form and magnitude of the thrombogram is dependent upon the trigger 
used. An excess of tissue factor (11 nM, as in a thromboplastin time estimation) 
will cause the mechanism of prothrombinase formation to take the extrinsic 
pathway, i.e. involve factors VII, V, X and TFPI. Decreasing the TF concentra-
tion changes the pathway of thrombin formation to include first factors VIII and 
IX and then factor XI [for a review, see ref. 37]. In the absence of any TF but 
with sufficient procoagulant phospholipids added, contact activation (‘intrinsic 
pathway’) will cause a burst of thrombin formation after ~10 min. Even though 
plastics are used throughout, contact activation cannot be entirely avoided 
unless blood is taken on corn trypsin inhibitor (CTI) containing citrate (results 
not shown). In samples with a high content of circulating TF [38], thrombin 
generation can be seen even in the presence of CTI (results to be published). 
If in PPP the test is run without added phospholipids, thrombin generation be-
comes dependent upon non-sedimentable PL present in the plasma, i.e. upon the 
presence of circulating procoagulant microparticles, which in the first place 
helps to check pre-analytical conditions. Variable amounts of PL can be intro-
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duced by the use of vacuum tubes, by insufficient centrifugation, by storing 
PRP, especially in the cold. Consequently, the conditions of centrifugation as 
given in the methods section should be strictly followed. 
Thrombin generation is dependent upon the concentrations of PL and TF added. 
In the lower ranges, the relation is practically linear, to approach an upper limit 
at higher values. The concentrations chosen in our standard procedure are such 
that the upper ranges of thrombin generation are attained but not excessively. 
Thus, the method is insensitive to small experimental variations in trigger, 
whereas an excess of trigger is avoided to not overrule modest inhibitions. The 
number of platelets was chosen on the basis of the observation that between 0 
and 75 x 109 platelets/l there is an almost linear increase in thrombin generation 
with increasing platelet count, which levels off subsequently to reach a plateau 
near 150 x 109 platelets/l. Higher platelet numbers hardly increase thrombin 
generation [18, 39], but thrombin generation is less sensitive to the influence of 
platelet-based mechanisms and their inhibitors. 
Normal Values, Normal Effects of Addition of APC or TM 
The normal values under our standard conditions are shown in table 2. Of note, 
the thrombin peak is much lower in PRP than in PPP, whereas the ETP is not 
significantly different. This is most likely explained by the fact that platelet pro-
coagulant activity is gradually noted in the course of the activation process, 
whereas in PPP the added procoagulant phospholipids are present at recalcifica-
tion, i.e. at zero time. 
The inhibitory effect of APC and TM on the thrombin generation curve (table 3) 
is significantly diminished in dysfunctions of the APC system, such as the use 
of oral contraceptives or factor VLeiden [to be published, 40]. A comparison of 
thrombin generation in the presence or absence of TM or APC enables to assess 
the function of the APC system even if the coagulation process is impaired. In 
figure 9, for example, thrombin generation is diminished by oral anticoagula-
tion, which concomitantly affects the APC mechanism, resulting in a dimin-
ished response to the addition of TM. It also has been shown that in the pres-
ence of the lupus anticoagulant severe resistance to APC and TM is accompa-
nied by a considerably prolonged lag time (clotting time) [16]. 
 
The experimental variation is within acceptable limits (table 2) and similar be-
tween the three instruments at two locations used in the experiments reported 
here. In our experience, the fluorescence intensity of an identical product solu-
tion (AMC) can differ severalfold between fluorometers, even if they are of the 
same type. This variation is compensated for by the use of the calibrator. 
The variation in the population is much higher than the day-to-day variation per 
individual. Thus, some individuals generate more thrombin than others. A cor-
relation between the clotting factor level and the occurrence of venous and/or 
arterial thrombotic disease has been reported for various clotting factors [41, 
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42], which strongly suggests a relationship between the thrombin generation 
capacity and thrombotic disease. Measurement of overall thrombin generation 
enables the assessment of simultaneous effects of numerous small changes, 
which may either reinforce each other (e.g. in pregnancy [43]) or compensate 
each other (e.g. a bleeding tendency and factor VLeiden [44–46]). 
 
 
Hemorrhagic diatheses 
It has been shown before [for a review, see ref. 5] that thrombin generation is 
diminished in haemophilia and rare clotting disorders [6–8]. Also, in PRP, it is 
diminished if von Willebrand factor is low [17] and increases upon DDAVP 
treatment [7]. As can be seen from figure 4 and 6, calibrated automated throm-
bography shows these effects as well as subsampling techniques. In an accom-
panying article by Turecek et al. [47] it is shown that in haemophiliacs, the ef-
fect of inhibitor bypassing therapy can be seen in uncalibrated fluorogenic ex-
periments, thus enabling the quantification by calibrated automated throm-
bography. 
Anticoagulant Treatment 
We hypothesize that in anticoagulant therapy diminished thrombin generation is 
of the essence. All anticoagulant drugs have this effect in common although 
they may achieve it in completely different ways: decreased prothrombin and 
prothrombin conversion (AVK), increased thrombin inactivation (heparin) or 
direct inhibition (hirudin, argatroban and melagatran). There is no single clot-
ting test that reacts similarly to these different types of anticoagulants. Clotting 
tests measure the length of the initiation stage of thrombin formation, i.e. the 
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Figure 9. Thrombogram in a patient under stable oral anticoagulant treatment (INR 2.5).  
A. PPP. B. PRP. + = Normal plasma: top curve (black) without TM, lower curve (gray) with 
TM; full line = patient plasma: top curve (black) without TM, lower curve (gray) with TM. 
Concentrations as in figure 7. Time axis truncated at t = 30. 
A B 
CHAPTER II 
 
 
 
50 
time during which no significant amount of thrombin (<5 nM) is formed. Clot-
ting occurs at the end of this initiation phase and is complete when >95% of all 
thrombin is still to appear. That the amount of thrombin formed in the clot is 
essential for thrombosis and haemostasis can be derived from comparisons of 
laboratory and clinical observations. Heparin, for example, has a minimal effect 
on the TF-induced clotting time (‘quick time’) but has an undeniable antithrom-
botic effect. Defects in the protein C system have a recognized prothrombotic 
effect; nevertheless this system only comes into action after APC is formed by 
the TM-thrombin complex, i.e. in the later stages of thrombin formation, long 
after the clot has formed. In figures 7 and 9, the effect of added TM is seen in 
the second half of the thrombin generation curve. In fact the use of clotting 
times is restricted to those cases where the length of the initiation phase indi-
cates the amount of thrombin to come, which is far from being a general rule. 
Some observations that are liable to be of clinical importance will readily es-
cape our attention unless thrombin generation curves are made. It is logical, for 
example, that AVK treatment impairs the function of the APC system as well as 
of the clotting system. A net anticoagulant effect must remain to explain the 
antithrombotic effect, but assessment of the combined effect remained difficult. 
In figure 9 it is not only seen that TM resistance accompanies oral anticoagula-
tion, the effect can also be quantified. 
Another example is seen in figure 5. Thrombin generation in PRP is far less in-
fluenced by heparin than thrombin generation in PPP. This must be ascribed to 
the effect of platelet factor 4 [31]. We recently demonstrated that in PPP all 
heparins have the same mode of action, independent of their molecular weight. 
Nevertheless, there may be important molecular-weight-dependent differences 
among heparins when tested in PRP – and hence in vivo.  
As a third example (not illustrated here), we mention that there are essential 
differences between irreversible (hirudin) and reversible (argatroban and mela-
gatran) direct thrombin inhibitors in that the first act primarily on the lag time, 
but the second also have a strong inhibitory effect on the thrombin peak.  
Alternative Methods Depending on Clot Formation  
Several methods exist that measure the moment of clot formation or changes in 
the mechanical or optical properties of the clot, such as thrombelastography 
[48], resonance thrombography [49], roTEG coagulation analysis [50], the 
sonoclot analyzer [51], measurement of platelet-mediated force development 
during clot formation [52] and free oscillation rheometry [53]. The results of 
such methods sometimes show a superficial similarity to thrombin generation 
curves [54]. These methods can often be applied to whole blood, which is an 
important practical advantage.  
The disadvantage of clot-based methods is that they depend upon thrombin 
formation as well as on properties such as fibrinogen content and quality, fibrin 
polymerization, crosslinking and fibrinolysis [50]. These two aspects may coun-
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teract each other, e.g. in a febrile patient (high fibrinogen) under anticoagulant 
or other antithrombotic treatment (e.g. aspirin). Clot formation is only one of 
the many functions of thrombin and not necessarily the most important one, as 
can be judged from the mild bleeding syndrome in hypofibrinogenaemia. 
Through selection of the right substrate and comparing the fluorescent signal to 
that of a calibrator with fixed activity we can obtain a correct estimate of the 
course of thrombin concentration in clotting plasma. Fibrinogen as a substrate is 
quickly exhausted and the signal from its product – i.e. one or the other me-
chanical or optical property – cannot be unequivocally related to the amount of 
thrombin formed. 
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Chapter III 
 
Mathematical procedure to obtain the 
thrombin generation curve starting from raw 
data (time course of fluorescent signal). 
Chapter III 
Calculation TG-curve 
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raw data. 
R. Wagenvoord, E. De Smedt and H.C. Hemker 
CHAPTER III 
 
 
 
56 
 
Introduction 
In the introduction of this thesis we discussed the relevance of measuring TG 
and in chapter 2 we presented the CAT-method as a practical solution for meas-
uring TG in plasma. We did not yet discuss the mathematical procedures re-
quired to convert raw data (fluorescent signal versus time) into TG curves. In 
the CAT-method as it is available on the market these procedures are part of the 
software that is not accessible to the client. Furthermore, these procedures are 
continuously being adapted in order to be able to convert raw data in correct 
TG-curves in an automated way as efficiently as possible what results in new 
versions of the software.  
Since it is important for the investigator to understand what is behind the soft-
ware and to give him the opportunity to calculate a TG-curve manually if the 
software does not succeed a procedure is presented in this chapter of how to 
calculate a TG-curve starting from the raw data. This procedure is not necessar-
ily the same as in the software, but it is accurate and can be applied on any raw 
data.  
To calculate a TG-curve is not as simple as it might seem. It does not suffice to 
take the derivative of the raw TG-data and to transform these data with a fixed 
calibration factor obtained from the initial rate of fluorescence production by a 
known thrombin activity. In any fluorogenic method, TG is monitored via 
added fluorogenic substrate and the thrombin generated converts this substrate 
into a product that gives a fluorescent signal which is recorded in time. In an 
ideal situation the rate of fluorescence increase would be proportional to the 
enzyme-concentration during the entire process. In an actual experiment this 
proportionality is disturbed by substrate-consumption and by the inner-filter 
effect. This means that the raw data have to be corrected for the influences of 
these two phenomena and this is one of the reasons why continuous calibration 
is required (see also chapter 2 and chapter 5).  
Another complication is that the signal generated in clotting plasma is the result 
of both the transient activity of free (α-)thrombin and the permanent activity of 
α2M-T. For the TG curve we only need the course of free thrombin, so the sig-
nal generated by α2M-T has to be subtracted from the total signal. This is done 
by a mathematical procedure that requires that the moment can be estimated at 
which free thrombin no longer contributes to the over-all activity, i.e. when only 
the activity of α2M-T is present. We here describe a procedure to determine 
objectively this end of the TG curve (‘end of tail’).  
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Methods and materials 
Thrombin generation was carried out in the presence of 416 µM ZGGR-AMC 
in a pool of normal platelet poor plasma using 5 pM TF and 4 μM PL as de-
scribed before (chapter 2 or [1]). In parallel the fluorescence was measured gen-
erated by 200 nM of bovine α2M-T (calibrator) in plasma in which no thrombin 
generation was triggered. All measurements were carried out in quadruplicate. 
The raw fluorescence data from the TG experiment and from the calibrator ex-
periment were exported to SIGMAPLOT version 9.0 (Systat Software Inc., 
Point Richmond, CA, USA) for further mathematical operations. 
Calculation of the TG curve from raw data 
Correction for substrate-depletion and inner-filter effect 
Both the calibrator- and the TG-data are influenced by substrate-depletion and 
inner-filter effect to an extent that is only dependent upon the amount of sub-
strate converted, i.e. to the amount of product formed, i.e. to the level of fluo-
rescence measured. Therefore we first determine the corrections that have to be 
carried out on the measured calibrator curve so as to produce the straight line 
that would be obtained if substrate depletion and the inner filter effect would 
not play a role. Next, these corrections will be applied to the TG-data and this 
will render the “ideal” course of fluorescence, i.e. the fluorescence curve that 
would be produced if the disturbing phenomena would not occur. In figure 1 the 
mean raw data are shown of the calibrator wells (gray curve) and the TG-wells 
(thick black line). The raw calibrator data are fitted with equation i (thin black 
line in the gray curve).  
  
y =  y0 + at + bt2 + ct3 + dt4 + et5 + gt6                  (i) 
 
This is a polynomial of the sixth order in which y is the fluorescent signal, t is 
time, y0 the fluorescent signal at time 0 and a, b, c, d, e and g constants that are 
found by fitting equation (i) to the experimental data. The first terms of this 
equation (y =  y0 + at) gives a straight line which is the tangent of the curve at 
time 0 (dotted line in figure 1), i.e. the “ideal” calibrator curve that would have 
been measured in the absence of substrate depletion and inner filter effect.  
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Figure 2. Relation between measured and ideal raw data 
Plot of ideal raw data against measured raw data of the calibrator of figure 1 
(gray curve). The thin black line in the gray curve is the fit using equation (ii).
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Figure 1. Conversion of raw data into ideal raw data. 
The reaction mixture contained normal platelet poor plasma in a 2/3 dilution, 
calibrator with an equivalent activity of 100 nM human thrombin, 16.7 mM 
CaCl2 and 417 µM ZGGR-AMC. The gray curve shows the measured raw 
data of the calibrator and the thin black line gives the fit using equation (i). 
The dotted straight line represents the ideal calibrator data after correction. 
The continuous thick black line and the short dash thick black line represent 
respectively the measured and the ideal raw TG data. 
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In a next step, the measured raw data and the ideal raw data of the calibrator are 
plotted against each other (figure 2, gray curve) and this plot is fitted with equa-
tion ii (thin black line in the gray curve).  
 
y =  y0 + ax + bx2 + cx3 + dx4 + ex5 + gx6 + hx7 + ix8 + jx9 + kx10       (ii) 
   
This is a polynomial of the tenth order in which x is the measured fluorescent 
signal and y is the ideal fluorescent signal and a, b, c, d, e, g, h, i, j and k are 
constants. Using equation (ii) and the constants of this fit the measured TG-data 
(x) can now be converted into ideal data (y) (figure 1, thick black short dash 
line). 
Determination of the thrombin generation curve 
From fluorescent signal to [thrombin]*time (progress-curve) 
These corrected TG-data are still expressed as fluorescent signal against time 
and so these data are multiplied with a calibration factor. This calibration factor 
is obtained from the calibrator concentration divided by the initial slope of the 
experimental calibrator line (constant a of equation (i)), which is the same as the 
slope of the corrected calibrator data. The calibrator concentration (~ 200 nM 
α2M-T) is  here expressed as thrombin concentration (100 nM thrombin) (see 
also [1]). As such, the fluorescent signal is converted into the progress variable: 
product of thrombin concentration and time ([Thrombin]*time). The obtained 
progress curve (figure 3, gray circles) represents the workload or the man-hours 
of thrombin (nM.min) responsible for the generated fluorescent signal. 
Fit procedure  
The progress-curve in figure 3 is not the result of thrombin only but is built up 
by two enzymes: the man-hours of transient present thrombin and the man-
hours of ongoing present α2M-T. Both enzymes hydrolyze ZGGR-AMC. We 
want to know the course of free thrombin, so the progress-curve has to be split 
mathematically in its thrombin-related part and its α2M-T-related part. As 
shown in [2] this can also be done after one has taken the first derivative of the 
progress-curve, but this necessarily introduces inconvenient experimental scat-
ter. We therefore prefer to first fit the experimental data (progress-curve) to a 
mathematical equation and to continue with this fit for further calculations. The 
essence of the fit procedure is described in [3]. In this article the W-function is 
presented which fits TG curves to a four parameter equation.  
 
T = W(a, b, c, t) = a. b. c. e(-b.c.t).(e(b.t)-1)(c-1)                            (iii) 
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In which T is thrombin concentration, t is time and a, b and c are constants (> 
0). (In some cases the sum of two W-functions is required for a good fit, which 
does not change the principle of the procedure however.)  
 
 
This original W-function describes only the course of free thrombin in time. 
The α2M-T part is not included. The concentration curve of α2M-T (concentra-
tion of α2M-T against time) has the shape of a sigmoid and α2M-T forms with a 
velocity proportional to the concentration of thrombin [2]. The concentration of 
α2M-thrombin therefore raises proportional with the integral of the W-function. 
Equation (iv) describes the course of free thrombin and α2M-T in time: 
 
 AA= W(a, b, c, t) + k. ∫(W(a, b, c, t))         (iv) 
 
In which AA is the sum of the free thrombin and α2M-T concentration and k is 
an additional constant. 
The progress-curve in figure 3 which represents the man-hours of thrombin and 
α2M-T can now be fitted with the integral of equation (iv), i.e.  
 
 P = ∫ (W(a, b, c, t) + k. ∫ (W(a, b, c, t)))          
 
 
Substituting the W function into this equation gives: 
Time (min)
0 10 20 30 40 50 60 70
M
an
-h
ou
rs
 th
ro
m
bi
n 
(n
M
.m
in
)
0
1000
2000
3000
4000
Figure 3. Fit on the product-curve (thrombin-minutes against time) 
The gray circles show the progress curve, the ideal TG-data of figure 1 after they were 
converted into [thrombin]*time. This curve is fitted with equation (vi) (thin black line).
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P = a . (1-e(-b.t))c + a .k . sum ((1-e(-b.t))c) / s                           (v) 
 
In which P is the sum of [thrombin]*time and [α2M-T]*time or the total man-
hours of thrombin and α2M-T, t is the time and a, b, c and k are constants; s is 
the time between each subsequent reading in the fluorometer.  
 
Equation (v) makes it possible to fit most of the progress-curves but not all. It 
was already mentioned that in ref [3] in some cases (e.g. in PRP) it was neces-
sary to fit with two waves instead of one (two W-functions with two sets of 
constants). We also found conditions (Von Willebrand patients) which had to be 
fitted with three waves (results not yet published). More waves however were 
not found to be necessary. Therefore it was decided to fit progress-curves with a 
three wave-function (equation vi) as is shown in figure 3 (thin black line in the 
gray curve). 
 
P = a . (1-e(-b.t))c + a .K . sum ((1-e(-b.t))c) / s 
      + d . (1-e(-e.t))g + d .K . sum ((1-e(-e.t))g) / s 
      + h . (1-e(-i.t))j + h .K . sum ((1-e(-i.t))j) / s        (vi) 
 
In which P is the sum of [thrombin]*time and [α2M-T]*time or the total man-
hours of thrombin and α2M-T; t is the time; K=k/(a+d+h); a, b, c, d, e, g, h, i, j 
and k are constants; s is the time between each subsequent reading in the 
fluorometer.  
Determination of the end of tail 
At the end of a thrombin generation experiment no free thrombin is left and 
only a fixed amount of α2M-thrombin is left. Therefore the corrected progress-
curve should increase linearly once thrombin generation is over. In practice this 
part of the curve sometimes shows slight deviations from a straight line, which 
can affect the outcome of the fitting procedure. Especially in those cases where 
the “straight” part is very long, slight deviations from a straight line can lead to 
rather big changes in the found ETP. The other parameters - peak height, lag-
time and time to peak - are hardly affected by this phenomenon. This poses the 
question how the end-point of the fit i.e. the ‘end of tail’ can be determined cor-
rectly. To objectify the fitting procedure we designed the following protocol. 
First the corrected progress curve is fitted with equation (vi) (thin black line in 
figure 3) and the derivative of the fit is determined. The part of the derivative 
after the peak is a sigmoid that starts high and decreases to a level determined 
by the residual α2M-T activity. The difference between peak and end-level we 
call Δ. Then the times (t75, t25) are determined at which the value of the curve is 
75% and 25% of Δ above the end level. The difference between the two time 
points (δ = (t25-t75)) is taken as an estimate of the half-life time of thrombin in-
activation. Because thrombin generation probably is still ongoing it can be an 
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overestimation but not an underestimation. The TG curve is considered to be 
finished at 7 x δ after t75. This time point we call ‘end of tail’. The amount of 
thrombin left then is less than 1% of the amount present at the t75 time. This 
procedure was applied on the data of figure 3 and it was found that TG was 
completed after 36 minutes. Next the fit procedure with equation (vi) was re-
peated taking only time points between 0 and 36 minutes into account. This fit 
is shown in figure 4. 
Correction for α2M-T activity  
Now that the end of tail is determined and the progress curve is fitted, it can be 
divided in its two partaking enzymes: thrombin and α2M-T (figure 4). This in-
volves splitting formula (vi) in its two constituent parts, i.e. the right parts rep-
resent the contribution of α2M-T to substrate hydrolysis (short dash thick black 
line), while the left parts represent the hydrolysis of the substrate by thrombin 
(continuous thick black line). 
The constant end-level due to the activity of free thrombin (continuous thick 
black line) is a good estimate of the ETP. The ETP is the surface under the 
thrombin generation curve and can also be calculated as the sum of a, d and h 
(constants of equation (vi)). If the final slope of the α2M-T activity curve is cal-
culated this gives the α2M-T end-concentration which equals the constant k of 
equation (vi) (or K times the ETP). So, the final α2M-T concentration is propor-
tional to the developed thrombin activity or ETP.  
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Figure 4. Splitting the corrected progress curve into the parts due to free 
thrombin and to α2M-T. 
The gray circles show the corrected progress curve of figure 3. The thin black line in 
the gray curve is the fitted curve (see text). The continuous thick black line shows the 
contribution of free thrombin and the short dash (thick black) line that of α2M-T. 
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Calculation of the thrombin generation curve 
The first derivative of the contribution of free-thrombin to the corrected pro-
gress curve (continuous thick black line in figure 4) gives the TG curve. Instead 
of taking the derivative of the calculated data (based on the fit) it is also possi-
ble to take the derivative of the measured data of the progress-curve (and then 
subtract the α2M-T-part). This derivative however has a tendency to scatter 
widely, especially towards the end of the curve, because its calculation involves 
the measurement of small differences between large fluorescence values. We 
therefore prefer to use the first derivative of the fitted curve, which can be con-
structed because from the fitting procedure the constants that describe this curve 
are known. In the case of the example shown in figure 5, where the fitting was 
done on the basis of the sum of three W-functions, this amounts to constructing 
the curve: 
 
T = d (a.(1-e(-b.t))c + d.(1-e(-e.t))g + h.(1-e(-i.t))j) / dt . s       (vii) 
            
in which T is thrombin concentration, t is time, s is the time in between two 
readings in the fluorometer. It is the derivative of equation (vi), but without the 
α2M-T-parts. To be able to determine the parameters of the TG curve with suf-
ficient accuracy the TG curve was calculated in steps of 0.02 min. 
 
 
From figure 5 it is clear that curve fitting to the corrected progress curve avoids 
the scattering inherent to working with the first derivative of experimental val-
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Figure 5. Thrombin generation curve
The open circles show the derivative of the measured progress curve of figure 4 
(grey curve) after correction for α2M-T activity. The black line is calculated 
with the mathematical description of equation (vii) using the constants of the fit 
in figure 4 (equation vi).  
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ues. This is the more important when the concentration of the formed thrombin 
is low. Since the noise is always of the same order, the signal to noise ratio de-
creases in this case. This is illustrated in figure 6. In this figure thrombin gen-
eration is measured in PRP of a Von Willebrand patient. Although there is low 
noise in the measured progress curve, this noise is blown up enormously when 
taking the derivative. 
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Figure 6. Thrombin generation curve of a Von Willebrand patient in PRP 
The upper figure shows the measured progress curve corrected for the α2M-T activity 
(gray symbols) and the three wave fit (thin black line in the gray curve). The lower fig-
ure shows the derivative of the two curves shown in the upper figure. The open circles 
show the measured data and the black line the fit.  
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Parameters of the thrombin generation curve 
The fit of figure 5 is used to calculate the parameters of the thrombin generation 
curve: ETP, lag-time, time to peak and peak-height. The ETP is the sum of the 
constants a, d and h and represents the area under the TG curve (nM.min). The 
lag-time is defined as the time at which the thrombin concentration reaches 10 
nM. Both the lag-time, the time to peak and the peak-height have to be read 
from the fit, because they cannot be determined mathematically.  
Discussion and conclusion 
It is shown how two fitting-procedures are needed for the conversion of the raw 
data into a thrombin generation curve. First the experimental fluorescence data 
obtained with the calibrator have to be fitted, so that it is possible to convert 
them into ideal fluorescence data, i.e. data that would have been obtained if sub-
strate consumption and inner filter effect would not occur. The same procedure 
is then applied to the experimental data from the parallel thrombin generation 
experiment. In other words, the fluorescence data from the thrombin generation 
experiment are transformed into “ideal” data.  
The second fit-procedure is needed to split the progress-curve into its thrombin-
part and α2M-T-part. By fitting the progress-curve we avoid the large experi-
mental scatter that arises from working with the first derivative of experimental 
data. Instead of first determining the first derivative of the ‘ideal’ experimental 
data and then mathematically split it into its thrombin-part and α2M-T-part, we 
first fit the ‘ideal’ experimental progress curve and then carry out the calcula-
tions on the fitted curve.  
The fit on the progress-curve is based on the W-function, i.e. a four parameter 
function that describes a simple thrombin generation curve (free thrombin only). 
The course of free-thrombin- and α2M-T-concentration in time (the AA-
function) is obtained by adding to the W-function a curve that is proportional to 
its own integral, thus introducing an extra parameter. The integral of the AA-
function then represents the progress-curve (P-function). In this way a theoreti-
cal function is obtained to which the ‘ideal’ progress curve is fitted.  
With the constants found, the W-function, i.e. the thrombin generation curve is 
then constructed. In practice it is sometimes required to use the sum of two or 
three W-functions to obtain an acceptable fit. This does not change the principle 
of the approach. It does raise the number of fitting parameters to a maximum of 
ten which is still small compared to the number of measuring points (> 120). 
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Chapter IV 
 
Mathematical procedure to calculate 
prothrombinase-activity during thrombin 
generation. 
Chapter IV 
Calculation FII-ase activity 
 
 
 
 
 
 
 
 
 
 
This chapter is based on a manuscript in preparation that will be submitted to 
Computers in Biology and Medicine: 
Mathematical procedure to calculate prothrombinase-activity during thrombin 
generation. 
R. Wagenvoord, E. De Smedt and H.C. Hemker 
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Introduction 
In the previous chapter it was shown how thrombin generation curves can be 
obtained from raw data. The amount of thrombin formed during the clotting 
process is - roughly spoken - dependent on three parameters, the prothrombin 
concentration, the activity of plasmatic antithrombins and the activity of the 
prothrombinase complex (FII-ase). The FII-ase activity is the final step in the 
formation of thrombin and is dependent on the components of the FII-ase com-
plex: factor Xa, factor Va and phospholipids, which in their turn are dependent 
upon the function of the other clotting factors and regulatory systems and the 
platelets. The FII-ase activity therefore reflects the activity of the clotting sys-
tem but not that of thrombin breakdown. In this chapter it is shown how the 
time-course of FII-ase activity during thrombin generation can be calculated 
starting from the thrombin generation curve if the initial concentration of AT is 
known. 
Methods and materials 
Thrombin generation was measured in quadruplicate in a pool of normal platelet 
poor plasma using 5 pM TF and 4 μM PL according to [1]. The TG curve, lag-
time, time to peak, peak height and ETP were obtained by mathematical opera-
tion of the raw data as described in chapter 3. Further mathematical operations 
for the calculation of the FII-ase curve were carried out in SIGMAPLOT ver-
sion 9.0 (Systat Software Inc., Point Richmond, CA, USA). 
Human AT in plasma was determined by adding a fixed amount of thrombin 
and heparin to a dilution series of plasma. The remaining thrombin-
concentration after 10 min at 37 ºC was measured in each dilution with the 
chromogenic substrate S2238 and these values were plotted against the amount 
of plasma in each dilution (µl plasma). The slope of this linear curve gives the 
concentration of thrombin that has been inactivated per µl plasma. This corre-
sponds with the concentration of AT present in this µl plasma.  
The kdec of the thrombin-AT reaction was determined in a reaction mixture that 
contains purified AT, a chromogenic substrate and the reaction is started by ad-
dition of thrombin. By using the formula kdec = (kcat.S)/(Km.Pend).ln[A/(A-E)] the 
kdec can then be calculated (S = substrate concentration, Pend = end-level hydro-
lyzed chromogenic substrate, A = AT concentration and E = enzyme (thrombin) 
concentration). 
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Calculation of the prothrombinase activity 
Principle 
To determine the FII-ase activity we first calculate the amount of thrombin gen-
erated by FII-ase at each time-point during thrombin generation. This is the 
course of (total) thrombin concentration against time. The derivative of this 
curve gives then the FII-ase activity or the thrombin forming velocity (nM/min) 
at each time-point during thrombin generation. 
Thrombin generation in plasma is the sum of two processes, thrombin formation 
by the action of FII-ase and thrombin inactivation by plasmatic inhibitors. To be 
able to calculate the amount of thrombin generated by FII-ase at each time-point 
we need to know the amount of thrombin-inhibitor complex formed at each 
moment besides the not yet inactivated thrombin (TG-curve). The TG curve is 
obtained as described in chapter 3. The course of the thrombin-inhibitor-
complexes we still have to calculate. The most important inhibitor is AT while 
α2M and α1-antitrypsin play a minor role in the inhibiton-process.  
Course of [TAT] against time (TAT-curve) 
The course of [thrombin-AT] or [TAT] in time can be calculated by numerical 
integration because the increment over the time interval between two readings 
of the thrombin generation curve can be calculated. If s is the time interval be-
tween two readings, than the increment is  
 
Δ[TAT]t = s . kdec. [AT]t . [T]t 
 
So to construct the course of [TAT] in time, three parameters are required: the 
decay constant of the thrombin-AT reaction (kdec), the initial AT concentration 
in the plasma ([AT0]) and the thrombin concentration at each time point ([T]). 
The decay constant of the thrombin-AT reaction was found to be 12000 (M.s)-1 
(see methods). Also [AT0] was determined independently (see methods). In the 
plasma we used it was found to be 2.15 μM. The thrombin concentration can be 
read from the TG-curve (see chapter 3). So in principle the amount of formed 
TAT can be calculated step by step, essentially in the same way as done earlier 
for the subsampling method [2, 3]. 
However, there is a complication due to the presence of the thrombin substrate 
in the reaction mixture. This makes that part of the thrombin is bound to the 
substrate and thus unavailable for reaction with AT and other plasmatic inhibi-
tors. The free fraction of thrombin follows from Michaelis-Menten kinetics and 
is [T].Km/(Km+[S]), in which [T] is the thrombin-concentration, Km the Micha-
elis constant (251 μM) and [S] the substrate concentration. It follows that the 
more S is present, the slower thrombin is inactivated by AT. We also have to 
take into account that [S], and consequently Km/(Km+[S]), is not constant be-
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cause the substrate is consumed. To calculate, numerically, the course of [S] as 
it develops in time we cannot use time as a progress variable because the en-
zyme concentration changes in time. As a progress variable we therefore use the 
product of time and enzyme concentration ([T]*time). This variable represents 
the “man-hours” of thrombin as we discussed in chapter 3. As the TG-curve 
approaches its end, this progress variable approaches the ETP. The course of 
product (hydrolyzed S) can be calculated stepwise via the formula   
 
ΔPt = ([T]t.Δt) . kcat . ([S] - Pt) / (Km + [S] - Pt) 
 
In which ΔPt is the amount of substrate hydrolyzed during a time interval of Δt 
at the prevailing enzyme concentration [T]t. Pt then is Σ1n (ΔPt), where n is the 
number of the interval at time point t.  
In figure 1 we calculate the remaining substrate as a function of the progress 
variable ([T]*time) in a model in which E is fixed at 100 nM human thrombin, 
[S] is 417 μM, Δt is 1 second, Km = 251 μM and kcat = 2.08 s-1, i.e. under the 
conditions of a TG-experiment.  
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Figure 1. Progress of substrate consumption at fixed enzyme activity. 
The residual amount of ZGRR-AMC and the progress-curve (thrombin*time) 
were numerically calculated in steps of 1 second in a mixture containing 100 
nM human thrombin and 417 μM ZGGR-AMC. The gray curve shows the 
calculated residual substrate versus the progress variable thrombin*time and 
the thin black line through the gray curve is a 5th order polynomial fit.  
The fit constants were: 4.1693e-4 (y0); -7.7613e-8 (a); 2.4622e-12 (b);  
2.3357e-16 (c); -2.6218e-21 (d); -8.1652e-25 (e).
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This curve can be fitted to a polynomial of the 5th order (figure 1, thin black line 
in the gray curve) 
 
S = S0 + a.x + b.x2 + c.x3 + d.x4 + e.x5 
  
In which S is the remaining [S], S0 is the initial [S], x is the progress-variable 
[T]*time and a, b, c, d and e are constants (see figure 1). As such we obtain the 
relation between the remaining substrate S and the progress variable [T]*time. 
 
For any given raw TG-data (fluorescent signal versus time) we can calculate the 
progress variable, [T]*time, as a function of time (see chapter 3) and hence, 
with the aid of the above formula the residual substrate can be calculated at any 
moment and hence the fraction of free thrombin at any moment.  
 
This enables us to calculate step by step the course of [TAT] in time. We can 
calculate the increment of [TAT] over any time-interval during the course of 
thrombin generation. If at moment t interval n starts (with a Δt), than  
 
ΔTATn = Δt . kdec . [Tt] . Km/(Km+[St]). (AT0-TATt)  
 
In which the subscript t indicates the value of the parameters at the time point t. 
The numerical integration is started at t=0 when no TAT is present. The result-
ing TAT-curve is shown in figure 2 (thin black curve). It gives the course of 
[TAT] in time. 
Course of [α2M-T] against time (α2M-T-curve) 
The progress-curve of the α2M-T complex during thrombin generation was al-
ready calculated in chapter 3 (figure 4, short dash thick black line). However, 
this curve is expressed as ‘man-hours’ thrombin, so we have to convert it into 
its α2M-T equivalent. The kinetic constants of human thrombin for ZGGR-
AMC hydrolysis are: Km = 251 μM and kcat = 2.08 s-1 while these constants of 
human α2M-T are: Km = 66.5 µM and kcat = 0.94 s-1. The initial [S] is 417 µM 
and under these conditions the velocity of substrate-conversion of human 
thrombin is 1.604 times higher than those of human α2M-T. As a consequence 
we have to multiply the progress curve by 1.604 to get the ‘man-hours’ α2M-T 
responsible for the same amount of hydrolyzed substrate (fluorescent signal). 
The derivative of this curve gives [α2M-T] as a function of time. 
Course of the α1-antitrypsin-thrombin complex in time.  
The shape of the α1antitrypsin-T curve is of the same shape as the α2M-T curve, 
because both products are formed with a rate proportional to the thrombin con-
centration in plasma at each time point. The plasma concentration of this 
thrombin inhibitor is 22 µM, so that, unlike the case of AT but like α2M (3.5 
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µM), we can neglect the decrease of the concentration through interaction with 
thrombin and use pseudo first order kinetics. The reaction constant of thrombin 
inactivation by α1-antitrypsin is about 250 (M.s)-1 (see [4] figure 1). These pa-
rameters for α2M are 3.5 µM and 1450 (M.s)-1, respectively. This means that the 
total amount of thrombin bound to α2M + α1AT is 2.1 times higher than the 
amount bound to α2M alone. For that reason the α2M-T-curve was multiplied 
with 2.1 giving the α2M-T + α1-antitrypsin-T-curve. This curve is shown in fig-
ure 2 (thick black curve). 
 
 
Calculation of FII-ase activity 
The amount of prothrombin converted by FII-ase at each time-point during 
thrombin generation can now be calculated by taking the sum of the TG-curve, 
the TAT-curve and the α2M-T + α1-antitrypsin-T-curve. This is shown in figure 
2 (gray curve). It can be seen that the inactivation of thrombin by the plasmatic 
inhibitors begins immediately after thrombin formation starts. Initially thrombin 
formation is faster than thrombin inactivation, but later the second process be-
comes the larger one. This results in the rise and fall of thrombin in clotting 
plasma and a continuous increase of thrombin-inhibitor complexes until all 
thrombin is inactivated. 
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Figure 2. Thrombin concentration [T] against time 
Short dash line: not yet inactivated [T] (TG-curve); Thin black curve: [T] 
bound to AT (TAT-curve); Thick black curve: [T] bound to α2M + α1-
antitrypsin (α2M-T + α1-antitrypsin-T-curve); gray curve: total [T] (sum of 
the other three curves). 
CALCULATION FII-ASE ACTIVITY 
 
 
 
73 
 
The course of prothrombin conversion velocity (FII-ase-curve) can now be cal-
culated by taking the derivative of the total thrombin curve of figure 2. In figure 
3 this is shown together with the derivative of the TAT-curve (TAT-forming 
velocity), the α2M-T + α1-antitrypsin-T-curve (α2M-T + α1-antitrypsin-T-
forming velocity) and the TG-curve (thrombin-forming velocity). The sum of 
these last three curves gives again the FII-ase curve.   
 
 
Conclusion 
A method has been developed to calculate the velocity of prothrombin conver-
sion, independent of thrombin decay processes. It can be expected – but it re-
mains to be demonstrated in practice – that this type of curve reflects the physi-
ology of thrombin forming processes with more sensitivity than the thrombin 
generation curve itself.  
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Figure 3. Thrombin forming velocity against time
Short dash black line: (not yet inactivated) thrombin forming velocity 
(dTG/dt); Thin black curve: TAT-forming velocity (dTAT/dt); Thick black 
curve: α2M-T + α1-antitrypsin-T-forming velocity (d(α2M-T + α1-
antitrypsin-T)/dt); Continuous gray line: total thrombin forming velocity 
(d(total T)/dt or sum of the other three curves) = FII-ase curve; Short dash 
gray line: TG-curve ([T] in nM). 
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Chapter V 
 
The necessity of continuous individual 
calibration in continuous fluorogenic 
measurement of the thrombin generation 
curve 
Chapter V 
Continuous individual calibration 
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Summary 
In fluorogenic thrombin generation (TG) experiments, the time course of 
thrombin is to be derived from the course of the concentration of the fluorescent 
product. Due to fluorescence quenching the signal from a fixed amount of prod-
uct in plasma (2:3 diluted) is 70 ± 13 % of that in buffer. Calculating a calibra-
tion factor (CF) from the (initial) rate of fluorescence change (dF/dt) caused by 
a known amount of thrombin in buffer therefore causes significant underestima-
tion of thrombin concentrations in plasma and adds >10% to experimental vari-
ability. Also, using a fixed CF does not account for the changes in CF that occur 
during the experiment due to substrate consumption and non-linearity of fluo-
rescence with product concentration and thus distorts the form of the TG-curve. 
Continuous individual calibration (CIC), in which CF is determined in a parallel 
sample of the plasma under investigation and varies with the changing condi-
tions during the experiment avoids these errors. 
We determined the intra-individual coefficients of variation (CV) of the peak-
height and ETP as obtained with CIC to those obtained with a fixed CF meas-
ured in buffer. With the fixed CF, CVs of these parameters varied between 18% 
and 49%; with CIC they lowered to 4–7%. We conclude that continuous com-
parison to a known thrombin activity in a parallel plasma sample is a necessary 
and sufficient condition for bringing the CV of TG-measurements into the range 
that is required for clinical application. 
Introduction 
Thrombin generation (TG) is undergoing a revival since it was recognized that 
it is a promising means of phenotyping the clotting system and that an over-all 
function test of the haemostatic-thrombotic system is a necessary complement 
to information on single factors and genes [1,2]. 
At this moment TG is being introduced in more and more clinical settings, no-
tably in cases where traditional tests give no, uncertain or ambiguous results 
such as the monitoring of factor VIII-inhibitor bypassing therapy [3-5], the dis-
crepancy between clotting factor levels and bleeding tendency in haemophilia 
[6] or in rare coagulation disorders [7], the monitoring of treatment by a mixture 
of different antithrombotics [8] or the anticoagulant effect of antiplatelet therapy 
[9]. Last but not least, thrombin generation appears to be a tool in the recogni-
tion of hypercoagulability. Thrombin generation is increased in patients at risk 
for venous thrombosis due to congenital inhibitor deficiencies [8, 10, 11] or ac-
quired through the use of oral contraceptives [12, 13]. Thrombin generation is 
increased in the elderly [14, 15] and in patients with a tendency to recurrent ve-
nous thromboembolism [16, 17]. 
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In all these fields the clinical usefulness of TG is being investigated and the 
above studies show promising results. Nevertheless the value of TG for clinical 
decision making remains to be demonstrated in larger studies. If it would be 
found to be of no clinical use in a given condition, then either that condition 
causes no change in TG or the method employed is not sensitive enough to de-
tect existing changes. It therefore is essential that the experimental error is re-
duced to a minimum. 
Among the techniques used to determine TG in a routine setting, those using 
fluorogenic substrates take a special place, because they allow to measure in 
non-defibrinated and platelet rich plasma [18, 19,3]. The problem then arises of 
how to relate the velocity of increase of the fluorescence intensity (dF/dt) to 
thrombin concentration. 
It is a disadvantage of this technique that fluorescence intensity is not only de-
pendent upon the concentration of the fluorophore (in our case AMC) but also 
upon the medium in which the fluorophore is present. The same amount of 
AMC causes a significant higher fluorescence in buffer than in plasma, because 
in plasma fluorescence is quenched. Further, the fluorescent product formed 
contributes to the quenching, the so called inner-filter effect. Therefore, a fixed 
thrombin activity in buffer will give an apparent initial reaction velocity that is 
higher than that in plasma. A second complication is that the relation between 
enzyme concentration and measured reaction velocity changes considerably 
during the experiment because of the innerfilter-effect and consumption of the 
substrate. Consequently a fixed enzyme activity causes a progressively lower 
increase of fluorescence. We therefore developed continuous individual calibra-
tion (CIC).  
Upon the introduction of the fluorogenic TG essay, we calibrated by compari-
son to a known thrombin activity added to plasma in which antithrombin activ-
ity was destroyed by heating [18]. Later we used the α2macroglobulin-thrombin 
complex (α2M-T) which has persistant amidolytic activity that is insensitive to 
plasma antithrombins [19]. Practically this means that the activity of a fixed 
known amount of calibrator (α2M-T) is measured in a parallel sample of the 
plasma under investigation and during the whole time course of the experiment. 
In this way at every level of fluorescence the appropriate calibration factor (CF) 
is available. This procedure thus compensates for the variations in quenching 
between plasmas and for the change in CF during the TG reaction. The draw-
back of CIC, evidently, is that it requires simultaneous measurement in two 
samples. With clinical application in mind, it therefore is a legitimate question 
to ask whether the precision brought by CIC is obligatory. This question is the 
more urgent since two different forms of the automated thrombin generation test 
are commercially available to the clinical laboratory, one of which (method A) 
uses a single sample and a fixed, buffer-based CF whereas the other (method B) 
uses CIC.  
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Materials and Methods 
Chemicals 
Z-Gly-Gly-Arg- aminomethylcoumadine (ZGGR-AMC) and aminomethylcou-
madine (AMC) were obtained from Bachem (Switzerland). Phospholipids for 
the preparation of initiation reagent B (method B) were obtained from Avanti 
(USA). The chromogenic thrombin substrates were S2238 (Chromogenics, 
Mölndahl, Sweden) and DEMZGR-pNA (synthesised in house). All other 
chemicals were reagent grade and obtained commercially. 
Solutions 
The initiation reagents of method A (RC high and RC low) contain 71.6 pM 
tissue factor and a “high” or a “low” concentration of procoagulant phospholip-
ids of unspecified composition and concentration. The initiation reagent B of 
method B consist of 30 pM relipidated recombinant human tissue factor, 24 µM 
of a suspension of phosphatidyl serine (20 %) phosphatidyl ethanolamine (20 
%) and phosphatidyl choline (60 %) in buffer, prepared as in ref 18. 
The buffer for method A was from the provider and described as Hepes-NaCl-
buffer containing 1% bovine serum albumin (BSA).For method B, two buffers 
are used. For dilution of reagents: 20 mM Hepes, 140 mM NaCl, 0.02% NaN3, 
5 mg/ml BSA at pH 7.35. For preparation of the fluorogenic substrate solution 
(Fluca): 20 mM Hepes, 0.02% NaN3, 60 mg/ml BSA at pH 7.35.  
The fluorogenic substrate solution for method A was from the provider and con-
tained 1 mM ZGGR-AMC and 15 mM CaCl2. The FluCa solution of method B 
contains ZGGR-AMC (2.5 mM) and CaCl2 (100 mM) in buffer with 60 mg/ml 
BSA. 
The calibrator solutions that came with the kit for method A (lots ST550OO and 
ST430PC) contained according to the label 865 and 768 nM thrombin. The 
calibrator solution for method B was obtained from Thrombinoscope (Maas-
tricht, The Netherlands). After reconstitution of the lyophilized material with 
distilled water it consists of α2M-thrombin with an activity that, according to 
the lable, is equal to that of 600 nM human thrombin in buffer.  
Plasma: 
Blood was obtained through antecubital venapuncture from consenting volun-
teers. Free flow or minimal suction is employed; vacuum containers are 
avoided. The blood is collected on 1:10 volume of sodium-citrate (0.13 M). The 
blood is centrifuged at 2900 g for 10 min at room temperature and the plasma is 
aspirated. This procedure is repeated once. The plasma is stored at -80 ºC in 1 
ml aliquots. Plasma samples for the determination of the intra-individual varia-
tion coefficient were taken, with informed consent, from volunteers in the pla-
cebo arm of a large phase 1 study. From each of six volunteers, twelve samples 
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were taken within 24 hours in a centre for pharmacological research. Plasma 
aliquots were prepared as described above and snap frozen in liquid nitrogen, 
stored at -80 °C until use and thawed at 37 °C for 15 minutes before analysis. 
Chromogenic thrombin measurements 
The calibrator activity on a slow chromogenic substrate in different plasmas 
was measured by adding to 80 µl plasma 20 µl of a 1200 nM solution of 
α2macroglobulin-thrombin (Calibrator for method B equivalent to 600 nM 
thrombin) and 20 µl DEMZZ (1.5 mM), so as to obtain a final concentration of 
250 µM substrate and the equivalent of 100 nM thrombin. 
Thrombin generation measurement 
Fluorescence intensities were measured in a 96-well plate fluorometer (Ascent 
Reader, Thermolabsystems, Helsinki, Finland) equipped with a 390/460 filter 
set (excitation/emission) and a dispenser was used for the addition of the sub-
strate-calcium-solution at t=0. Round-bottom 96-well plates (Immulon 2HB) 
were used.  
The method using buffer-calibration (method A) was that according to Varadi 
[4] commercialised as Technothrombin TGA, by Technoclone (Vienna, Aus-
tria). Calibration was carried out with the thrombin preparation provided at a 
series of concentrations (approximately 500, 250, 50 and 5 nM). According to 
the instructions the wells contained 40 µl of thrombin dilution and 50 µl ZGGR-
AMC at 1 mM. It did not escape our attention that, if 10 µL buffer would have 
been added as well, the substrate concentrations in the TG-experiment and the 
calibration experiment would have been identical and a 10% mistake in the 
reading of the thrombin concentrations from the calibrator curve would have 
been avoided; we faithfully followed the instructions, however. TG measure-
ment wells contained 40 µl plasma and 10 µl initiation reagent A. The reaction 
was started by adding 50 µl of the substrate-Ca++ s lution. The end-
concentrations thus were: plasma 2:5 diluted, substrate 500 µM (TG-wells), tis-
sue factor 7.16 pM, procoagulant phospholipids of unknown concentration and 
composition. The Ca++-concentration after recalcification was 0.34 mM (7.5 
mM added). The fluorescent traces were recorded as such and imported into the 
spreadsheet provided by the manufacturer for the calculation of the thrombin 
generation parameters. 
The method using continuous individual calibration (method B)  was that of 
Hemker [19] as commercialised by Thrombinoscope (Maastricht, The Nether-
lands) under the name Calibrated Automated Thrombinography (CAT). In this 
method each experiment consists of two sets of readings, one with a known 
fixed amount of thrombin activity i.e. the calibrator (CAL-wells) and the other 
in which thrombin generation occurs (TG-wells). By continuous comparison of 
the signal from the two wells the course of thrombin concentration is calculated 
in real time and displayed on the screen by a dedicated software program. TG-
 o  
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wells contained 20 µl initiation reagent B and 80 µl plasma. CAL-wells were 
filled with 20 µl calibrator and 80 µl plasma. The reaction was started by add-
ing, via the dispenser, 20 µl of the FluCa solution to both the CAL- and TG-
wells at t=0. The final concentrations for the TG-wells were: plasma 2:3 diluted, 
416 µM ZGGR-AMC, 5 pM recombinant tissue factor and 4 µM procoagulant 
phospholipids. The Ca++-concentration after recalcification was 4.8 mM (16.7 
mM added). The same end-concentrations hold for the CAL-wells but then 
without tissue factor or procoagulant phospholipids but with the equivalent of 
100 nM free human thrombin. 
The raw fluorometer readings from method B (TG-wells) were also imported 
into a spreadsheet according to that used for method A for calculation of the 
parameters of the thrombogram using a fixed, buffer-based CF (see further 
method B2 in table 2). 
Results and Discussion 
The role of fluorescence quenching by plasma 
In fig.1, left frame, two types of fluorescent traces are shown. Those obtained 
with a fixed amount of thrombin activity (200 nM of α2MT, equivalent to 100 
nM αthrombin) in buffer and in 2:3 and 2:5 diluted plasma and those caused by 
thrombin generation in plasma of these two dilutions. It is seen that the fixed 
activity gives a significantly higher velocity of fluorescence increase (dF/dt) in 
buffer than in plasma and that it is higher when plasma is more diluted. The 
calibration factor (CF) is calculated as CF=100/(dF/dt) (dimension: nM.min per 
arbitrary unit of fluorescence). So CF calculated on basis of dF/dt in buffer is 
smaller than that on basis of dF/dt in plasma and thrombin concentrations in 
plasma will be underestimated if calculated with CF based on dF/dt in buffer 
(fig.1, right frame). When these plasmas are compared to a standard measured 
in the same plasma and in the same dilution as in the TG experiment this under-
estimation is avoided and significantly higher peaks are obtained (fig.1, right 
frame). Comparison of thrombin generation calculated with the appropriate CF 
in 2:3- and in 2:5 diluted plasma shows that dilution enhances the fluorescent 
signal but does not influence peak thrombin generation significantly (see also 
Chapter VIII). 
In figure 2 it is seen that, when 100 nM thrombin activity is added to different 
plasma samples, the dF/dt is always considerably lower than that in buffer and 
varies significantly. The plasma samples used in figure 2 were obtained from 
the same individual in the course of 24 hour. This experiment was repeated in 
five more volunteers and table 1 shows the mean of five intra-individual aver-
ages and standard deviations. 
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Figure 2. Intra-individual variation of reaction velocity in plasma compared to 
buffer 
Fluorescent traces of 200 nM α2M-T in buffer (top line) and in 12 plasma samples 
from the same individual, diluted 2:3 in buffer (other lines). The thick line represents 
the average of the 12 progress curves obtained in plasma. Upper horizontal line: End-
level of the buffer trace; Middle horizontal line: average end-level of the plasma 
traces ± SD. 
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Figure 1. Calibration against buffer and against an identical sample
Left frame: fluorescent traces. 
Drawn line: Calibrator in buffer; −-−: calibrator in plasma final dilution 2:5, ∆-∆: 
calibrator in plasma final dilution 2:3; +-+: TG trace in plasma at final dilution 2:5; 
{-{: TG trace in plasma at final dilution 2:3. 
Right frame: TG curves calculated from the data in the left frame. 
Drawn line: plasma diluted 2:5 read against calibrator in buffer, ∆-∆: plasma diluted 
2:3 read against calibrator in buffer, +-+: TG trace in plasma diluted 2:5 read against 
calibrator in plasma diluted 2:5, {-{: TG trace in plasma diluted 2:3 read against 
calibrator in plasma diluted 2:3.
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We discarded the data from one volunteer in which some samples showed evi-
dent haemolysis and that consequently showed even lower fluorescence and 
much higher variation than the others. It is seen that the velocities measured in 
plasma are less than ~80% ± 10% of that in buffer and that in the course of time 
they become still lower (see below). Consequently comparison to a fixed initial 
velocity measured in buffer underestimates thrombin concentrations by 10 – 
50%, dependent upon the sample and the duration of the experiment. This vari-
ability necessarily adds to the variability of the concentration dependent pa-
rameters of the thrombogram that thus is increased by >10%. 
 
 
 
We quantified the degree of quenching by measuring the signal caused by 70 
µM of AMC (the amount formed half way during a normal TG experiment) in 
these plasma samples (2:3 diluted) and in buffer. The fluorescent yield of each 
plasma was expressed as a percentage of that in buffer and the mean of the 5 
intra-individual averages was found to be 70.4% ± 13.6 %. This corresponds to 
the average value found for the initial velocity if expressed as a percentage of 
that in buffer (table 1, 2:3 diluted plasma). When we corrected each individual 
initial velocity for the effect of quenching, the average initial velocity increased 
to the level of that measured in buffer and the standard deviation was reduced 
(104.4% ± 8.8%). That dF/dt at 100 nM thrombin activity is not the same in 
different reaction media (buffer/plasma) might in theory also be caused by the 
presence of modifyers of reaction velocity in the plasma-samples. We therefore 
determined the amidolytic activity (dOD/dt) of 200 nM of α2M-thrombin on a 
chromogenic substrate (250 µM DEMZ) in these plasma-samples (2:3 dilution) 
and expressed it as % of the value measured in buffer. The measured amidolytic 
 
 Buffer Plasma Plasma 
Dilution  2:3 2:5 
N 24 5 x 12 5 x 12 
t=0 100.0 ± 2.7 73.5 ± 12.5 82.0 ± 11.1 
0-30 min 93.5 ± 1.4 64.6 ± 10.7 73.1 ± 9.2 
t=30 min 76.3 ± 1.7 46.7 ± 7.5 55.4 ± 7.6 
 
                      Table 1. Intra-individual variation of the velocities of fluorescence increase  
                      at fixed thrombin activity (200 nM α2M-T) 
                      All velocities are expressed as % of the initial velocity in buffer (average ± SD).  
                      Twelve PPP-samples from each of 5 volunteers. Means of the average values  
                       per volunteer. 
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activity was somewhat smaller in plasma than in buffer (average 87.5 % ± 
8.3%) but a correction procedure for each inidividual initial velocity (in 2:3 di-
luted plasma) on basis of the amidolytic activity in each plasma resulted in an 
average value which is still much lower than in buffer and in an increase of ex-
perimental variation (84 ± 17 %). 
We conclude that variable quenching of fluorescence between plasma samples 
contributes significantly to the experimental variation in dF/dt at constant 
thrombin activity and therefore needs to be taken into account when dF/dt val-
ues are to be converted in thrombin concentrations. In line with this conclusion 
samples with observable haemolysis or icterus show a more pronounced under-
estimation and variability if calculated with a CF measured in buffer than 
“clean” samples do (results not shown). 
Variance of the calibration factor during the experiment 
In figs 1 and 2 and in table 1 it is seen that, at constant thrombin activity, the 
measured reaction velocity drops by about one third in the course of 30 min. 
This decrease is caused by substrate consumption in combination with the fact 
that the amount of fluorescent light emitted per µM AMC decreases as the 
AMC concentration increases (inner filter effect). Both effects are uniquely re-
lated to the amount of product formed and thereby to the measured fluores-
cence. Constant thrombin activity therefore will cause an increasingly lower 
dF/dt as the reaction proceeds.  
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Figure 3. Change of calibration factor with time and with the level of fluorescence 
Left frame: CF as a function of time. Drawn black line: 100 nM α2M-T, dashed line: 
200 nM α2M-T, dotted line: 400 nM α2M-T. Average of 12 experiments. Gray lines: 
the ±2 SD values of the 200 nM α2M-T trace. 
Right frame: Same experiment as in the left frame, plot of CF against fluorescence in-
tensity. Continuous line: 100 nM, dashed line: 200 nM, dotted line: 400 nM.  
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Consequently CF, i.e. T/(dF/dt) (T= thrombin concentration), increases as the 
reaction proceeds and this increase is faster at higher calibrator concentrations 
(figure 3, left frame, CF plotted as a function of time). When plotted as a func-
tion of fluorescence, CF remains a unique function of the fluorescence level 
(figure 3, right frame).  
 
Plasmas with a high thrombin generating capacity (ETP) will generate more 
fluorescence then plasmas with a low ETP. Therefore they will pass through a 
larger range of increasing CFs during the experiment than plasmas having a low 
thrombin generating capacity (figure 3, left frame). This makes that one cannot 
simply compensate for calibration errors by comparison to standard normal 
plasma. High activities would be underestimated in that way and low activities 
overestimated. 
Substrate exhaustion 
Due to substrate consumption the reaction rate at constant enzyme activity de-
creases during a TG experiment. In the limit, in plasmas with high thrombin 
generating capacity, substrate can drop to zero level. If this is not recognised it 
can be interpreted as zero thrombin activity. This is seen in figure 4 but can also 
be found in the literature [20].  
 
 
 
Figure 4. Substrate exhaustion recognized and unrecognized 
Normal plasma and normal plasma spiked with 1 µM prothrombin and 2 µM prothrom-
bin were measured with method A (gray lines) and method B (black lines). In both 
methods 5 pM TF and 4 µM PL was used as trigger. Left frame: fluorescent traces. 
Right frame: TG curves derived from the fluorescent traces of the left frame following 
the procedure of method A or B. 
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In the experiment of figure 4 we determined the fluorescent traces from a TG 
experiment in which normal plasma was spiked with prothrombin so as to ob-
tain 1 and 2 µM in excess of the endogenous prothrombin (1.6 µM). Such high 
concentrations of prothrombin can be approached during factor VIII inhibitor 
bypassing therapy with prothrombin containing preparations [4]. The fluores-
cent traces were measured using as well method A as method B. In both meth-
ods 5 pM TF and 4 µM PL was used as trigger. The fluorescent traces were 
transformed into TG-curves following the recommended procedures of the 
manufacturers. Method A: with a fixed calibration constant obtained from activ-
ity measurements of thrombin in buffer and method B: by comparison to a con-
tinuously measured CF in a parallel plasma sample. From the fluorescent traces 
it is seen that at the highest prothrombin concentration fluorescence reaches an 
upper limit that must be ascribed to substrate exhaustion but that, in method A, 
is interpreted as zero thrombin activity. Zero amidolytic activity cannot be at-
tained, however, because a considerable amount of α2M-T complex has built up 
during the experiment. In a parallel experiment we found this to be equivalent to 
50, 87 and 151 nM thrombin at the prothrombin concentrations used in the ex-
periments of figure 4. In method B the software signals substrate exhaustion and 
the program stops calculating when it occurs (figure 4: right frame – higher 
curve). 
 
Again it can be seen that buffer-calibration leads to underestimation. An addi-
tional disadvantage of calibration in buffer is that the steady end-level activity 
due to α2M-T cannot be observed, so that its contribution to the amidolytic ac-
tivity, as it develops during the experiment, cannot be calculated and hence no 
curve of the real thrombin concentrations can be obtained. 
Experimental accuracy 
From the above it is clear that CIC is required for accurate measurement of TG. 
The question remains whether this accuracy is of enough practical importance 
to justify the measurement in two samples simultaneously, as required for CIC. 
We therefore determined thrombin generation curves with the two commer-
cially available methods. Method A uses a fixed CF, obtained from known 
thrombin activities measured in buffer, whereas method B uses CIC. Of method 
A both the “high” and the “low” phospholipid variant was tested. Method A1 
uses RC high and method A2 uses RC low. Methods A and B differ not only in 
the manner of calibration but also in plasma dilution, tissue factor, phospholipid 
concentration and Ca++ concentration. In order to see what the influence is of 
the calibration method per se, we also calculated the parameters of the throm-
bogram from the raw data of method B using a fixed CF measured in buffer 
(method B2). As samples we used the same plasmas as those in table 1, i.e. 12 
samples of each of six normal volunteers (and we again excluded the data from 
the one volunteer that showed haemolysis). For each volunteer we calculated 
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the average and the coefficient of variation of the twelve values and the results 
in table 2 are the mean of these five intra-individual averages and CVs.  
 
 
 
In order to be able to compare the results we expressed all thrombin concentra-
tions as final concentrations in the wells as is done in method B1. This means 
that we recalculated the results obtained with the worksheet provided by the 
manufacturer of method A since the concentrations of thrombin obtained with 
this worksheet are concentrations in plasma. Obiously, the manufacturer of 
method A takes into account the dilution of plasma that is used and supposes 
that the concentration of thrombin formed in diluted plasma decreases propor-
tionally with the dilution. As we already saw in figure 1 and as will be seen in 
chapter VIII, this is far from being true. 
With method A, the distortion of the TG curve that is brought about by the use 
of a fixed CF makes that the steady end level of amidolytic activity from α2M-
thrombin formed during TG cannot be determined and consequently this activ-
ity cannot be subtracted to obtain the activity of free thrombin only. Therefore 
the ETP is arbitrarily, measured as the area under the curve until a fixed time 
point (60 min, as in ref.4) and comprises a significant amount of α2M-T activ-
ity. The same is true for method B2. 
From table 2 it is evident that method B1, the only one to use CIC, shows a 
much lower experimental variation than the other ones. From comparison with 
method B2, that is identical to B1 except for the method of calibration, it is seen 
that CIC reduces the CV of the concentration dependent parameters (ETP, peak, 
 
 A1 A2 B1 B2 
 Average  ± SD 
CV 
(%) 
Average  
± SD 
CV 
(%) 
Average  
± SD 
CV 
(%) 
Average  
± SD 
CV 
(%) 
ETP (nM.min) 2332 ± 345 18 2385 ± 412 21 1976 ± 112 6 1389 ± 260 20 
Peak (nM) 208 ± 50 29 171 ± 40 26 413 ± 14 4 244 ± 42 18 
Slope (nM/min) 51 ± 20 49 37 ± 15 43 288 ± 19 7 179 ± 30 18 
Lag-time (min) 22.6 ± 4.7 21 23.4 ± 4.7 18 2.8 ± 0.2 6 2.7 ± 0.2 7 
TTP (min) 31.8 ± 5.6 18 31.7 ± 5.7 17 4.8 ± 0.3 5 4.5 ± 0.2 5 
 
Table 2. Intra-individual coefficients of variation of the parameters of the thrombogram. 
Influence of the method of calibration. 
Method A1: fixed CF in buffer with RC high 
Method A2: fixed CF in buffer with RC low 
Method B1: CIC 
Method B2: raw data of method B1 recalculated with a fixed CF in buffer 
CONTINUOUS INDIVIDUAL CALIBRATION 
 
 
 
87 
slope) by >10%. As was to be expected, for the time dependent parameters no 
difference in CV was found. It is also seen that the values in B1 are higher than 
in B2, in line with the underestimation that is inherent to using a fixed CF de-
termined in buffer under initial reaction conditions. Except ETP, all parameters 
determined with methods A1 and A2 show higher CVs than those in method 
B2, indicating that the method of calibration cannot be the sole cause of the 
high CVs found with methods A. 
The absolute values of the different parameters cannot be compared directly 
between methods A and B because the reaction mixtures are different as to tis-
sue factor and phospholipid content, Ca++ concentration and dilution. However, 
looking at the high values of the ETP in both methods A1 and A2 one might 
think that this is due to the fact that the contribution of the α2M-thrombin com-
ponent to the ETP is not subtracted (see above). This however counts also for 
method B2 which shows much lower ETP. In real, these high ETP-values are 
the result of the broad curves showing up with both methods A1 and A2 (look at 
the very low slope-values!). The time-course of a thrombogram in method A is 
about the double (or even more) of that of a thrombogram in method B. The 
reason(s) for these broad curves compared to method B probably have to be 
searched in the different reaction-conditions as e.g. the PL-concentration (not 
known) or calcium-concentration after recalcification (see methods and materi-
als). Also the higher substrate-concentration and higher dilution of plasma that 
is used in method A can contribute to the higher ETP observed in this method 
(see respectively chapter VI and chapter VIII).  
The intra-individual CV-values obtained with the different methods and shown 
in table 2 are very similar to those reported from the collaborative study carried 
out by the working group of the scientific and standardisation committee (SSC) 
of the international society of thrombosis and haemostasis (ISTH) (Chairman 
Elaine Gray, PhD) as reported at their meeting in Geneva in 2007 (oral commu-
nication).      
 
These results clearly show that CIC is required for accurate measurement of 
TG-parameters. Nevertheless an important result has been obtained by Hron et 
al. [17] using method A. They showed that TG can be used to distinguish pa-
tients at low risk for recurrent VTE from those at high risk. In view of the fact 
that measurement of the aPTT also allows a certain stratification of such pa-
tients [21], a role of the clotting system seems certain. If we assume that the 
degree of quenching of fluorescence by plasma is not predictive of thrombotic 
risk, it follows that the use of CIC in thrombin generation analysis is very likely 
to allow an even better distinction between low and high risk groups. 
We conclude that calibration by continuous comparison to a known thrombin 
activity in a parallel plasma sample is a necessary and sufficient condition to 
obtain the concentration dependent parameters of the thrombin generation curve 
with an experimental variation that is small enough to serve as a useful basis for 
clinical decision making. 
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Chapter VI 
 
Influence of the signaling substrate on the 
parameters of the thrombogram 
influence of the substrate on TG 
Chapter VI 
 
 
 
 
 
 
Butenas S and K.G. Mann published an article in Journal of Thrombosis & 
Haemostasis entitled ‘Caution in the interpretation of continuous thrombin gen-
eration assays’ in which they express their concern about the influence of the 
signaling substrate on thrombin generation [1]. In this chapter we give a short 
summary of this article followed by our rebuttal (complete letter) as published 
in the same edition of Journal of Thrombosis & Haemostasis [2]. 
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Summary of ‘Caution in the interpretation of continuous 
thrombin generation assays.’[1] 
S. Butenas and K.G. Mann 
 
Thrombin plays a crucial role in its own formation. Adding an exogenous 
thrombin substrate to clotting plasma therefore inevitably influences these feed-
back mechanisms. During the initiation phase (lag-time) an artificial added sub-
strate will compete with critical endogenous thrombin substrates present in 
plasma. As a consequence the initiation phase prolongs while the propagation 
phase is delayed. During the propagation phase the signaling substrate also in-
terferes with the natural thrombin inhibitors present in plasma causing elevated 
values for total thrombin as well as higher peak thrombin concentrations. 
This is illustrated in figure 1 where thrombin generation is measured in the syn-
thetic coagulation proteome in the absence and presence of 416 µM ZGGR-
AMC. This coagulation proteome is a mixture of factors II, V, VIII, IX, X and 
XI, TFPI and AT-III all at mean physiologic concentrations. The addition of 
substrate prolongs the initiation phase from 120 s to 340 s and the peak throm-
bin concentration increases from 330 nM to 430 nM. Total thrombin generated 
is doubled (1210 and 2370 nM.min, respectively). (Note: here the author actu-
ally means the ETP, the man-hours of thrombin, not the concentration of throm-
bin). 
         
 
Figure 1 
Thrombin generation measured in the synthetic coagulation proteome with 5 pM 
TF and 4 µM PL in the absence (◊) and presence (♦) of 416 µM ZGGR-AMC. 
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In conclusion, all parameters measured during the coagulation process are influ-
enced by the presence of the synthetic substrate i.e. the initiation phase (~ clot-
ting time), peak thrombin concentration and total thrombin generated during the 
reaction. This is of course inevitable and is the more important if coagulation 
factor deficiencies, such as haemophilia A, B and C are investigated since in 
these experiments low trigger-concentrations are used. This results in a pro-
longed initiation phase and an increased sensitivity to an exogenous substrate. 
 
These considerations do not question the utility of continuous thrombin genera-
tion assays in clinical diagnosis. But one has to be careful with the quantitative 
interpretation of natural processes occurring during thrombin generation. 
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Caution in the interpretation of continuous thrombin 
generation assays: a rebuttal (H.C. Hemker and E. De 
Smedt) (full letter) 
We share the concern of Butenas and Mann [1] about the influence of the sig-
naling substrate in continuous measurement of thrombin generation. Any sub-
strate necessarily binds to thrombin and, moreover, is liable to bind to other 
clotting proteases. It therefore always inhibits thrombin and is potentially an 
inhibitor of the clotting mechanism at other sites as well. Given the importance 
of thrombin-driven feedback reactions, inhibition of thrombin will, theoreti-
cally, always influence prothrombin conversion. Whether and under what con-
ditions this is of practical importance remains to be answered for each single 
substrate. In the articles in which we introduced continuous thrombin generation 
measurement with chromogenic [2] or with fluorogenic [3] substrates, we have 
shown that prothrombin conversion is not significantly affected by the proposed 
substrates but thrombin decay is slowed down in a predictable manner because 
plasmatic antithrombins cannot interact with thrombin that is occupied by the 
substrate. It might suffice to refer to these articles but in view of its accruing 
clinical relevance we readdress the subject for the currently most-used substrate: 
Z-Gly-Gly-Arg-AMC. 
Effects on the lag time 
From table 1 it can be seen that Z-Gly-Gly-Arg-AMC indeed prolongs the ini-
tiation phase (lag time) of thrombin generation at low tissue factor (TF) concen-
trations, be it less in our experiments than in those of Butenas and Mann. We 
agree that this is likely to be due to inhibition of thrombin driven feedback reac-
tions. The effect on the lag time in TF induced thrombin generation in plasma is 
weaker than that on the reconstituted ‘coagulosome’, which suggests that cau-
tion is in its place when extrapolating from reconstituted systems to the ‘isolated 
organ’ plasma. The information contained in the lag time is essentially the same 
as that in conventional clotting times. It is a key question whether the substrate 
interferes with the information that is unique for the thrombogram, i.e. that on 
the amount of prothrombin converted and on the time course of the thrombin 
production. 
Effects on the amount of prothrombin converted 
Plasma contains the natural antithrombin α2M, the ‘bait region’ of which is split 
by thrombin after which thrombin remains bound to the α2M molecule and, al-
though biologically inactive, retains its activity towards the signal substrate. The 
residual amidolytic activity, after thrombin generation is over, is due to this 
complex.The total amount of complex formed is a measure of the amount of 
thrombin molecules that have been available for reaction with α2M (see further 
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[4]), whether they have been reversibly bound to the substrate or not. In figure 
1A, we see that thrombin generation curves that are determined at different sub-
strate concentrations (104–832 µM, 5 pM TF) eventually yield identical 
amounts of α2M-T activity. Also, at 1 pM of TF, a concentration at which 
thrombin generation is dependent upon antihemophilic factors [5], the level is 
independent of the substrate concentration (table 1). Identical (low) end-levels 
of α2M-T were also found when hemophilic plasmas were tested at different 
substrate concentrations (results not shown). We conclude that the presence of 
substrate did not alter the extent of prothrombin conversion. 
 
As expected, the end-level of α2M-T drops when a natural inhibitor of pro-
thrombin activation is induced through addition of thrombomodulin. This de-
crease is more important when no substrate is present than it is at high substrate 
concentrations (table 1). So the thrombin-driven negative feedback through the 
activated protein C system is affected by the presence of substrate, be it that at 
the usual substrate concentration (416 µM) the effect is barely significant. 
Effects on thrombin decay 
Peaks of amidolytic activity increase significantly with the substrate concentra-
tion (figure 1A). This is not due to the higher reaction velocity at higher sub-
strate concentration, because the reaction velocities are converted into enzyme 
concentrations by comparison with a fixed amount of thrombin activity meas-
ured at the relevant substrate concentration. The increase must be ascribed to 
the fact that thrombin is protected from antithrombins by the substrate. This is 
especially evident when the activity due to α2M-T is subtracted (see [4] for the 
method employed) (figure 1B). In the reaction mixture, thrombin is partitioned 
 
Substrate (μM) n 0 104 208 416 832 
Lag-time 5 pM TF  (s) 16   105 ± 6 104 ± 6 107 ± 8 127 ± 7 
Lag-time  1 pM TF (s) 16   225 ± 13 226 ± 13 234 ± 11 253 ± 12 
α2M-T end-level  
5 pM TF (nM) 8 92.2 ± 5.7 90.6 ± 6.5 93.9 ± 6.4 96.8 ± 5.9 94.8 ± 6.2 
α2M-T end-level  
1 pM TF (nM) 8 74.7 ± 5.4 70.8 ± 6.3 79.8 ± 5.0 77.7 ± 4.9 77.2 ± 5.0 
Inhib. by 10 nM TM, 
 5 pM TF (%) 8 68 ± 5 69 ± 4 67 ± 5 62 ± 4 45 ± 3 
Inhib. by 4 nM TM,  
1 pM TF (%) 8 81 ± 6 83 ± 7 78 ± 6 77 ± 5 63 ± 6 
 
Table 1. Effect of substrate on feedback phenomena 
The lag-time is defined as the moment that the thrombin concentration curve crosses the thrombin 
concentration value of 10 nM. Inhib.: the inhibition by TM (%) is defined as the α2M-T end-level 
without TM (100 %) minus the α2M-T end-level with TM (%). 
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between the free form and that bound by substrate. Antithrombin acts on the 
free form only, i.e. on a fraction that is Km/(Km +S) of the total enzyme. Multi-
plication of measured thrombin concentrations by Km/(Km + S) should therefore 
compensate for the slowing down of thrombin decay by substrate. In accordance 
with this hypothesis, this multiplication produces curves that in good approxi-
mation are identical and independent of substrate concentration (figure 1C, see 
also [2]). 
 
 
 
 
Effects on the course of prothrombin conversion 
In figure 1C, the effect of substrate binding on thrombin breakdown has been 
abolished. The resulting curves represent thrombin generation as if antithrombin 
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Figure 1. Influence of substrate concentration on thrombin activity. 
(A) Amidolytic activity, i.e. thrombin and α2M-T activity; (B) thrombin activity only; (C) 
thrombin activity compensated for binding to substrate. Defibrinated pooled normal 
plasma. Reaction conditions as in [2]. Five pM tissue factor. Substrate concentrations from 
top to bottom: 832 µM (black), 416 µM (gray), 208 µM (black), 104 µM (gray). 
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action would have been normal. The curves are so similar as to be indistin-
guishable, except for the effect on the lag phase. We conclude that not only the 
amount of prothrombin converted is not influenced by the substrate but also the 
time course of prothrombin conversion is hardly or not influenced. 
 
In conclusion, to probe a system means disturbing it, so when proposing a new 
technique one has to investigate what this disturbance amounts to. This we did 
in our original publications and here we show additional evidence that the ex-
tent and the time course of prothrombin conversion are minimally disturbed by 
the presence of Z-Gly-Gly-Arg-AMC at 416 µM. Thrombin inactivation is 
slowed down to an exactly predictable extent. The necessary effect on throm-
bin-driven feedback, in plasma, does not cause an important increase in the lag 
time but does diminish the action of added thrombomodulin by about 10%. 
 
These conclusions pertain to Z-Gly-Gly-Arg-AMC at the usual concentration, 
i.e. at around twice its Km.They should not be extrapolated to other substrates or 
to higher concentrations. They certainly should not be interpreted as a laissez 
passer for any other substrate. Thrombin generation experiments with high-
affinity substrates, e.g. those performed in [6] are very likely to reflect a coagu-
lation mechanism in which feedback mechanisms are severely disturbed. 
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Chapter VII 
 
During thrombin generation there is a shift 
from chemical to diffusional control 
 
Chapter VII 
Diffusion 
 
 
 
 
In 2005 we published an article in Journal of Thrombosis & Haemostasis about 
the shift from chemical to diffusional control in thrombin-generation during 
coagulation [1]. As reaction on the above article Orfeo T. and K.G. Mann wrote 
a comment in which they question our conclusions and give their point of view 
about the use of mathematical and biological models [2]; on which we pub-
lished a rebuttal [3]. 
In this chapter we render this discussion about diffusion. We present our first 
article as it was published [1] after which the comments of Orfeo T. and K.G. 
Mann are reproduced, each one followed by a summary of our refutation. For 
the sake of completeness the rebuttal itself [3] is also added. 
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During coagulation thrombin generation shifts from 
chemical to diffusional control. 
H. C. Hemker, E. De Smedt, P. W. Hemker  
 
Haemostasis and thrombosis hinge on the formation of thrombin. The underly-
ing reaction mechanism is a web of proenzyme-enzyme conversions, controlled 
by positive and negative feedback reactions [1]. Current paradigm has it that 
thrombin formation is the result of chemical interactions between the compo-
nents of this web and therefore is uniquely determined by the initial concentra-
tions and reaction constants of its components [2,3]. 
Essential steps of the thrombin forming process occur at membranes that con-
tain negatively charged phospholipids [1]. In an in vitro model system such pro-
coagulant phospholipids are normally added in the form of relatively small 
vesicles that remain in suspension, so that the binding sites for the clotting fac-
tors are available in free solution. In vivo the binding takes place on membrane 
surfaces that present in a wound or ruptured plaque [4]. Factor VII(a) binds to 
tissue factor incorporated in cell membranes and factors II, X(a), V(a), IX(a) 
and VII(a) on adhering and aggregating activated platelets and on membrane 
remnants. Experiments in the presence of platelets and tissue factor bearing 
cells suggest that, as soon as such structures are present, physical transport 
through diffusion might play a role in determining thrombin generation veloci-
ties [5,6,7]. In coagulation experiments in plasma in vitro, procoagulant phos-
pholipids are added to PPP in the form of vesicles; in PRP they are provided by 
activated platelets [8]. At the moment that a clot forms ~98 % of thrombin is 
still to be generated [9, 10]. The total amount of thrombin formed is an impor-
tant determinant of the quality of haemostasis or the extent of thrombosis [11] 
and this thrombin is almost all formed within the fibrin mesh of the clot. In that 
mesh the plasma is stagnant and the procoagulant surfaces of blood platelets and 
membrane fragments stick to the fibrin fibres [12]. Prothrombin conversion and 
other activation reactions thus are likely to be located on the insoluble fibrin 
mesh rather than in free and homogeneous solution and it is conceivable that not 
only chemical reaction rates but also diffusional transport to these surfaces de-
termines the rate of thrombin formation. 
Whether diffusion or chemical interaction is rate limiting can be decided on ba-
sis of temperature dependence. Diffusion velocity is proportional to absolute 
temperature, i.e. will show a ~14% increase between 10 and 50 °C, whereas 
biochemical reactions will roughly double their pace if the temperature is raised 
by 10 °C (see e.g. [13]). Here we show that the temperature dependency of 
thrombin generation in clotting plasma is such that we must assume that, when a 
clot has formed, diffusion starts to co-determine the rate of thrombin formation. 
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Thrombin inactivation, on the contrary, is caused by stoichiometric reaction 
with specific plasma proteins, the most important of which is AT. In contrast to 
the activation reactions, inactivation takes place in free solution and therefore is 
less likely to be diffusion limited. 
 
                 Prothrombinase            Antithrombins 
Prothrombin  Thrombin  Inactivated Thrombin  
                       at Membrane       in Solution 
 
If the velocities of both activation and inactivation are determined by chemical 
reaction rates, a rise in temperature will enhance both reactions to roughly the 
same extent and the change in thrombin activity with temperature will be small. 
If diffusional transport would govern activation but thrombin inactivation would 
be a chemical reaction, then activation would increase ~3% by raising the tem-
perature from 25 to 35 °C, but inactivation would double so that a 50% decrease 
of the free thrombin formed would result. If diffusion plays a limited role that is 
more important in the activation reaction than in the inactivation, a limited de-
crease of thrombin activity would be seen with rising temperatures. 
We tested thrombin generation in plasma at four temperatures: 25, 30, 35 and 
40°C under three conditions. A: in defibrinated plasma with added procoagulant 
phospholipids; B: in normal plasma with the same amount of added phospholip-
ids and C: in platelet rich plasma (figure 1). Defibrination with Arvin is known 
to precipitate fibrin but not otherwise to affect the clotting system [14].  
To 80 μl of citrated plasma we added 20 µl of a mixture of 30 pM recombinant 
tissue factor and 24 µM phospholipid vesicles (20% dioleoyl phosphatidyl ser-
ine, 20% dioleoyl phosphatidyl ethanolamine and 52% dioleoyl phosphatidyl 
choline and 8% cholesterol). Thrombin generation was started by adding 20 µl 
CaCl2 containing 2.5 mM of the thrombin substrate Z-Gly-Gly-Arg-AMC. The 
fluorescent product AMC was detected by its emission at 460 nm upon excita-
tion at 390 nm [15]. When fibrinogen is present, the clot forms at the moment 
that also the fluorogenic thrombin substrate starts to be converted, the bulk of 
thrombin being formed within the clot. 
In figure 1 it is seen that, with increasing temperature, the lag-time of thrombin 
formation shortens under all circumstances. This is to be expected because dur-
ing the lag-time all reactions take place in free solution and will follow chemi-
cal rate laws, i.e. are accelerated significantly by a rise in temperature. 
In figure 1B and 1C it is seen that, as soon as fibrin is present less thrombin is 
formed at higher temperatures than at lower ones. This indicates that thrombin 
forming reactions are less accelerated by a rise in temperature than thrombin 
inactivating reactions are, which can be explained by assuming that the role of 
diffusion in the generation of thrombin is more important than in its decay. 
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This effect of diffusion starts to play a rate determining role in the generation of 
thrombin around the moment of clot formation. So, whereas the initiation phase 
is a purely chemical process, the contribution of physical restraints to thrombin 
generation during the propagation phase is not to be neglected. In mixtures wit-
hout fibrinogen (e.g. [2]) or in mathematical simulation (e.g. [3]), thrombin ge-
neration velocity is governed by chemical conversion rates only and diffusion is 
not taken into account. In models where the prothrombin converting enzyme is 
adsorbed at a macroscopic surface, thrombin generation is diffusion limited at 
all but extreme concentrations of the reactants [16]. Because of the transition of 
chemical- to diffusional limited reaction velocity around the moment of clotting 
neither of these approaches can be quantitatively extrapolated to the in vivo si-
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Figure 1. Fluorescence development from a thrombin specific substrate in plasma 
A: Defibrinated platelet poor plasma with added phospholipids; B: non-defibrinated 
platelet poor plasma with added phospholipids; C: platelet rich plasma. In all experi-
ments the fluorescence was measured in 120 µL of citrated plasma to which were added 
at zero-time (final concentrations) 5 pM TF, 16.7 mM CaCl2 and 0.42 mM ZGGR-
AMC. In each frame, from right to left the temperatures were: 25 °C (black), 30 °C 
(gray), 35 °C (black) and 40 °C (gray). 
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tuation. It follows that thrombin generation in the body is best modelled by 
measuring it directly in a sample of isolated organ i.e. in clotting platelet rich 
plasma with addition of the relevant components of the vessel wall (tissue fac-
tor, thrombomodulin) and/or white cells. 
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Citations of the comment of Orfeo T and KG Mann and 
our refutation in short 
Orfeo and Mann: The authors have attempted to extend the ETP methodology 
(?) to examine whether a fundamental change in reactant availability (delivery 
or type of rate limiting steps) is influenced by fibrin formation in clotting 
plasma. Pivotal to their interpretation of temperature dependence of thrombin 
generation is the simplifying assumption that the enthalpies of activation defin-
ing the entire ensemble of binding and catalytic events are relatively uniform. 
This assumption appears rash. 
 
Hemker, de Smedt and Hemker: Present common knowledge agrees precisely 
that the dependence upon temperature (which is what enthalpy means in this 
context) of the ensemble of chemical reactions is more important than that of 
the ensemble of diffusional transport. Probably Orfeo and Mann want to suggest 
that we need to know the details on each and every reaction within the ensem-
ble. This obviously is impossible. It also is unnecessary, were it only because 
we compare the temperature dependence of two situations that differ in the 
presence of fibrin only. The chemical mechanism of thrombin generation is not 
altered by the presence of fibrin, so the large majority of thermodynamics of the 
reactions will be identical in both conditions. Unless Orfeo et al. postulate that 
fibrin has an influence on the enthalpies of reactions in which it does not par-
ticipate. Physical conditions change dramatically however: the medium be-
comes unstirred and inhomogeneous on the µ-meter scale which necessitates 
diffusional transport to and from phospholipid surfaces. 
 
Orfeo and Mann: A number of initial assumptions in this letter are incorrect. 
The lag phase of the reaction is a consequence of the generation of catalysts 
required to provide the factor Xa, factor IXa and thrombin which participate in 
intrinsic factor Xase and prothrombinase generation on platelet surfaces. All 
these reactions involve complexes localized on membrane surfaces, including 
the triggering complex VIIa-TF, which activates factor X and factor IX on the 
surface of exogenously introduced vesicles but requires diffusional transfer of 
these reactants to activated platelet surfaces (or synthetic phospholipid vesicles) 
for the efficient progression of the reaction. None of these proteolytic or binding 
reactions take place in solution and all involve diffusional transfer of proteins 
on and off membranes and diffusional events constrained to surfaces. 
 
Hemker, de Smedt and Hemker: An interesting remark is made by Orfeo and 
Mann on the role of diffusion in thrombin generation on vesicle surfaces before 
fibrin forms. Indeed lateral diffusion of molecules adsorbed at the phospholipid-
solute interface plays a role in all reactions that are located at such an interface, 
whether in suspension or caught on a fibrin web. As our laboratory was the first 
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to demonstrate lateral diffusion we are unlikely to underestimate its role. We 
also recall, however, that lateral diffusion only can be made rate limiting under 
extreme conditions, i.e. at macroscopic surfaces and very low prothrombinase 
concentrations. Therefore its influence is not observed with vesicles in suspen-
sion and the interactions between vesicles and clotting factors and between clot-
ting factors on a vesicle surface can be described by normal chemical collision 
theory. This type of diffusion therefore can, and is, justifiably left out of the 
equations both in Dr Mann’s chemical and computational models as well as in 
ours. 
Most of our readers must be familiar with the pictures of a fibrin web onto 
which phospholipid platelets and/or phospholipid particles adhere and we know 
of no other mechanism for reactants to be transported to and from such immobi-
lised surfaces in a stagnant fluid than diffusion through the liquid phase. To the 
understanding reader it must be evident that we meant this type of diffusional 
transport in our letter and we see no flaw in our reasoning that such diffusional 
transport will start to count at the moment of clotting. 
 
Orfeo and Mann:  “A brief examination of the data provided highlights the in-
terpretive challenge that using a diluted, citrated plasma system to elucidate 
events at the level of thermodynamics and physical chemistry presents. The au-
thors provide time course data displaying the generation of a fluorescent signal 
derived from hydrolysis of a fluorogenic substrate by thrombin produced during 
a series of tissue factor initiated reactions in recalcified, citrated plasma con-
ducted at different temperatures.” 
“We have estimated the maximum slope (dF/dT) for each of the presented time 
courses and present the temperature dependence of these slopes for the cases of 
defibrinated and non-defibrinated plasma (figure 1, solid lines). Note that at each 
temperature the maximum thrombin level achieved is greater in the presence of 
fibrinogen/fibrin. However, in principle, to convert substrate hydrolysis rate 
data measured at different temperatures to thrombin concentrations, standard 
curves must be constructed at each temperature. The data presented by Hemker 
et al. appear to be ‘raw’; that is uncorrected for the expected temperature de-
pendence of thrombin activity on the substrate. This makes interpretation of the 
data either by visual inspection or secondary manipulation problematic. To ad-
dress this issue we have measured the temperature dependence between 25 and 
40°C of thrombin hydrolysis of the synthetic substrate Spectrozyme TH 
(American Diagnostica Inc, Greenwich, CT, USA) and have used that value 
(approximately 40% change in rate per 5°C change in temperature) to correct 
maximum slope values extracted from the presented time courses so that they 
reflect only the amount of thrombin present. These corrected data (dashed lines) 
are also presented in figure 1. Two observations can be made here: at any given 
temperature, the maximum level of thrombin achieved is greater in the presence 
of fibrinogen/fibrin; and maximum thrombin levels in the two reaction systems 
(±fibrinogen/fibrin) actually decrease uniformly and in parallel with increasing 
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temperature. These trends are not consistent with the hypothesis that the onset 
of fibrin formation represents a transitional point between two qualitatively dif-
ferent reaction milieus. 
 
 
 
Hemker, de Smedt and Hemker: We preferred to show the raw data because we 
know that a conclusion is more transparent and convincing if it does not depend 
on data handling. The finding as such appeared to us of sufficiently general in-
terest to attempt a presentation that is maximally clear to the non specialist. 
From our graphs anybody can see that in the absence of fibrin the sum of effects 
on all the reactions playing (including that of thrombin converting substrate) 
equals out, so that as much thrombin product is formed at higher temperatures 
as at lower ones. In the presence of fibrin, however, less product is formed at 
higher temperatures, i.e. the balance between thrombin activation and thrombin 
inactivation shifts in favour of the latter. This conclusion can be arrived at with 
the naked eye and does not require any special treatment of the data. However, 
standard curves were measured at each temperature but they were not presented 
or used for data handling because it might be confusing and was not necessary 
to demonstrate the phenomena. 
Figure 1.  Secondary analyses of fluorescence vs. time plots resulting from the 
clotting of plasma in the presence of a thrombin specific substrate. 
Maximum slopes (dF/dT) of each progress curves at 25, 30, 35 and 40°C were esti-
mated for the reactions in defibrinated plasma (Hemker et al. [1], figure 1, left frame) 
and non-defibrinated plasma (Hemker et al. [1], figure 1, middle frame). Solid lines 
represent uncorrected dF/dT values, dotted lines represent dF/dT values corrected for 
the effect of temperature on fluorogenic substrate hydrolysis, using our estimate of 
the temperature dependence of thrombin hydrolysis of the synthetic substrate Spec-
trozyme TH. defibrinated plasma; plasma with fibrinogen. 
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Orfeo and Mann, from our data, derive that the peak velocity of product forma-
tion does not show the same temperature dependence as the total amount of 
substrate converted. They omit to say how this could influence our conclusions. 
Little experience with plasmatic thrombin generation curves suffices to learn 
that there is no strict relation between thrombin peak-height and total thrombin 
activity. Because the relative contribution of diffusion and chemistry shifts dur-
ing the process, we have to take into account the integral time range of the proc-
ess. Therefore it is the total amount of thrombin that should be discussed and 
not the peak values only. This again underlines why it is sometimes better to 
have a look at the raw data in order not to confuse ourselves. Concerning the 
correction made for the temperature dependence of thrombin activity on the 
substrate, we did not see the relevance of doing this since this effect is the same 
in both conditions (with and without fibrinogen). 
Further confusion is caused by the remark that more thrombin is generated in 
the presence of fibrin than in its absence. This is perfectly true and has been 
observed by us before. It is caused by the changes that fibrin brings about in the 
pattern of interaction between thrombin and antithrombins. Antithrombin is not 
able to inactivate fibrin-bound thrombin meaning that fibrin as such does not 
increase thrombin inactivation but in contrary reduces it. Nevertheless, despite 
this, the balance between formation and inactivation shifts in the presence of 
fibrinogen in the sense of the latter at higher temperatures. This point thus 
strengthens our argument rather than invalidating it. 
We conclude that the remarks of Orfeo and Mann on our observations are cor-
rect but do not purport to our interpretation and conclusions. 
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Mathematical and biological models of blood coagulation. 
A rebuttal. (Full letter) 
H. C. Hemker, E. De Smedt, P. W. Hemker. 
 
The comment of Orfeo and Mann [1] on the letter in which we showed that 
thrombin generation in a clot is not dependent on chemical reaction rates only 
but on diffusional phenomena as well [2] raises some interesting points that we 
are glad to discuss further. 
We preferred to show the raw data because we know that a conclusion is more 
transparent and convincing if it does not depend on data handling. The finding 
as such appeared to us of sufficiently general interest to attempt a presentation 
that would be most clear to the non-specialist. From our graphs [2] it is readily 
apparent that in the absence of fibrin the sum of effects on all of the participat-
ing reactions (including hydrolysis of the fluorogenic substrate by thrombin) 
balances out, such that as much thrombin product is formed at higher tempera-
tures as at lower ones. In the presence of fibrin, however, less thrombin is 
formed at higher temperatures, i.e. the balance between thrombin activation and 
thrombin inactivation shifts in favour of the latter. This conclusion can be ar-
rived at by inspection and does not require any special treatment of the data. 
We are well acquainted with the ways in which fluorescence data can be con-
verted into thrombin concentrations, as these techniques were developed in our 
laboratory [3]. In further investigations on the role of diffusion in thrombin gen-
eration we will certainly use such approaches to study the phenomenon in more 
quantitative detail, but for the demonstration of its existence this is not neces-
sary and may be confusing. 
Orfeo and Mann themselves furnish an excellent example of such confusion. 
From our data they derive that the maximal velocity of substrate hydrolysis does 
not show the same temperature dependence as the total amount of fluorogenic 
substrate converted. They omit to say how this could influence our conclusions. 
The maximal velocity of product formation indicates the peak thrombin activity. 
Experience with plasmatic thrombin generation curves demonstrates that there 
is no strict relationship between thrombin peak height and total thrombin activ-
ity (i.e. the endogenous thrombin potential [4]). Because the relative contribu-
tion of diffusion and chemistry shifts during the process, we have to take into 
account the integral time range of the process. Therefore it is the total amount of 
thrombin that should be discussed and not the peak values only. 
Further confusion is caused by the remark that more thrombin is generated in 
the presence of fibrin than in its absence. This is perfectly true and has been 
observed by us before [3]. It is caused by the changes that fibrin brings about in 
the pattern of interaction between thrombin and antithrombins. It shows that 
fibrin as such does not increase thrombin inactivation but nevertheless shifts the 
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balance between formation and inactivation toward the latter at higher tempera-
tures. This point thus strengthens our argument rather than invalidating it. 
We conclude that the remarks of Orfeo and Mann on our observations are cor-
rect but are not relevant to our interpretation and conclusions. 
An interesting remark is made by Orfeo and Mann on the role of diffusion in 
thrombin generation on vesicle surfaces before fibrin forms. Indeed lateral dif-
fusion of molecules adsorbed at the phospholipid-solute interface plays a role in 
all reactions that are located at such an interface, whether in suspension or 
caught in a fibrin web. As our laboratory was the first to demonstrate lateral 
diffusion [5], we do not underestimate its role. We also recall, however, that 
lateral diffusion can only be rate limiting under extreme conditions, i.e. at mac-
roscopic surfaces and very low prothrombinase concentrations. Therefore its 
influence is not observed in reactions between clotting factors in solution on 
vesicles in suspension and hence these interactions can be described by normal 
chemical collision theory. This type of diffusion therefore can, and is, justifiably 
left out of the equations both in Dr Mann’s chemical and computational models 
(as cited in [1]) as well as in ours. (In technical terms: the interaction between 
clotting factors and the surface of a free phospholipid vesicle in aqueous me-
dium is limited by the diffusion controlled maximal rate (109 M-1s-1) like any 
chemical reaction while the interaction between molecules at the phospholipid 
surface is determined by the much higher lateral diffusion rate (1016 M-1s-1). 
This latter step therefore never becomes rate limiting.) 
Most of our readers must be familiar with the pictures of a fibrin web onto 
which platelets and/or phospholipid particles adhere and we know of no other 
mechanism for reactants to be transported to and from such immobilised sur-
faces in a stagnant fluid than diffusion through the liquid phase. To the under-
standing reader it must be evident that we meant this type of diffusional trans-
port in our letter and we see no flaw in our reasoning that such diffusional 
transport will start to contribute at the moment of clotting. 
As to our interpretation, Orfeo and Mann state “pivotal to [our] interpretation of 
the temperature dependence of thrombin generation is the simplifying assump-
tion that the enthalpies of activation defining the entire ensemble of binding and 
catalytic events are relatively uniform”. Present common knowledge agrees pre-
cisely with the dependence upon temperature (which is what enthalpy means in 
this context) of the ensemble of chemical reactions being more important than 
that of the ensemble of diffusional transport. Perhaps Orfeo and Mann wanted 
to suggest that we need to know the temperature dependence of all individual 
reactions within the ensemble. This is obviously impossible. It is also unneces-
sary, because we compared the temperature dependence of two situations that 
differ only in the presence of fibrin. Unless Orfeo and Mann postulate that fibrin 
has an influence on the enthalpies of reactions in which it does not partake, the 
large majority of the thermodynamics of the reactions in presence and absence 
of fibrin will be identical because the chemical mechanism of thrombin genera-
tion is not altered by the presence of fibrin. Physical conditions change dramati-
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cally however: the medium becomes unstirred and inhomogeneous on the µ-
meter scale which necessitates diffusional transport to and from phospholipid 
surfaces. 
The general impression that the comment of Orfeo and Mann left with us repre-
sented a certain resistance to the idea that there may be more to the coagulation 
process than chemistry alone. We regret the absence of a more constructive 
view, such as the proposition of an alternative hypothesis to explain our obser-
vations. 
References 
1. Orfeo T, Mann KG. Mathematical and biological models of blood coagulation. J Thromb 
Haemost 2005;3:2397-8. 
2. Hemker HC, De Smedt E, Hemker PW. During coagulation thrombin generation shifts 
from chemical to diffusional control. J. Thromb Haemost 2005. 
3. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, 
Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hy-
per- and hypocoagulability. Pathophysiol Haemost Thromb 2002;32:249-53. 
4. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous 
thrombin potential. Thromb Haemost 1995;74:134-8. 
5. Giesen PL, Willems GM, Hermens WT. Production of thrombin by the prothrombinase 
complex is regulated by membrane-mediated transport of prothrombin. J Biol Chem 
1991;266:1379-82. 
 
 
Until now Orfeo T. and Mann K.G. refrained from answering to our rebuttal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
Chapter VIII 
 
The effect of plasma dilution on thrombin 
generation 
Dilution of plasma reduces the participation of the intrinsic 
pathway and the Josso-loop during thrombin generation 
and shifts it towards the direct extrinsic pathway. Dilution 
induces a second wave of prothrombinase-activity due to 
suppression of protein S dependent inhibition. 
Chapter VIII 
Diluted plasma 
 
 
 
 
 
 
 
 
 
 
In preparation. Will be submitted to Thrombosis and Haemostasis as the third 
manuscript of a series of manuscripts with working title:  
Assessment of Thrombin Generation with Fluorogenic Substrates. 3. The effect 
of plasma dilution on thrombin generation. 
E. De Smedt, R. Wagenvoord, H.C. Hemker 
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Introduction 
Several methods exist to determine thrombin generation that use different dilu-
tions of plasma or whole blood. In thrombelastography (TEG) [1] almost undi-
luted whole blood is used because the natural thrombin substrate fibrinogen is 
used as an indicator. As fibrinogen is exhausted long before thrombin genera-
tion is over, this cannot serve to measure the entire thrombin generation curve. 
So adding an artificial substrate is obligatory and the blood / plasma inevitably 
has to be diluted. Also calcium, trigger and/or phospholipids have to be added. 
In the ‘thrombin generation time’ [2] whole blood is diluted 1/3, meaning that 
plasma is diluted ~ 1/5. Other methods determine thrombin generation in plate-
let poor plasma like there are the CAT-method (plasma diluted 2/3) [3] and the 
Technoclone-method (plasma diluted 2/5) [4]. This poses the question how 
thrombin generation is influenced by dilution of plasma. Also from a practical 
point of view it is interesting to investigate this question since it can possibly 
reduce the amount of blood or plasma required for measuring thrombin genera-
tion.    
In this article we use the CAT-method to investigate the effect of dilution on 
thrombin generation in platelet poor plasma. In a first stage platelet poor plasma 
was diluted at constant concentrations of calcium and citrate. In a second stage 
we kept prothrombin and antithrombin constant as well, so as to investigate the 
effect of dilution on prothrombinase formation. We will see that as a rule of 
thumb, dilution fosters procoagulant mechanisms and defavorises inhibitory 
mechanisms. Furthermore a shift is observed from the intrinsic system and 
Josso-loop towards the direct extrinsic system. 
Materials and methods 
Materials 
Platelet poor plasma 
Blood is obtained through antecubital venipuncture. Free flow or minimal suc-
tion is employed; vacuum containers are avoided. The blood is collected in plas-
tic tubes of 10 ml containing 1 ml sodium-citrate (0.13 M) put on room tem-
perature 1h in advance. While collecting the blood each tube is tilted slowly 
three times so as to mix the content well. The blood is centrifuged at 4000 rpm 
for 10 min at room temperature and the plasma is centrifuged a second time 
(idem). Finally all plasma is collected and ultra-centrifuged at 18000 rpm for 1h 
at 4ºC giving platelet poor plasma. In order to avoid contamination with proco-
agulant microparticles from aging platelets, PPP is prepared as quick as possi-
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ble. A pool of platelet poor plasma is collected from healthy subjects and is 
used as reference plasma (NPPP). 
Haemophilia plasma (informed and with consent) was obtained from Yessim 
Dargaud. 
Proteins 
Human prothrombin was prepared according to [5], human antithrombin ac-
cording to [6]. 
TFPI was a kind gift of Dr. Theo Lindhout, PS was a kind gift of Dr. Tilman 
Hackeng. Recombinant human TM and APC were a kind gift of Asahi (Japan). 
Buffers 
BSA5 contains 20 mM Hepes, 140 mM NaCl, 0.02% NaN3 and 5 mg/ml bovine 
serum albumine (BSA) at pH 7.35. BSA60 contains 20 mM Hepes, 0.02 % 
NaN3 and 60 mg/ml BSA at pH 7.35. 
Reagents 
The phospholipids used are a mixture of 60% Phosphatidyl choline, 20% phos-
phatidyl serine and 20% phosphatidyl ethanolamine. The stocks are obtained by 
Avanti (USA). 
Trigger and substrate are commercially available: lyophilized innovin from 
Dade-Behring and Z-Gly-Gly-Arg-AMC from Bachem, Switserland. 
Methods 
TG-curves 
All thrombin generation curves were obtained using the CAT-method in which 
plasma is diluted 4/6: 80 µl plasma + 20 µl reagents + 20 µl FluCa (substrate + 
calcium) [3]. In our investigation we used also higher dilutions of plasma ob-
tained with the same buffer as for preparation of FluCa (20 mM Hepes, 60 
mg/ml BSA, pH 7.35). To this buffer is added 21.7 mM citrate and 2.4 mM cal-
cium so as to keep their concentration at a constant level independent of the di-
lution of plasma. In a further stage also 1.26 µM human prothrombin and 2.15 
µM human antithrombin was added. As a result citrate and calcium are always 
kept constant and prothrombin and antithrombin if desired. 
Determination of h-prothrombin and h-antithrombin in plasma 
Human prothrombin in plasma was determined by activating it with an excess 
of staphylocoagulase. Then the thrombin-concentration was measured with the 
chromogenic substrate S2238.  
Human antithrombin in plasma was determined by adding a fixed amount of 
thrombin and heparin to a dilution series of plasma. The remaining thrombin-
concentration after 10’ at 37 ºC was measured with S2238 in each dilution and 
these values were plotted against the amount of plasma in each dilution (μl 
plasma). The slope of this linear curve gives the concentration of thrombin that 
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has been inactivated per μl plasma. This corresponds with the concentration of 
antithrombin present in this μl plasma. 
Determination of prothrombinase curves 
FII-ase curves were calculated following the procedure described in chapter 4. 
Results 
The concentration of TF available determines the pathway of coagulation [7-
10]. As a rule of thumb, the lower the trigger concentration the more complex 
the mechanism of thrombin generation is. Under our standard conditions (2:3 
diluted plasma), 5 pM TF triggers mainly the extrinsic pathway and thrombin 
generation is just slightly dependent upon factors VIII and IX. If less trigger is 
used, the contribution of factors VIII and IX via the Josso-loop increases sig-
nificantly and at 1 pM TF the Josso-loop is the main pathway during thrombin 
generation. At concentrations lower than 1 pM TF also factor XI starts to play a 
role (intrinsic system). Without TF, contact activation triggers the intrinsic 
pathway while the extrinsic pathway and Josso-loop do not contribute anymore. 
This is illustrated in figure 1. 
 
 
 
We used three different concentrations of TF so as to trigger respectively 
mainly the extrinsic system (5 pM TF), mostly the Josso-loop (1 pM TF) or 
only the intrinsic system (no TF). If no trigger is added, one depends upon the 
minimal contact activation provided by the plastic 96-well plates and lag-times 
are long and variable. So to obtain reproducible lag-times we activated the 
plasma with kaolin before. Under these conditions thrombin generation was 
measured in NPPP and a severe haemophilia patient (<5% VIII). Figure 1 
Figure 1. Different pathways of 
thrombin generation 
TG is measured in NPPP (NP) and 
a severe haemophiliac (Haem) (4:6 
dilution). The first number gives 
the trigger concentration (pM TF), 
the second number the PL-
concentration (µM). When no TF 
was added, the plasma was acti-
vated with kaolin to obtain repro-
ducable lag-times. 
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shows that thrombin generation becomes increasingly dependent of factor VIII 
the less trigger is used. 
 
 
 
So, thrombin generation was measured using no TF, 1 pM TF and 5 pM TF in a 
dilution series of NPPP at constant concentration of calcium and citrate (figure 
2). The evolution upon dilution of the three most important parameters of the 
thrombogram (lag-time, peak-height and ETP) is presented in figure 3. 
Surprisingly, the ETP increases in dilutions up to 1:6, drops thereafter and at-
tains the level of the 4:6 dilution until the 1:24 dilution. The peak-height shows 
a qualitatively similar pattern but starts decreasing earlier, after 2:6 dilution. 
The lag-time has a tendency to shorten if TF is present and only prolongs sig-
nificantly in the absence of TF. The high values of ETP, despite low peak-
heights, are mainly caused by the broadening of the thrombin generation curves 
upon dilution. This phenomenon must be due to slower inactivation of thrombin 
or to prolonged formation of thrombin or to both.  
 
 
 
Figure 2. TG in diluted NPPP at con-
stant concentration of calcium and cit-
rate.  
TG is measured in the presence of  
5 pM TF, 4 µM PL (figure A) 
1 pM TF, 4 µM PL (figure B)  
 no TF (+ kaolin) with 1 µM PL (figure C) 
A: 5 pM TF
0
100
200
300
400
0 20 40 60
Time (min)
TG
 (n
M
)
 4/6
 3/6
 2/6
 1/6
 1/12
 1/24
 1/32
 1/48
 1/96
B: 1 pM TF
0
100
200
300
400
0 20 40 60
Time (min)
TG
 (n
M
)
 4/6
 3/6
 2/6
 1/6
 1/12
 1/24
 1/32
 1/48
 1/96
C: no TF (+ kaolin)
0
100
200
300
400
0 20 40 60 80 100
Time (min)
TG
(n
M
)
 4/6
 3/6
 2/6
 1/6
 1/12
 1/24
 1/32
 1/48
 1/96
CHAPTER VIII 
 
 
 
116
 
 
 
Figure 3. Evolution of the parameters 
of the TG of figure 2. 
TG was measured in diluted NPPP at 
constant concentration of calcium and 
citrate in three different conditions (see 
figure 2). Evolution of lag-time (A) 
peak-height (B) and ETP (C) is pre-
sented against the dilution of plasma 
(plotted on a logarithmic scale) for each 
of the three conditions: 5 pM TF, 4 µM 
PL (blue), 1 pM TF, 4 µM PL (green) 
and no TF (+ kaolin) with 1 µM PL 
(red). 
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Figure 4. The effect of dilution on thrombin decay
A: thrombin generation curves of figure 2A plotted as Log thrombin-
concentration against time. A trendline was calculated through the decay-phase 
so as to obtain the down-slopes. Two dilutions (1:6 and 1:24) are not shown to 
not overload the figure. The colors fit with the colors used in figure 2A. 
B: down-slopes of the semi-logarithmic decay of the thrombin generation curves 
of figure 2A (see trendlines of figure 4A). 
A: Log thrombin concentration
0.2
0.6
1
1.4
1.8
0 10 20 30 40 50
Time (min)
Lo
g.
 th
ro
m
bi
n 
co
nc
. (
nM
)
B: down-slopes upon dilution
0
0.04
0.08
0.12
0.16
Dilution
Do
w
n-
sl
op
e 
(m
in
-1
)
                            4/6            3/6           2/6           1/6   1/12    
                                                                        --> 1/96 
DILUTED PLASMA 
 
 
 
117 
To estimate the effect on thrombin decay we plotted the thrombin generation 
curves of figure 2A as logarithm of thrombin-concentration against time. It ap-
peared that almost the entire down-slope became a straight line, suggesting 
semi-logarithmic decay (figure 4A). The obtained down-slopes were propor-
tional to the plasma dilution (figure 4B). Also in the other conditions the same 
evolution in down-slopes was observed (results not shown). We concluded that 
dilution of antithrombin is the main cause of the minor response of ETP to dilu-
tion 
 
To single out the effect of dilution on prothrombinase activity we kept the con-
centrations of prothrombin and antithrombin constant and equal to that of 4:6 
diluted plasma and repeated the experiments (figures 5 and 6). 
 
 
 
 
 
Figure 5. TG in diluted NPPP at con-
stant concentration of calcium, citrate, 
prothrombin and antithrombin.  
TG is measured in the presence of  
5 pM TF, 4 µM PL (figure A) 
1 pM TF, 4 µM PL (figure B)  
 no TF (+ kaolin) with 1 µM PL (figure C) 
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We observed that: 
A. Thrombin generation hardly decreases in TF triggered plasmas even up 
to 1:96 dilution. The ETP in 1:96 diluted plasma is even higher than in 
4:6 diluted plasma. In sharp contrast, contact activated plasma loses all 
activity if diluted more than 24 times. 
B.  In TF triggered plasma, despite the constant concentration of prothrom-
bin and antithrombin the down-slopes are again less steep, the higher 
the dilution of plasma, not however in contact activated plasma. 
 
We will first focus on observation A and later on we will discuss observation B. 
 
Observation A 
The difference in behavior of the intrinsic and the extrinsic system suggests that 
dilution of an inhibitor of extrinsic thrombin generation plays a role, TFPI being 
an obvious candidate. We therefore repeated the experiments keeping TFPI at a 
concentration equal to that in 4:6 diluted plasma (figure 7). This causes throm-
Figure 6. Evolution of the parameters 
of the TG of figure 5 
Thrombin generation was measured in 
diluted NPPP at constant concentration 
of calcium, citrate, prothrombin and 
antithrombin in three different condi-
tions (see figure 5). Evolution of lag-
time (A) peak-height (B) and ETP (C) is 
presented against the dilution of plasma 
(plotted on a logarithmic scale) for each 
of the three conditions: 5 pM TF, 4 µM 
PL (blue), 1 pM TF, 4 µM PL (green) 
and no TF (+ kaolin) with 1 µM PL 
(red). 
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bin generation to decrease with plasma dilution. Like in the intrinsic system al-
most no thrombin generation is seen anymore in the high dilutions. We there-
fore hold dilution of TFPI responsible for the persistent activity of the extrinsic 
pathway and the Josso-Loop at high dilutions in figures 5A and 5B. This also 
explains the shortening lag-time in the low dilutions (figures 3A and 6A). 
 
 
 
The intrinsic system however, in which TFPI does not play a role, is seriously 
diminished in 1:6 diluted plasma and is completely inactive if plasma is diluted 
more than 24 times (figure 5C).  The absence of thrombin generation at 1:24 
dilution in figure 5C/6C needs not to be in contradiction to the persistence of 
low thrombin generation in figure 2C/3C because in the latter case antithrombin 
is diluted and in the former not. The inactivity of the intrinsic system at high 
dilutions poses the question of the role of factors VIII and IX at low TF concen-
tration. Indeed, although we know that the Josso-loop is the main pathway at 1 
pM TF under our standard conditions (figure 1 – 4:6 diluted plasma), we don’t 
know if and how much the Josso-loop contributes to thrombin generation upon 
dilution. To investigate this further we measured two samples of a haemophilia 
patient, the one drawn before and the other drawn after infusion with FVIII 
(<5% and 80% FVIII) triggered with 1 pM TF and keeping calcium, citrate, 
prothrombin and antithrombin constant (figure 8). The plasma with FVIII (dot-
ted lines in figure 8C) shows the same evolution in lag-time, peak-height and 
ETP as NPPP (figure 5B). The plasma without FVIII (full lines in figure 8C), 
however, shows very low peak-height and ETP in the low dilutions but ap-
proaches the values of the sample after infusion upon dilution. The two samples 
of this patient can easily be distinguished in 4:6 diluted plasma but it becomes 
increasingly harder to distinguish them the more the plasma is diluted. At dilu-
tions > 6x the samples become identical. 
 
Figure 7. Constant concentration 
of TFPI 
TG in diluted NPPP at constant 
concentration of calcium, citrate, 
prothrombin, antithrombin and 
TFPI (2 nM). TG is measured in 
the presence of 1 pM TF and 4 µM 
PL. 
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This indicates that in highly diluted plasma the Josso-loop does not function 
anymore, just as observed for the intrinsic system. In agreement with this de-
creasing contribution of the Josso-loop upon dilution, is the observation that 
also when prothrombin and antithrombin are not kept constant, the difference 
between plasma with and without factor VIII disappears upon dilution (figure 
9). 
 
Figure 8. TG in diluted haemophiliac plasma at constant concentration of 
prothrombin and antithrombin 
Measured at constant concentration of calcium, citrate, prothrombin and antithrombin 
in the presence of 1 pM TF and 4 µM PL. Figure A: TG before infusion with FVIII 
(<5% FVIII).  Figure B: TG after infusion with FVIII (80% FVIII). Figure C: evolu-
tion of lag-time (blue), peak-height (green) and ETP (red) against the dilution of 
plasma (plotted on a logarithmic scale) for the haemophiliac before infusion with 
FVIII (full line) and for the haemophiliac after infusion with FVIII (dotted line). 
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Observation B 
We concluded before (figure 4) that dilution of antithrombin was the main cause 
for the minor response of ETP to dilution (broadening curves). However, since 
in figure 5 the concentration of antithrombin and prothrombin is the same in 
each dilution and since the break-down velocity of thrombin during thrombin 
generation is a second order reaction given by v = kdec . [IIa] . [AT] in which 
kdec is a constant, the reason for the protracting down-slopes has to be found in 
the production-phase i.e. the conversion of prothrombin into thrombin by 
prothrombinase. Also, at dilutions > 12x a change in the shape of the thrombin 
Figure 9.  Thrombin generation in diluted haemophiliac plasma  
Measured at constant concentration of calcium and citrate in the presence of 1 pM TF 
and 4 µM PL. Figure A: TG before infusion with FVIII (<5% FVIII).  Figure B: TG 
after infusion with FVIII (80% FVIII). Figure C: evolution of lag-time (blue), peak-
height (green) and ETP (red) against the dilution of plasma (plotted on a logarithmic 
scale) for the haemophiliac before infusion with FVIII (full line) and for the haemo-
philiac after infusion with FVIII (dotted line). 
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B: TG after infusion with FVIII
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generation curves is observed (most clear at 1 pM TF) suggesting that there is a 
second wave of prothrombinase activity. We concluded that probably an inhibi-
tor of prothrombinase is affected by dilution, maybe activated protein C [11, 
12]. 
To investigate the role of the APC-system, the experiment of figure 5B (1 pM 
TF, constant concentration of prothrombin and antithrombin) was repeated with 
3 nM TM or 3 nM APC added. The inhibition caused by adding TM or APC 
decreased with increasing dilution (figures 10A and 10B).  
 
 
 
This reduction is not unexpected since both PC and PS are diluted. Despite the 
low concentration of PS, APC (activated by TM or added exogenously) reduces 
clearly the broadening of the thrombin-generation peak in 1:96 diluted plasma. 
Therefore prothrombinase-activities were calculated from the thrombin genera-
tion-curves presented in figures 10A and 10B following the procedure as de-
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Figure 10. Influence of TM and APC on TG and FII-ase activity in diluted plasma 
TG measured in diluted NPPP at constant conc. of calcium, citrate, prothrombin and 
antithrombin in the presence of 4 µM PL, 1 pM TF ± TM (figure A) and in the presence 
of 4 µM PL, 1 pM TF ± APC (figure B). Only the lowest and highest dilution are shown 
in order to not overload the figures. In figures C and D the prothrombinase-curves of 
figures A and B are presented . 
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scribed in chapter 4. These prothrombinase-curves are presented in figures 10C 
and 10D. As expected, a second wave of prothrombinase-activity is observed in 
1:96 diluted plasma. This second peak is partly reduced if PC is activated by 
TM and completely if APC is added exogenously. 
 
This poses the question why this extra activity of prothrombinase is not seen in 
low dilutions (e.g. 4:6) while the APC-system is not activated, or added exoge-
nously. To further investigate the role of dilution of protein S, we repeated dilu-
tion 1:96 keeping PS at a concentration equal to that in 4:6 diluted plasma and 
measured thrombin generation with 5 pM TF, 1 pM TF, 1 pM TF + 3 nM TM 
and 1 pM TF + 3 nM APC (figure 11).  
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Figure 11. Influence of PS on thrombin generation in diluted plasma 
TG measured in diluted NPPP at constant conc. of calcium, citrate, prothrombin and 
antithrombin in the presence of 4 µM PL, 5 pM TF (figure A); 4 µM PL, 1 pM TF (fig-
ure B); 4 µM PL, 1 pM TF + TM (figure C) and 4 µM PL, 1 pM TF + APC (figure D). 
In each condition thrombin generation was also measured while PS was hold at a con-
centration equal to that in 4:6 diluted plasma. 
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We concluded that PS has the same effect as APC: it abolishes the broadening 
of the thrombin generation curves. Again prothrombinase-activity was calcula-
ted from the thrombin generation peaks (figure 12) and indeed, the second pro-
thrombinase-wave showing-up in 1:96 diluted plasma disappears if PS is not 
diluted. Even more, PS inhibits the whole prothrombinase-curves and prolongs 
the lag-times (figures 11 and 12). We can only conclude that PS, just as APC 
and independent of APC, has an inhibitory effect on prothrombinase. The inver-
se is true as well: APC is able to inhibit prothrombinase if PS is diluted 96 times 
(figure 11D/12D). However, if APC and PS are allowed to cooperate, their in-
hibitory effect on prothrombinase is much stronger and thrombin generation is 
completely inhibited. 
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Figure 12. Prothrombinase-curves of figure 11 
TG measured in diluted NPPP at constant concentration of calcium, citrate, 
prothrombin and antithrombin in the presence of 4 µM PL, 5 pM TF (figure A); 4 µM 
PL, 1 pM TF (figure B); 4 µM PL, 1 pM TF + TM (figure C) and 4 µM PL, 1 pM TF 
+ APC (figure D). In each condition thrombin generation was also measured while 
PS was hold at a concentration equal to that in 4:6 diluted plasma. 
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Conclusions 
The more the plasma is diluted the less the Josso-loop and the intrinsic system 
participate in thrombin generation. The direct extrinsic pathway, in contrary, is 
unchained by the dilution of TFPI and this compensates amply for the loss of 
contribution of the Josso-loop in the 1 pM TF condition. As a result, the relative 
participation of the Josso-loop in prothrombinase formation decreases signifi-
cantly and becomes negligible if plasma is diluted more than six times as illus-
trated in figure 9. This figure shows that it becomes very hard to distinguish two 
samples of a haemophiliac (<5% and 80% FVIII) if thrombin generation is 
measured in six times diluted plasma. It is essential to be aware of these shifts 
when results obtained with methods using higher dilutions of plasma are to be 
interpreted. This is the more important since methods exist in which whole 
blood is diluted three times (i.e. plasma ~ 5 times) [2]. 
The experimental condition that is nearest to normal plasma is still 2:3 diluted 
plasma. Therefore the question remains how the contribution of the different 
pathways to prothrombinase formation in undiluted plasma would be (in-vivo 
condition). In the light of the experiments presented in this article we expect 
that the contribution of the Josso-loop to prothrombinase formation in the in-
vivo situation may be more important than hitherto thought. 
 
The broadening of the thrombin generation curves upon dilution results from a 
second wave of prothrombinase activity which is caused by dilution of PS. If PS 
is not diluted or if the APC-system is activated or added exogenously, this sec-
ond wave is suppressed. However, PS is able to inhibit prothrombinase-activity 
right from the beginning and independent of APC (figure 12). This is confirmed 
by the prolonging lag-times if PS is not diluted (figure 11). It supports the idea 
of an independent down regulation of prothrombinase activity by protein S [13, 
14]. Hackeng et al. observed this APC-independent anticoagulant effect of PS 
particularly at low TF-concentrations and described an interplay between TFPI 
and PS in the inhibition of TF-activity [15]. Our data, the contrary, suggest that 
PS may not need TFPI to down-regulate thrombin-generation in an APC-
independent way since also TFPI is diluted 96 times in the experiments shown 
in figure 11. We also observe inhibition by PS at high TF-concentration (figure 
11A). Our data further suggest that APC is able to inhibit prothrombinase-
activity independent of PS since PS is diluted 96 times in figure 11D. So, both 
are able to inhibit prothrombinase on their own (ETP ± 50% inhibition), but 
their effect is much higher (ETP ± 95% inhibition) if they are allowed to coop-
erate (figure 11D). 
As a rule of thumb it can be postulated that dilution affects more the negative 
feedback mechanisms of coagulation (TFPI and protein S) than the pro-
coagulant actors of the system. As a result the highest ETP is obtained if plasma 
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is diluted about six times (figure 2). Further a shift is observed from the intrinsic 
system and Josso-loop towards the direct extrinsic system. 
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Protocols for measuring thrombin generation 
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I. Timed subsampling onto a fibrinogen solution 
II. Timed subsampling onto a chromogenic substrate 
III. Continuous chromogenic measurement of TG 
IV. Continuous fluorogenic measurement of TG (CAT) 
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Preface 
In this chapter a short protocol is given of the techniques used for measuring 
thrombin generation from the early fifties until now. Of the CAT-method a 
more extensive description is given together with possible applications. As such 
an overview is given of measuring thrombin generation during half a century. 
Each of these methods has its benefits and disadvantages and each of them can 
still be required to solve a specific research problem.  
 
Timed subsampling onto a fibrinogen solution is the oldest method and may 
seem outdated. However, it is the only method able to measure α-thrombin 
alone without meizo-thrombin and α2M-thrombin since only α-thrombin is able 
to convert fibrinogen into fibrin. This technique can be applied as well in PPP, 
PRP as in whole blood. It requires extraordinary skill however and no auto-
mated or semi-automated form is available.  
 
Timed subsampling onto a chromogenic substrate measures α-thrombin as well 
as meizo-thrombin and α2M-thrombin. It can be carried out in PPP and in PRP 
but only the free activity, in the fluid phase, is measured. This technique allows 
the researcher to add drugs or other components (e.g. a clot) to the system while 
TG is going on. It is also possible to induce shear-stress by stirring. This has 
been shown to be important in patients with von Willebrand’s disease. Throm-
bin generation is significantly impaired in patients with von Willebrand’s dis-
ease. Using the subsampling method the defect is much more pronounced in 
PRP than in PPP [1] while in the CAT-method this could not be demonstrated 
[2]. This is due to the fact that the role of vWF in the thrombin-induced proco-
agulant response of platelets requires at least a minimal shear, as shown by 
Briede et al. [3]. 
A variation on this technique is subsampling onto an AT-heparin mixture which 
makes it possible to measure only α2M-thrombin and meizo-thrombin. 
 
Continuous chromogenic measurement of TG detects also α-thrombin, meizo-
thrombin and α2M-thrombin. It can only be carried out in defibrinated PPP but 
this technique makes it possible to measure thrombin generation curves at high 
throughput. Furthermore, there is no need for continuous individual calibration 
(in opposite with the next method) since there is no inner-filter-effect or signifi-
cant substrate-depletion because substrates with favourable kinetic profile and 
solubility are available. Also the color of plasma has no influence on this type 
of measurements. The method is at the basis of a commercial thrombin genera-
tion measurement setup. 
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Continuous fluorogenic measurement of TG detects α-thrombin, meizo-
thrombin and α2M-thrombin and is just as the previous technique able to meas-
ure thrombin generation curves at high throughput. The big advantage of this 
method is that TG can be measured in the presence of fibrin and platelets and 
that not only the free thrombin is measured but also the clot-bound thrombin. 
Continuous individual calibration is an absolute requirement because of inner-
filter-effect, substrate depletion and the influence of the color of plasma (see 
chapter V). 
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Timed subsampling onto a fibrinogen solution [1, 2] 
General procedure: 
In the early fifties, thrombin generation was obtained by timed subsampling of 
aliquots of clotting whole blood or recalcified citrated plasma onto a fibrinogen 
solution. Clotting times were measured for each time-point and converted into 
thrombin units via a calibration curve established with an international thrombin 
standard. As such a thrombin generation curve was constructed. 
Preparation and handling materials: 
Here is described how the materials were obtained at that time. Nowadays, if 
one would perform this experiment, other materials might be preferred. 
Fibrinogen Solution 
Plasma was treated with Al(OH)3 to remove prothrombin and the fibrinogen 
was separated from this prothrombin-free plasma by two successive precipita-
tions with ammonium-sulfate (pH 6.6) and dialysis against citrate saline. 
The fibrinogen solutions used had a concentration of 2.5 g/l in 0.15 M NaCl. 
Thrombin calibration curve 
A curve was constructed relating fibrinogen clotting times to concentrations of 
thrombin (repeated for each batch of fibrinogen). The international thrombin 
standard used was defined as followed: one thrombin unit is the amount of 
thrombin that converts one ml of fibrinogen at 2.5 g/l in 15 seconds. A series of 
10 thrombin-dilutions was made (0.5 – 20 U/ml) and 100 µl of each dilution 
was added to a tube at 37ºC containing 300 µl of fibrinogen solution. The clot-
ting time in each tube was recorded and a simple curve of clotting times plotted 
against concentration of thrombin was used for determining the thrombin con-
tent of an unknown solution (U/ml). 
Protocol: 
Immediately after venipuncture, 2 ml of blood is added to a siliconised glass 
centrifuge tube containing 200 µl of saline. This tube is shaken gently to mix 
the content well and set at 37ºC. The purpose of the saline is to control the vol-
ume of reagents added in other experiments. After 1 minute 100 µl of the blood 
is added to the first of a row of tubes, also at 37ºC, each containing 300 µl of 
fibrinogen solution. This is repeated further at one-minute intervals as soon as 
possible and the clotting times of these blood-fibrinogen mixtures are recorded. 
From these clotting times the thrombin concentration in the whole blood at each 
time of sampling is assessed via the thrombin calibration curve. By plotting 
thrombin concentration against time, a thrombin generation curve is obtained. 
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The fibrin formed in the centrifuge tube during this sampling process is pressed 
to one side of the tube and removed by mean of a wooden swab-stick to which it 
adheres conveniently. In this way fluid samples can continue to be taken with-
out interruption. 
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Timed subsampling onto a chromogenic substrate [1, 2] 
General procedure: 
Thrombin itself is measured directly with the aid of a chromogenic substrate 
(S2238). The thrombogram is obtained via determination of the thrombin con-
tent in small subsamples taken at short intervals from clotting blood or plasma. 
Usually defibrinated plasma is used but it is also possible to measure thrombin 
generation in normal PPP or PRP. In this case the fibrin clot formed in the reac-
tion mixture during the sampling process is wound on a small spatula and dis-
carded. In this way fluid samples can continue to be taken without interruption. 
The sampling time is automatic recorded and also semi-automatic measurement 
of the thrombin activities is possible which allows executing experiments in 
parallel. 
Preparation and handling materials: 
1) Platelet poor plasma: 
The blood is obtained through antecubital venipuncture. Free flow or minimal 
suction is employed; vacuum containers are avoided. The blood is collected in 
plastic tubes of 10 ml containing 1 ml sodium-citrate (0.13 M) put on room 
temperature 0.5 h in advance. While collecting the blood each tube is tilted 
slowly three times so as to mix the content well without causing contact-
activation. Presenting air bubbles are pricked through. The blood is centrifuged 
at 2900 g for 10 min at room temperature and the plasma is aspirated with a pi-
pette and centrifuged a second time (idem). In order to avoid contamination 
with procoagulant microparticles from aging platelets, PPP is prepared as quick 
as possible.  
Defibrinated PPP: 
Ancrod is added to PPP so as to reach a final concentration of 1 U/ml. The 
plasma is mixed well (vortex) and kept at 37 ºC for 10 minutes. Then it is put on 
ice for 10 minutes. To remove the clot one has to turn very slowly with a spoon 
against the wall of the tube and take out the clot. Because Ancrod does not 
cause haemolysis, it can also be added to whole blood, rendering defibrinated 
plasma directly upon centrifugation. 
Ancrod, the fibrinogen clotting enzyme of the Malayan Pit Viper, was the 
commercial preparation Arvin (Knoll AG, Ludwigshafen, Germany). 
Buffers: 
Buffer A: 50 mM Tris.HCl, 100 mM NaCl, 0.5 g/l bovine serum albumin, pH 
7.35 
Buffer B: 50 mM Tris.HCl, 100 mM NaCl, 0.5 g/l BSA, 20 mM EDTA, pH 7.9 
CHAPTER IX 
 
 
 
134
Substrate: 
The chromogenic substrate used for thrombin is S2238 (H-D-Phe-Pip-Arg-
pNA.2HCl). 
Trigger 
As a trigger recombinant tissue factor (rTF) is used. Recombinant tissue factor 
not containing polybrene or Ca++ was a kind gift from Dade Behring (Marburg, 
Germany). 
Phospholipids vesicles: 
20% phosphatidylserine and 80% phosphatidylcholine 
Protocol: 
Set-up: 
To 240 µl defibrinated plasma is added 40 µl of buffer A and 20 µl phospholip-
ids-solution and this mixture is incubated at 37 ºC for 5 minutes. Buffer A may 
contain any substance of which the influence on thrombin generation has to be 
investigated. Coagulation is triggered at zero time with 60 µl trigger-solution 
containing CaCl2 and rTF (for the extrinsic pathway).  For the intrinsic pathway 
defibrinated plasma is incubated with 40 µl of buffer A in which 0.25 mg/ml 
kaolin is suspended. After 4 min, 20 µl phospholipids-solution is added and 5 
min after the start of the incubation thrombin generation was triggered with 60 
µl trigger-solution containing CaCl2. If necessary the volumes indicated may be 
proportionally altered.  
 
After addition of the trigger, 10 µl of the reaction mixture is sampled at inter-
vals of about 10-15 seconds in disposable plastic microcuvettes (at 37 ºC) with 
490 µl buffer B containing 200 µM of S2238. After sampling the cuvette is im-
mediately and rigorously mixed on a Vortex mixer. The EDTA in buffer B neu-
tralizes the Ca2+ present in the cuvette what makes coagulation to stop. The al-
ready formed thrombin reacts with S2238 and after about 2 minutes the reaction 
in the cuvette is stopped by the addition of 300 µl citric acid (1 M). The cuvette 
is again thoroughly mixed and can be kept at room temperature until reading. 
The optical density (OD) is read at 405 nm in a suitable spectrophotometer 
(LKB-Ultrospec) or Hemker-photometer. The generation of p-Nitroaniline is 
linear in time up to an OD of 0.9. If necessary incubation times longer or shorter 
than two minutes can be used so as to obtain a suitable sensitivity and not to 
exceed 0.9 OD. 
The subsampling and the stopping pipettes are time recording pipettes (Gilson, 
France). It is essential to keep the plunger of the pipette down after subsampling 
and to wipe the pipette tip carefully in order to avoid contamination of the incu-
bation mixtures with EDTA from the buffer in the cuvette. Plastic tubes can be 
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used instead of cuvettes but glass tubes have to be avoided because they adsorb 
thrombin and give unpredictable results. 
 
If TG is measured in PRP, 240 µl of plasma is diluted with 60 µl buffer A and 
incubated at 37ºC for 5 min. Coagulation is triggered with 60 µl CaCl2 (100 
mM) containing rTF equivalent to a final concentration of 7.5 pg/ml. 
Material-list: 
Defibrinated PPP, buffer A and B, substrate, rTF, CaCl2, phospholipids (20% 
PhS, 80% PhC) 
Preparations: 
Trigger solution for the extrinsic system contains rTF (1/240) in 100 mM CaCl2 
(final concentration 16.7 mM). Clotting time around 30 s. 
Trigger solution for the intrinsic system contains 100 mM CaCl2. 
Phospholipids-solution contains 20 µM PhS/PhC. 
Data-handling: 
The spectrophotometer as well as the time recording pipette is connected to a 
personal computer that calculates the increase of OD in time (OD/min) from the 
measured OD values and the times of subsampling and stopping. Thrombin 
amidolytic activities are calculated by comparing the OD/min values of the 
samples to those of a standard calibration curve prepared using known amounts 
of human α-thrombin (active site titration). Also a correction has to be made for 
the α2M-T complex. This is done by a simple algorithm based on the fact that 
the α2M-T formation velocity is proportional to the concentration of free 
thrombin. This algorithm is used in a computer program that calculates free 
thrombin curves from the amidolytic activity curves. 
Protocol for determining the decay constant of thrombin in plasma: 
In the same way, using the sub-sampling technique, the decay constant of 
thrombin in plasma can be determined. Instead of triggering thrombin genera-
tion, a known amount of thrombin is added to defibrinated PPP and by subsam-
pling the rate of reaction with AT (in plasma) is measured. 
Method: 
At zero time 60 µl of h-T (1500 nM) is added to 240 µl defibrinated PPP and 60 
µl buffer A, at 37ºC. Sub-sampling is started immediately at suitable intervals 
(5-10 s) by adding aliquots of 10 µl into cuvettes with 490 µl Buffer B contain-
ing 200 µM S2238. After sampling the cuvette is quickly and rigorously mixed 
on a Vortex mixer and after about 2.5 minutes the reaction in the cuvette is 
stopped by the addition of 300 µl citric acid (1 M). The cuvette is thoroughly 
mixed and kept at room temperature until reading. The optical density (OD) is 
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read at 405 nm and amidolytic activities are calculated (see before: data han-
dling). 
 
The amidolytic activities (Ct) were fitted to the three parameter curve Ct = C∞ 
+ (C0 - C∞) . e-kdec.t, where C0 is the initial amidolytic activity and C∞ is the 
residual, steady end-level activity due to the α2M-T complex. 
The decay constant (kdec) is the sum of the AT dependent part (k1) and the α2M 
dependent part (k2). The ratio R = kdec/k2 is equal to C0/C∞, i.e. the ratio of the 
amount of thrombin added and the amount of α2M-T at the end of the experi-
ment. This ratio can be determined because of the persistent amidolytic activity 
of the α2M-T complex. 
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Continuous chromogenic measurement of TG [1, 2] 
General procedure: 
A slow reacting chromogenic substrate (SQ68) is added directly to clotting 
plasma. The reaction mixture consists of four parts of defibrinated plasma, one 
part of trigger solution and one part of start solution. The reactions are carried 
out in a laboratory automaton as e.g. the Cobas Bio and Cobas Fara centrifugal 
analysers (F. Hoffmann-La Roche, Basel, Switzerland) capable of measuring 
the optical density at 405 nm at 30 s intervals during 12 to 15 min. This method 
is restricted to defibrinated platelet poor plasma since clot-formation would dis-
turb the OD-measurement. Defibrination of large series of samples is the rate 
limiting step of the procedure. 
Preparation and handling materials: 
Platelet poor plasma: 
Idem see ‘Timed subsampling onto a chromogenic substrate’. 
Defibrinated PPP: 
Idem see ‘Timed subsampling onto a chromogenic substrate’. 
Buffers: 
Hepes-buffer: 20 mM Hepes-NaOH, 150 mM NaCl, 0.5 g/l bovine serum albu-
min, pH 7.35 
Substrate: 
Malonyl-α-aminoisobutyryl-arginine para-nitroanilide methyl ester hydrochlo-
ride (SQ68) was synthesized by Serbio Laboratories, France. 
Trigger 
As a trigger recombinant tissue factor and Actin FS® is used. Recombinant tis-
sue factor not containing polybrene or Ca++ was a kind gift from Dade Behring 
(Marburg, Germany). Actin FS® was a kind gift of Dade Productions (Düdin-
gen, Switzerland), a suspension of ellagic acid and soy bean phosphatides. 
Protocol: 
Set-up: 
In the Cobas machine 80 µl of defibrinated plasma with 20 µl of rTF without 
Ca2+ are incubated for 30 seconds at 37 ºC, which is sufficient for temperature 
equilibration. Thrombin generation is started by adding 20 µl of a pre-warmed 
start solution containing 100 mM CaCl2 and 3 mM substrate. After the start of 
the reaction the optical density at 405 nm is recorded at intervals of maximally 
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30 s for at least 12 min. Instead of 80 µl plasma it is also possible to add 75 µl 
plasma and 5 µl of a substance to be tested. 
Material-list: 
Defibrinated PPP, Tris-buffer, Hepes-buffer, substrate, rTF, Actin FS®, CaCl2 
Preparations: 
Trigger solution for the extrinsic system contains about 300 pM rTF in Hepes-
buffer. 
Trigger solution for the intrinsic system contains 1: 2.5 diluted Actin FS® in 
Hepes-buffer. 
Start solution contains 100 mM CaCl2 and 3 mM substrate in Hepes-buffer. 
Data handling: 
Data handling is undertaken on a personal computer connected to the centrifu-
gal analysers. A series of OD readings and the times of the readings are trans-
formed to give the OD as a function of time and from these data the ETP can be 
calculated off-line. A correction has to be made for the α2M-T complex as seen 
in the subsampling method with a chromogenic substrate. This is done by a 
simple algorithm based on the fact that the α2M-T formation velocity is propor-
tional to the concentration of free thrombin. This algorithm is used in a com-
puter program that calculates free thrombin curves from the amidolytic activity 
curves. 
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Continuous fluorogenic measurement of TG: CAT-method 
General procedure: 
Principle 
Thrombin generation is monitored by a fluorogenic substrate (ZGGR-AMC) 
added to the plasma at time zero together with the trigger (calcium). The throm-
bogram is measured in a 96-well plate fluorometer (Ascent Reader, Thermolab-
systems, Helsinki, Finland) equipped with a 390/460 filter set (excita-
tion/emission) and a dispenser used for the addition of the substrate-calcium-
solution. Transparent round-bottom 96-well plates (Immulon 2HB) have to be 
used. If flat-bottom plates are used the optical unit has to be changed so as to 
read from beneath. Each experiment consists of two sets of readings, one with a 
known fixed amount of thrombin activity (calibrator, CAL), the other in which 
thrombin generation (TG) occurs. By continuous comparison of the signal from 
the two wells the course of thrombin concentration is calculated in real time and 
displayed on the screen by a dedicated software program (Thrombinoscope BV, 
Maastricht, The Netherlands). For explanation about the use of the software see 
the manual of Thrombinoscope BV. 
Set-up of an experiment 
Each plasma-sample requires its own calibrator-measurement (see chapter II 
and IV). The recommended set-up of an experiment is in quadruplicate. This 
means 4 CAL-wells and 4 TG-wells per plasma-sample. This is called a group. 
As such 12 groups can be measured in one experiment. If the same plasma is 
measured under different conditions (e.g. another drug tested) different groups 
can share the same calibrator. 
Before measuring thrombin generation each well is filled with 20 µl calibrator 
(CAL-wells) or reagents (TG-wells) and 80 µl plasma. The reaction is started 
with 20 µl of a solution, containing calcium and substrate, added via the dis-
penser (t=0). This solution of calcium and substrate is called FluCa. The final 
volume in each well is 120 µl. The reagents (RG) consist of a buffer-solution 
containing trigger, procoagulant phospholipids and/or any reagent one likes to 
test. As trigger recombinant tissue factor or innovin is used (commercially 
available).  FluCa is a buffer-solution containing substrate (2.5 mM) and Ca2+ 
(100 mM). After the plate is filled with calibrator, reagents and plasma, the 
plate is put in the fluorometer at 37ºC for minimally 5’. Meanwhile the dis-
penser of the fluorometer is flushed with a warm Ca2+-solution (100 mM), emp-
tied and flushed again with FluCa. The reaction is started by dispensing 20 µl 
FluCa into the wells. The software program registers this as zero-time, shakes 
the plate for 10 s and starts reading. The interval between two readings of the 
fluorescence signal and the total time that TG is measured can be chosen. 
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Preparation and handling materials: 
1) Platelet poor plasma: 
Idem see ‘Timed subsampling onto a chromogenic substrate’. 
Also a pool of platelet poor plasma from healthy subjects is made (NPPP). This 
is used as reference plasma. All the plasma of these subjects is collected and the 
pool is ultra-centrifuged at 2900 g for 1h at 4 ºC. PPP and NPPP are stored in 
the freezer at -80 ºC. Just before each experiment the plasma is thawed, held on 
ice and a few minutes in advance the plasma is put at room temperature. 
2) Platelet rich plasma: 
The blood is collected identically as for PPP. Eventually CTI is added together 
with the sodium-citrate to avoid contact-activation (0.8 µM final concentration). 
The blood is centrifuged at 265 g for 10 min at room temperature (>20 ºC) and 
the plasma is aspirated with a pipette. The result is PRP. 
PRP does not always contain the same amount of platelets. For a standard PRP 
measurement it is advised to adjust the platelets at 150 000 pt/µl. To do so, a 
few ml of the PRP is kept at 37 ºC, 200 µl is kept separately to measure the 
platelets and the rest of the PRP is centrifuged at room temperature (>20 ºC) at 
2900 g for 10 minutes. The result is PPP and does not contain any platelets 
anymore. 
During this centrifugation step the platelets of the PRP are measured in the 
Coulter-counter (~ 300 000 tot 500 000 pt/µl) which is turned on and primed 0.5 
h in advance. Avoid air bubbles during the measurement. Next, the few ml PRP 
at 37 ºC is adjusted with PPP to obtain 150 000 pt/µl. The PRP has to be tilted 
slowly a few times before pipetting. The adjusted PRP is kept at 37 ºC. 
 
PRP has to be handled gently (do not vortex!) and kept above 20 ºC to avoid 
activation of the platelets. The experiment should be started within 1 h after 
venipuncture. The PRP can not be frozen because this would cause the platelets 
to breakdown. 
3) Calibrator 
The calibrator is provided by Thrombinoscope (Maastricht, The Netherlands) 
and contains lyophilized α2M-T equal to an activity of 600 nM h-T after recon-
stitution. It is stored at 4 ºC and is dissolved in 1 ml milli-Q and kept on ice. 
4) Buffers 
Two buffers are used: ‘BSA5’ for preparing dilutions of the reagents and 
‘BSA60’ for the FluCa. BSA5 contains 20 mM Hepes, 140 mM NaCl, 0.02% 
NaN3 and 5 mg/ml BSA at pH 7.35. BSA60 contains 20 mM Hepes, 0.02 % 
NaN3 and 60 mg/ml BSA at pH 7.35. To dissolve BSA it is brought on top of 
the buffer without stirring to allow it to dissolve slowly. This can take more 
than an hour. Next the buffer is filtered using a corning filter system 255 ml 
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with 0.2 µm PES membrane. The buffers are stored in the freezer at -20 ºC. 
They are kept at room temperature during an experiment. 
5) Phospholipids (PL) 
The phospholipids used are a mixture of 60% Phosphatidyl choline (PhC), 20% 
phosphatidyl serine (PhS) and 20% phosphatidyl ethanolamine (PhE). The 
stocks are obtained at Avanti (USA). The phospholipids are stored in the freezer 
at -80 ºC. They are kept at room temperature during an experiment. 
 
Example of a 2 ml preparation of 1 mM PhS-PhE-PhC (20-20-60): 
Stocks:  - PhS (10 mg/ml; 2.5 ml; MW: 810.03; CHCl3) Æ 12.34 mM 
  - PhE (25 mg/ml; 4 ml; MW: 744.04; CHCl3) Æ 33.60 mM 
  - PhC (25 mg/ml; 4 ml; MW: 786.15; CHCl3) Æ 31.80 mM 
32 µl PhS + 12 µl PhE + 38 µl PhC is pipetted in a glass tube. Nitrogen-gas is 
blown in the tube until all CHCl3 has disappeared and two ml buffer is added 
(140 mM NaCl, 20 mM Hepes, pH 7.35). The resulting solution is a trouble 
suspension and has to be sonicated for 10 min with a MSE Mark II 150-watt 
ultrasonic disintegrator, set at 9 microns peak to peak amplitude until the solu-
tion is clear. Alternatively the trouble PL-suspension can also be extruded 
through a 400 nm filter until the solution is clear. 
6) Trigger 
As a trigger both recombinant tissue factor and innovin (Inn) can be used. Re-
combinant tissue factor not containing polybrene or Ca++ was a kind gift from 
Dade Behring (Marburg, Germany) and was used previously in our lab. Lyophi-
lized innovin is commercially available (Dade-Behring) and is used nowadays 
in our lab. It has to be dissolved in 10 ml milli-Q and this solution has the same 
activity as a TF-solution of 6 nM. Dissolved Inn is stored in the freezer at -80 
ºC and is kept on ice during an experiment. 
7) Substrate 
The substrate (Z-Gly-Gly-Arg-AMC) is commercially available (Bachem, Swit-
serland). A solution is made of 100 mM substrate in DMSO and stored in the 
freezer at -80 ºC. 
8) FluCa 
About 10 minutes before measuring thrombin generation the FluCa solution is 
prepared. This is a mixture of buffer (BSA60), substrate and CaCl2 so as to ob-
tain a concentration of 2.5 mM substrate and 100 mM CaCl2. This mixture is 
immediately vigorously mixed and the resulting clear solution is kept at 37 ºC. 
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9) TM, APC, CTI, kaolin, Arvin, heparin, hirudin, melagatran, penta-
saccharide 
These reagents are commercially available and are stored in the freezer at -80 
ºC. Kaolin is stored in the fridge. They are thawed and kept on ice during an 
experiment. Kaolin is kept at 37 ºC. 
Protocol for PPP 
Thrombin generation is measured in PPP at a final concentration of 4 µM PL 
and 1/1200 Inn (5 pM rTF) or 1/12000 Inn (0.5 pM rTF). 
Set-up: 
2 groups (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL and 1/1200 Inn    (RG A) 
- 4 wells with 4 µM PL and 1/12000 Inn   (RG B) 
Material-list: 
PPP; PL (1 mM); Inn; calibrator; substrate (100 mM); buffers (BSA5, BSA60); 
CaCl2 (1 M) 
Preparations: 
RG A contains 1/200 Inn and 24 µM PL in BSA5. 
RG B contains 1/2000 Inn and 24 µM PL in BSA5. 
 
TG is measured during 40 min at 15 s time-intervals. 
Protocol for PRP 
Thrombin generation is measured in PRP at a final concentration of 1/12000 Inn 
(without PL). The PRP first has to be adjusted at 150 000 platelets/µl. 
Set-up: 
1 group 
- 4 wells with calibrator 
- 4 wells with 1/12000 Inn   (RG A) 
Material-list: 
PRP; Inn; calibrator; substrate (100 mM); buffers (BSA5, BSA60); CaCl2 (1 M) 
Preparations: 
RG A contains 1/2000 Inn in BSA5. 
 
TG is measured during 60 min at 15 s time-intervals. 
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Applications: 
1) Check quality of platelet poor plasma 
TG is measured in PPP without Inn (only PL) and without PL (only Inn). So the 
reaction mixture contains 4 µM PL or 1/1200 Inn. 
Set-up: 
2 groups (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL   (RG A) 
- 4 wells with 1/1200 Inn   (RG B) 
Material-list: 
PPP; PL (1 mM); Inn; calibrator; substrate (100 mM); buffers (BSA5, BSA60); 
CaCl2 (1 M) 
Preparations: 
RG A contains 24 µM PL in BSA5. 
RG B contains 1/200 Inn in BSA5. 
 
TG is measured during 60’ at 15” time-intervals. 
2) Measure the intrinsic system in PPP 
TG is measured in PPP activated with kaolin at a final concentration of 1 µM 
PL (no trigger). 
Set-up: 
2 groups (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL and 1/1200 Inn   (RG A) 
- 4 wells with 1 µM PL (kaolin-activated PPP)  (RG B) 
 
Î The wells with kaolin-activated plasma have to be filled with 90 µl plasma 
(instead of 80 µl) and 10 µl RG-solution (instead of 20 µl) so as to compensate 
for the extra dilution of the plasma during activation. For the same reason the 
calibrator needs not to be measured separately in kaolin-activated plasma since 
the plasmas are diluted equally in the well. 
Material-list: 
PPP; PL (1 mM); Inn; kaolin (0.5 mg/ml); CTI (83 µM); calibrator; substrate 
(100 mM); buffers (BSA5, BSA60); CaCl2 (1 M) 
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Preparations: 
RG A contains 1/200 Inn and 24 µM PL in BSA5. 
RG B contains 12 µM PL in BSA5. 
 
Kaolin-activated plasma: 
Kaolin has to be kept at 37ºC and needs to be mixed well (vortex) before use. 80 
µl PPP is activated with 10 µl kaolin (0.5 mg/ml) and the plasma is kept at 37 
ºC for 7 minutes. The time is important and has to be followed exactly because 
de-activation of clotting-factors by kaolin can happen if the time is preceded. 
The plasma-tube has to be tilted a few times during these 7 minutes so as to 
avoid sedimentation of the kaolin. After this activation step the plasma is centri-
fuged for 5 minutes at 10 000 g. A little pellet of kaolin can be seen at the bot-
tom of the tube and the plasma is separated from this pellet. All these steps have 
to be done as fast as possible. 
 
TG is measured during 60 min at 15 s time-intervals. 
 
Remark: if PPP is treated with CTI the contact-activation by kaolin is inhibited. 
The standard concentration of CTI used to inhibit contact-activation is 0.72 µM. 
3) Check the APC-system of plasma in PPP and PRP 
TG is measured in PPP with TM to activate the APC-system of the plasma or 
with exogenous added APC to check its influence on thrombin generation. 
Set-up: 
3 groups (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL and 1/1200 Inn   (RG A) 
- 4 wells with 4 µM PL, 1/1200 I and 6 nM TM  (RG B) 
- 4 wells with 4 µM PL, 1/1200 I and 6 nM APC  (RG C) 
Material-list: 
PPP; PL (1 mM); Inn; TM (1 µM); APC (600 nM); calibrator; substrate (100 
mM); buffers (BSA5, BSA60); CaCl2 (1 M) 
Preparations: 
RG A contains 1/200 Inn and 24 µM PL in BSA5. 
RG B contains 1/200 Inn, 24 µM PL and 36 nM TM in BSA5. 
RG C contains 1/200 Inn, 24 µM PL and 36 nM APC in BSA5. 
 
TG is measured during 40 min at 15 s time-intervals. 
 
Remark: The effect of the APC-system can also be measured in PRP but in this 
case only 1/12000 Innovin is added and no PL. 
PROTOCOLS 
 
 
 
145 
4) Check the influence of fibrinogen on TG in PPP 
TG is measured in PPP and in PPP defibrinated with Arvin. 
Set-up: 
2 groups with normal PPP (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL and 1/1200 Inn   (RG A) 
- 4 wells with 4 µM PL and 1/12000 Inn   (RG B) 
2 groups with PPP without fibrinogen (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL and 1/1200 Inn   (RG A) 
- 4 wells with 4 µM PL and 1/12000 Inn   (RG B) 
Material-list: 
PPP; PL (1 mM); Inn; Arvin or Ancrod (50 U/ml); calibrator; substrate (100 
mM); buffers (BSA5, BSA60); CaCl2 (1 M) 
Preparations: 
RG A contains 1/200 Inn and 24 µM PL in BSA5. 
RG B contains 1/2000 Inn and 24 µM PL in BSA5. 
 
PPP without fibrinogen: 
Arvin is added to PPP so as to reach a final concentration of 1 U/ml. The 
plasma is mixed well (vortex) and kept at 37 ºC for 10 minutes. Then it is put on 
ice for 10 minutes. To remove the clot one has to turn very slowly with a spoon 
against the wall of the tube and take out the clot. 
 
TG is measured during 60 min at 15 s time-intervals. 
 
Remark: This is only possible in PPP because in PRP platelets would be re-
moved as well together with the clot. 
5) The effect of several anti-coagulantia on thrombin generation in PPP 
and PRP 
TG is measured in PPP with several anti-coagulantia as there are unfractionated 
heparin (UFH), Melagatran (M), Hirudin (H) and Penta-saccharide (Penta-S) 
Set-up: 
10 groups (same calibrator) 
- 4 wells with calibrator 
- 4 wells with 4 µM PL and 1/1200 Inn    (RG A) 
- 4 wells with 4 µM PL, 1/1200 Inn and 0.04 U/ml UFH  (RG B) 
- 4 wells with 4 µM PL, 1/1200 Inn and 0.3 µM M  (RG C) 
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- 4 wells with 4 µM PL, 1/1200 Inn and 0.4 µg/ml H  (RG D) 
- 4 wells with 4 µM PL, 1/1200 Inn and 5 µg/ml Penta-S  (RG E) 
- 4 wells with 4 µM PL and 1/12000 Inn    (RG F) 
- 4 wells with 4 µM PL, 1/12000 Inn and 0.04 U/ml UFH (RG G)  
- 4 wells with 4 µM PL, 1/12000 Inn and 0.3 µM M  (RG H) 
- 4 wells with 4 µM PL, 1/12000 Inn and 0.4 µg/ml H  (RG I) 
- 4 wells with 4 µM PL, 1/12000 Inn and 5 µg/ml Penta-S (RG J) 
Material-list: 
PPP; PL (1 mM); Inn; UFH (1 U/ml); Hirudin (100 µg/ml); Melagatran (30 
µM); Penta-saccharide (100 µg/ml); calibrator; substrate (100 mM); buffers 
(BSA5, BSA60); CaCl2 (1 M) 
Preparations: 
RG A contains 1/200 Inn and 24 µM PL in BSA5. 
RG B contains 1/200 Inn, 24 µM PL and 0.24 U/ml UFH in BSA5. 
RG C contains 1/200 Inn, 24 µM PL and 1.8 µM M in BSA5. 
RG D contains 1/200 Inn, 24 µM PL and 2.4 µg/ml H in BSA5. 
RG E contains 1/200 Inn, 24 µM PL and 30 µg/ml Penat-S in BSA5. 
RG F contains 1/2000 Inn and 24 µM PL in BSA5. 
RG G contains 1/2000 Inn, 24 µM PL and 0.24 U/ml UFH in BSA5. 
RG H contains 1/2000 Inn, 24 µM PL and 1.8 µM M in BSA5. 
RG I contains 1/2000 Inn, 24 µM PL and 2.4 µg/ml H in BSA5. 
RG J contains 1/2000 Inn, 24 µM PL and 30 µg/ml Penta-S in BSA5. 
 
TG is measured during 80 min at 15 s time-intervals. 
 
Remark: The effect of these anti-coagulantia on thrombin generation can also be 
measured in PRP but in this case only 1/12000 Innovin is added and no PL. 
6) Multiple-dose studies on new drugs 
See standard-protocol of PPP. 
Important is here that each plasma-sample is measured with its own calibrator.  
7) Determine pharmaco-dynamics of new drugs 
See standard-protocol of PPP. 
Important is here that each plasma-sample is measured with its own calibrator. 
 
 
 
 
 
 
 
147 
Chapter X 
 
General discussion and conclusions 
Chapter X 
General discussion and conclusions  
CHAPTER X 
 
 
 
148
Thrombin generation as an overall-function test in clinical 
labs 
Thrombosis is the cause behind common diseases as stroke and myocardial in-
farction and thereby has become the second cause of death and disease in the 
western world [1]. Of the three components that, according to Virchow, foster 
thrombosis, i.e. the vessel wall, blood flow and coagulability, the latter one re-
mains the most elusive. The mechanism of blood coagulation may be known in 
astonishing detail but, despite decades of investigation in the field, clinicians do 
not have a universal test at their disposal to determine this “coagulability”. Sev-
eral clotting-time tests are available, each one giving information about another 
detail of the complicated web of blood coagulation reactions. None of these is 
an adequate overall function test like e.g. the electro-cardiogram for heart 
rhythm problems. This thesis contributes to the question whether thrombin gen-
eration is a suitable candidate for this role. 
How is it possible that a test that is known for over half a century only now pos-
tulates for this function ? Three main raisons can be pointed out.  
In the first place the test was “out of fashion” and pushed into oblivion by the 
advent of modern biochemical and molecular biology techniques. In the second 
place it was labor intensive and unsuitable for application in the modern, largely 
automated, clinical laboratory and in the third place – maybe the most important 
- it did not fit in the traditional view of primary and secondary haemostasis.  
During the last few years things are changing. In research laboratories it be-
comes more and more recognized that thrombin plays a pivotal role not only in 
secondary haemostasis and venous thrombosis but also in arterial thrombosis 
and primary haemostasis, right from the beginning when the platelet-reactions 
start. Therefore the thrombin generating capacity of blood is more and more 
being accepted as a – if not the - central element in the physiological function of 
haemostasis.  
Thrombin generation was slowly being brought back into fashion by the work 
of Béguin and Hemker, that in a series of articles that started in 1986 showed 
how this technique could be used for the unraveling of the mode of action of 
heparins and other antithrombotics and for the recognition of the receptors that 
are responsible for the platelet procoagulant reaction.  
As a consequence several research laboratories are exploring manners to follow-
up thrombin generation in the fluid organ blood. The ideal way to assess the 
function of the thrombin generating system in a patient would be measuring the 
concentration of thrombin as a function of time and space in a platelet aggregate 
at the site of a lesion. This is technically impossible at this moment but a good 
approximation became feasible with the arrival of Calibrated Automated 
Thrombography. With this method it is possible to measure thrombin generation 
in platelet rich plasma or platelet poor plasma in the presence of elements of the 
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vessel wall, i.e. tissue factor and thrombomodulin. This technique is the issue of 
this thesis. 
Calibrated Automated Thrombography (CAT) 
The CAT-method, presented in chapter II, makes it possible to measure throm-
bin generation at high throughput and with an acceptable experimental error 
(<5%) which makes it a promising tool for clinical routine-labs. Von Wille-
brand’s disease can be detected [2] and the effect of platelet-inhibitors (e.g. as-
pirin, clopidogrel) can easily be followed [3, 4]. It is also possible to obtain use-
ful partial information from observations in PPP e.g. detect deficiencies in clot-
ting factors (except factor XIII) or observe the effect of anticoagulants (Anti-
vitamin K, heparin (-likes), direct thrombin- or FXa-inhibitors). This is the more 
important since there is no single clotting-time test that reacts similarly to these 
different types of anticoagulants. Also the function of the protein C system can 
be probed both in PPP and in PRP. Addition of TM allows to detect the function 
of the entire system, but, as thrombin is required for TM to express its activity, 
TM only affects the second half of the thrombin generation curve (peak-height, 
ETP) but not the lag-time which makes its effects not detectable with clotting-
time tests. 
Particularly interesting is the lupus anticoagulant. This antibody causes an in-
crease of the clotting time and thus is deemed “anticoagulant” but it also brings 
about a thrombotic tendency. This is called the ‘LAC paradox’. The LAC-
paradox disappears as soon as one resorts to thrombin generation where it is 
seen that indeed the lag-time (=clotting time) is prolonged but also that throm-
bin generation is not inhibited by activation of the protein C system [5]. This 
underlines that there exists no strict relation-ship between the length of the ini-
tiation phase (~clotting-time) and the amount of thrombin to be formed (95% of 
thrombin is formed after clotting). Therefore measuring a thrombogram pro-
duces much more information than a clotting time.  
Calculation of the TG curve starting from raw data 
In chapter III it is shown that two fit-procedures are needed for the conversion 
of the raw data into a TG curve. The first one is needed to convert the raw data 
into ‘ideal data’ i.e. data that would have been obtained if substrate consump-
tion and inner filter effect would not occur. The second one is carried out on the 
‘ideal’ progress curve and is needed to obtain the course of free thrombin from 
the course of amidolytic activity, the latter being the sum of free thrombin and 
α2M-T. Another advantage of fitting the progress-curve is that we avoid large 
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experimental scatter that arises from working with the first derivative of ex-
perimental data. 
Calculation of prothrombinase-activity 
Thrombin is the pivotal enzyme in the coagulation cascade and FII-ase activity 
is the final step in the formation of thrombin. The FII-ase activity is dependent 
on the components of the FII-ase complex: factor Xa, factor Va and the phos-
pholipids, which in their turn are dependent upon the function of the other clot-
ting factors and regulatory systems and the platelets. The FII-ase activity there-
fore reflects the activity of the clotting system but not that of thrombin break-
down. In chapter IV it is shown how the FII-ase activity can be calculated 
starting from the thrombin generation curve, if the initial concentration of AT is 
known. It can be expected – but it remains to be demonstrated in practice – that 
this type of curve reflects the physiology of thrombin forming processes with 
more sensitivity than the thrombin generation curve itself.  
Necessity of continuous individual calibration 
In order not to miss abnormalities in thrombin generation it is of the utmost im-
portance that the experimental error is reduced to a minimum. In the CAT-
method the splitting of a fluorogenic substrate is monitored by comparing it to a 
constant known thrombin activity in a parallel, non-clotting sample. As such a 
calibration factor (CF) is assessed during the complete experiment under the 
same conditions as that prevailing in the thrombin generation experiments. This 
is necessary to obtain clinically acceptable intra-individual coefficients of varia-
tion as is shown in chapter V. There we compared the intra-individual experi-
mental error obtained with two commercial available methods. One is the CAT-
method [6] using continuous individual plasma calibration, the other one the 
Technoclone-method [7] using a fixed CF based on initial thrombin activity 
measured in buffer. It is shown that a fixed CF in buffer introduces serious un-
derestimation since the yield of fluorescent signal depends strongly on the color 
of plasma. This underestimation is not constant but increases during TG due to 
substrate consumption and to absorption of fluorescent light by the forming 
fluorescent product (inner filter effect). This introduces large coefficients of 
variation which can be reduced to clinically meaningful levels by using con-
tinuous individual plasma calibration. 
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Influence of signaling substrate on thrombin generation 
Measuring a system always means disturbing it. During thrombin generation a 
signaling substrate is added which binds to thrombin and therefore also inhibits 
thrombin. Since thrombin plays a pivotal role in its own formation via several 
feedback mechanisms, inhibition of thrombin will, theoretically, influence 
prothrombin conversion. We investigated already what this disturbance amounts 
to at the time that we proposed the CAT-method (chapter 2). We showed that 
under our conditions the proposed substrate did not affect prothrombin conver-
sion significantly and that thrombin decay is slowed down in a predictable man-
ner because the artificial substrate added inhibits the inactivation of thrombin by 
plasmatic antithrombins.  Since this subject is clinically extremely relevant and 
since Butenas S and K.G. Mann expressed their concern about this issue we 
showed additional evidence as presented in chapter VI. We concluded that not 
only the amount of prothrombin converted but also the time course of 
prothrombin conversion are minimally affected by the presence of ZGGR-AMC 
at 416 µM. The inactivation of thrombin by plasmatic antithrombins is slowed 
down in an exactly predictable extent. Thrombin-driven feedback mechanisms 
are affected although this does not cause an important increase in the lag-time. 
They do cause, however, a reduction in the inhibition of added TM by about 
10%. It is important to stress that these conclusions are restricted to the pre-
sented substrate at the usual concentration (416 µM).  
In order to restrict the discussion to the soluble system, as did Butenas and 
Mann, we used defibrinated plasma in these experiments. The effect of the pres-
ence of fibrin(-ogen) is further discussed in chapter VII. 
Shift from chemical to diffusional control 
With the arrival of the CAT-method it became possible to measure thrombin 
generation in the presence and in the absence of fibrinogen. This was done in 
platelet poor plasma at different temperatures as shown in chapter VII. Out of 
these experiments we concluded that thrombin generation shifts from chemical 
to diffusional control during coagulation. Until now it was granted for true that 
thrombin generation was determined by the initial concentrations and reaction 
constants of the participating components. Nevertheless, as soon as a fibrin-web 
forms, phospholipid platelets and/or phospholipid particles adhere onto this web 
and the reactants can only be transported to and from such immobilized surfaces 
in a stagnant fluid by diffusion through the liquid phase. Such diffusional trans-
port will start to count at the moment of clotting. This means that diffusion 
starts to co-determine the rate of thrombin formation from the moment clotting 
takes place. In mixtures without fibrinogen or in mathematical simulation, 
thrombin generation is uniquely determined by the initial concentrations and 
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reaction constants of the components and diffusion is not taken into account. In 
models where prothrombinase is adsorbed at a macroscopic surface diffusion is 
rate-limiting at all but extreme concentrations of the reactants. None of these 
approaches is true since there is a shift from chemical to diffusional control dur-
ing coagulation around the moment of clotting. As a consequence the best ap-
proach for assessing thrombin generation in the body is measuring it directly in 
a sample of the isolated organ i.e. in clotting PRP with addition of the relevant 
components of the vessel wall (TF, TM). 
The effect of plasma dilution on thrombin generation 
Measuring a system not only means disturbing it (chapter 4) it also means dilut-
ing it since a signaling substrate, calcium, trigger and/or phospholipids need to 
be added. In chapter VIII it is investigated what the influence is of dilution on 
thrombin generation in platelet poor plasma using the CAT-method. It is shown 
that the ETP increases upon 1:6 dilution of plasma and drops thereafter. This is 
caused by dilution of tissue factor pathway inhibitor (TFPI) and protein S. Dilu-
tion of these inhibitory mechanisms affects thrombin generation more than dilu-
tion of procoagulant mechanisms. Dilution suppresses protein S dependent inhi-
bition and this induces a second wave of FII-ase activity which results in a pro-
longed decay-phase. Dilution of TFPI unchains the direct extrinsic pathway. 
Both phenomena result in higher (or prolonged) thrombin-activity. At the same 
time the intrinsic pathway and Josso-loop are significantly reduced by dilution. 
The intrinsic pathway looses all activity at dilutions > 24x while the contribu-
tion of the Josso-loop at low trigger-concentration becomes almost zero in 1:6 
diluted plasma. As a consequence one has to be very careful with the interpreta-
tion of results obtained in highly diluted plasma. This is especially the case in 
conditions where the Josso loop is involved as e.g. in phenotyping haemophili-
acs. 
Relevance for science and society 
Thrombin generation is undergoing a revival since it is recognized that it is a 
promising means of phenotyping the clotting system. Since about half of us all 
will die from thrombotic disease, the medical importance of a valid overall 
function-test of the haemostatic-thrombotic system is hard to overestimate. In 
the clinical laboratories there is a great need for such a test to be able to classify 
patients with increased risk on thrombosis or bleeding and to follow-up and op-
timize anti-thrombotic or anti-bleeding therapy. Measuring thrombin generation 
seems promising to fulfill this need. It looks as if it is a suitable candidate for 
being the electro-cardiogram of the haemostatic-thrombotic system. This com-
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parison, however, should not be carried beyond its limits. The thrombin forming 
capacity of the blood is a typical “on demand” function, whereas the ECG 
monitors a necessarily continuous function. Continuously ongoing thrombin 
generation does occur and may be increased in diseased states [8, 9]. It is de-
tected via by-products of the coagulation process in the circulation (TAT com-
plexes, prothrombin fragment 1-2, fibrin degradation products). Such products 
can be seen as “smoke-detectors” signaling an ongoing fire. The thrombin gen-
erating potential is to be seen as an indicator of the “fire-risk” i.e. the potential 
thrombin-forming capacity of the non triggered fluid organ blood. Another dif-
ference is that not the entire person has to be available to measure the throm-
bogram, a few ml of blood is sufficient, be it that the nearer the test is to physio-
logical conditions, the nearer the patient should be to the laboratory. Thrombin 
generation in PPP can be conveniently carried out on frozen and thawed sam-
ples that thus can be stored and shipped. Thrombin generation in PRP needs to 
be done within the hour after venapuncture.  
 
In this thesis we presented the CAT-method as a technique to measure thrombin 
generation. The CAT-method was originally designed as an automated routine-
method to perform quick semi-automated thrombin generation experiments in 
the research laboratory with essentially more possibilities than previous chro-
mogenic techniques or subsampling. However, the CAT-method is not only a 
technical innovation; it is also a new and better concept to probe the mecha-
nisms behind haemostasis and thrombosis since it investigates an essentially 
larger portion of the physiological mechanism than previous tests. Because of 
the use of fluorescence as a detection mechanism turbid media can be studied. 
Therefore the role of the platelets, the role of fibrin, the role of fibrin-platelet 
interaction and the role of diffusion-controlled mechanisms are reflected as 
well. In principle it is also possible to add white blood cells and to carry out the 
experiments in wells lined with cultured endothelium. So, until the advent of a 
whole blood method or measurement of thrombin in a wound in situ, the CAT-
method appears to be the most comprehensive way for measuring thrombin 
generation.  
 
A number of investigations were presented in this thesis that are required before 
clinical studies can be undertaken to establish the actual value of measuring 
thrombin generation as a clinical test. Studies on clinical applications are being 
undertaken in several laboratories around the world and in various fields e.g.  
A: Phenotyping of patients at high risk for thrombosis (hyper-coagulability) 
[10] or bleeding (hypo-coagulability) [11, 12]: high or low thrombin generation 
is a risk factor as such, independent of its cause.  
B: Control and optimize anti-thrombotic therapy: reduction of the thrombin 
generation capacity is probably the essence of anti-thrombotic therapy, so 
measuring thrombin generation is possibly a universal test for the control of 
anticoagulant therapy.  
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C: Control and optimize anti-bleeding therapy: reinforce thrombin generation 
capacity is probably the essence of anti-bleeding therapy, so the effects of both 
factor VIII-inhibitor bypassing therapy (FEIBA) and Novoseven can probably 
be monitored by measuring thrombin generation [7, 13]. 
D: Finding and testing of new anti-thrombotics: on basis of the available evi-
dence one may safely assume that a candidate drug that inhibits thrombin gen-
eration by about 50% will have an anti-thrombotic effect and not cause bleed-
ing. The CAT-method provides a mean to monitor the efficacy of new drugs in 
human experiments and clinical trials.  
 
In short: The data available at this moment – and increasing from day to day – 
are promising. Future research will certainly also delineate its limitations but it 
does not seem overdone to expect that thrombin generation will be a lasting and 
valuable addition to the possibilities of the clinical haemostatic laboratory. 
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Trombine generatie als een algemene functie-test in 
linische laboratoria 
Trombose is de tweede grootste oorzaak van dood en ziekte (beroerte, embolie) 
in de westerse wereld. Volgens Virchow zijn drie zaken van belang bij het ont-
staan van trombose nl. de vaatwand, de bloedstroming en de stolbaarheid van 
het bloed waarvan de laatste het moeilijkst te bepalen is. We mogen dan wel 
heel veel weten van het mechanisme achter de bloedstolling na tientallen jaren 
aan onderzoek, toch beschikken klinici nog steeds niet over een universele test 
om de stolbaarheid van bloed te bepalen. Er bestaan nochtans verschillende tes-
ten die gebaseerd zijn op stollingstijden maar elke test geeft informatie over een 
ander detail van het complexe web dat bloedstolling is. Geen enkele van deze 
testen kan dienen als een algemene functionerings-test zoals het elektro-
cardiogram voor hart-ritme stoornissen. De vraag kan dan ook gesteld worden 
of het meten van trombine generatie geen mogelijke kandidaat is voor zo een 
test en dit proefschrift wil bijdragen tot het antwoord op deze vraag.  
Er zijn drie belangrijke redenen waarom het meten van trombine generatie, wat 
toch al een halve eeuw gekend is, nooit eerder naar voren is geschoven om deze 
rol te vervullen. Ten eerste duwde de vooruitgang in de moderne biochemische 
en moleculair biologische technieken de techniek wat in de vergetelheid. Ten 
tweede was het meten van trombine generatie heel erg arbeids-intensief en dus 
niet geschikt om te implementeren in de erg geautomatiseerde klinische labora-
toria. Ten derde en misschien is dat wel de belangrijkste reden, paste deze tech-
niek niet in het heersende denkbeeld van ‘primaire hemostase’ en ‘secundaire 
hemostase’. 
De laatste jaren wordt het echter meer en meer erkend dat trombine niet alleen 
een belangrijke rol speelt in ‘secundaire hemostase’ en veneuze trombose maar 
ook in ‘primaire hemostase’ en arteriële trombose. En dit vanaf het allereerste 
begin als de plaatjes-reacties starten. Als gevolg hiervan wordt de trombine 
vormende capaciteit van bloed meer en meer aanvaard als een – of zelfs het – 
centrale element in de fysiologie van de hemostase. Verder brachten Béguin en 
Hemker deze techniek langzaam opnieuw in de belangstelling met een serie ar-
tikelen, gestart in 1986, waarin werd aangetoond hoe deze techniek kan worden 
gebruikt om de werking van heparines en andere anti-stollingsmiddelen te ver-
klaren en om de receptoren te bepalen die verantwoordelijk zijn voor de 
plaatjes-reacties. 
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Ondertussen zijn verschillende laboratoria op zoek naar manieren om de trom-
bine generatie in het orgaan bloed te meten. De ideale manier om het functione-
ren van het trombine generatie-systeem in een patient op te volgen zou  
er in bestaan de trombine concentratie te meten in functie van tijd en ruimte in 
het plaatjes-aggregaat in de wonde. Tot op heden is dit technisch niet mogelijk 
maar een goede benadering is wel beschikbaar onder de vorm van de CAT-
methode ofwel ‘Calibrated Automated Thrombography’. Deze methode maakt 
het mogelijk trombine generatie op te volgen in zowel plaatjes-arm als plaatjes-
rijk plasma en dit in de aanwezigheid van elementen van de vaatwand zoals tis-
sue-factor en trombomoduline. Deze techniek is het onderwerp van dit proef-
schrift. 
Calibrated Automated Thrombography (CAT) 
De CAT-methode, voorgesteld in hoofdstuk II, maakt het mogelijk om trombi-
ne generatie te meten in 48 monsters tegelijk met een aanvaardbare experimen-
tele fout van minder dan 5%. Bijgevolg is het een beloftevolle techniek voor 
klinische routine-laboratoria. De ziekte van Von Willebrand kan opgespoord 
worden en het effect van plaatjes-remmers zoals aspirine en clopidogrel kan 
worden gevolgd. Het is ook mogelijk om nuttige informatie te verkrijgen uit 
metingen in PPP zoals bvb. het opsporen van tekorten aan stollingsfactoren (be-
halve FXIII) of het vaststellen van het effect van anti-stollingsmiddelen (anti-
vitamine K, heparines, directe trombine- of FXa-remmers). Dit is des te belang-
rijker aangezien er geen enkele stollingstijd-test bestaat die gelijkaardig reageert 
op al deze anti-stollingsmiddelen. Ook de functie van het proteine C-systeem 
kan worden getest zowel in PPP als in PRP. Als TM wordt toegevoegd kan het 
hele systeem worden getest maar aangezien TM trombine nodig heeft om actief 
te zijn, is het effect van TM alleen maar te zien in de tweede helft van de trom-
bine generatie-curve (piek-hoogte, ETP) en niet in de lag-time. Vandaar ook dat 
het effect niet te zien is in stollingstijd-testen. 
Bijzonder interessant is het ‘lupus anticoagulant’. Dit antilichaam veroorzaakt 
een toename van de stollingstijd en wordt dus beschouwd als een anti-
stollingsmiddel maar het vertoont ook een stollingsbevorderende werking. Dit 
wordt de ‘LAC-paradox’ genoemd. De LAC-paradox verdwijnt als men zich 
baseert op trombine generatie waarbij men kan zien dat de lag-time of stollings-
tijd inderdaad toeneemt maar ook dat de trombine generatie niet geremd wordt 
als het proteine C-systeem wordt geactiveerd. Dit onderstreept dat er geen strikt 
verband bestaat tussen stollingstijd en de hoeveelheid trombine die gevormd 
wordt (95% van de trombine wordt gevormd na de stolling). Bijgevolg geeft het 
meten van een trombogram veel meer informatie dan een stollingstijd. 
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Berekening van de TG-curve vertrekkende van de ruwe 
data 
Zoals uitgelegd in hoofdstuk III zijn er twee fit-procedures nodig om de ruwe 
data om te zetten in een TG-curve. De eerste fit-procedure is nodig om de ruwe 
data om te zetten in ‘ideale data’ d.w.z. data die we zouden verkrijgen indien er 
geen substraat-uitputting of inner-filter effect zou aanwezig zijn. De tweede fit-
procedure wordt uitgevoerd op de ideale voortgangs-curve (‘progress-curve’) en 
is nodig om de vrije trombine te berekenen op basis van de totale amidolytische 
activiteit. De amidolytische activiteit is immers het resultaat van zowel vrij 
trombine als α2M-T. Een bijkomend voordeel van het fitten van de voortgangs-
curve is dat men een grote spreiding van de meetpunten vermijdt die men zou 
krijgen indien men met de eerste afgeleide van de ruwe data zou werken. 
Berekening van de protrombinase-curve 
Trombine is het centrale enzym in het complexe web van de bloedstolling en 
FII-ase activiteit is de laatste stap in de vorming van trombine. De FII-ase acti-
viteit is afhankelijk  van de componenten van het FII-ase complex: FXa, FVa en 
de phospholipiden die op hun beurt weer afhankelijk zijn van het functioneren 
van de andere stollings-factoren en regulatie-mechanismen en de plaatjes. Bij-
gevolg geeft de FII-ase activiteit een beeld van het hele stollings-systeem zon-
der de trombine afbraak. In hoofdstuk IV wordt uitgelegd hoe de FII-ase activi-
teit kan worden berekend vertrekkende van de TG-curve, als de beginconcentra-
tie van AT bekend is. Het valt te verwachten – maar dat moet nog bewezen 
worden in de praktijk – dat de FII-ase curve een veel beter beeld geeft van de 
fysiologie van trombine vormende processen dan de TG-curve zelf. 
De noodzakelijkheid van continue individuele calibratie 
Het is van het allergrootste belang dat de experimentele fout beperkt wordt tot 
het minimum om afwijkingen in trombine generatie te kunnen detecteren. In de 
CAT-methode wordt de splitsing van het fluorescerende substraat opgevolgd en 
vergeleken met die van een bekende constante hoeveelheid trombine in een pa-
rallel niet-stollend monster. Op die manier wordt de calibratie-factor (CF) gedu-
rende de hele meting bepaald onder dezelfde condities als dewelke heersen in de 
TG-experimenten. Dit is noodzakelijk om klinisch aanvaardbare intra-
individuele variatie-coefficiënten te bekomen zoals wordt aangetoond in hoofd-
stuk V. We vergeleken de intra-individuele experimentele fout verkregen met 
twee commerciële methodes. Enerzijds de CAT-methode die continue individu-
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ele calibratie gebruikt en anderzijds de Technoclone-methode die een vaste CF 
gebruikt die verkregen is door de beginsnelheid te meten van een bekende 
trombine concentratie in buffer. Zoals men kan zien zorgt het gebruik van een 
vaste CF bepaald in buffer voor een ernstige onderschatting omdat de opbrengst 
van het fluorescerende signaal erg afhankelijk is van de kleur van het plasma. 
Deze onderschatting is niet constant maar neemt toe tijdens de meting van de 
TG-curve omwille van substraat-uitputting en inner-filter effect. Dit zorgt voor 
grote variatie-coefficienten die teruggebracht kunnen worden tot een klinisch 
aanvaardbaar niveau door gebruik te maken van continue individuele calibratie. 
De invloed van het substraat op de TG 
Een systeem meten betekent altijd dat het systeem verstoord wordt. Tijdens het 
meten van trombine generatie wordt er een substraat toegevoegd dat aan trom-
bine bindt en bijgevolg trombine ook remt. Aangezien trombine een belangrijke 
rol speelt in zijn eigen vorming via allerlei feedback-mechanismen valt theore-
tisch te verwachten dat deze remming van trombine ook de trombine vorming 
beïnvloedt. Hoe groot dit effect wel is, werd reeds onderzocht toen we de CAT-
methode voorstelden (hoofdstuk II). In dit artikel toonden we reeds aan dat het 
substraat onder onze omstandigheden geen significante invloed heeft op de om-
zetting van protrombine en dat de trombine afbraak op een voorspelbare manier 
wordt vertraagd omdat het toegevoegde substraat de afbraak van trombine door 
remmers aanwezig in het plasma vertraagt. Omdat dit onderwerp klinisch uiterst 
relevant is en omdat Butenas S. en K.G. Mann hun bezorgdheid te kennen ga-
ven over dit onderwerp werd dit opnieuw onderzocht en deze exra bewijzen 
worden getoond in hoofdstuk VI. Uit deze experimenten konden we besluiten 
dat niet alleen de hoeveelheid protrombine die wordt omgezet maar ook de tijd 
waarin dit gebeurt minimaal worden beïnvloed door het aanwezige substraat 
(416 µM ZGGR-AMC). De inactivering van trombine door de remmers aanwe-
zig in het plasma wordt op een perfect voorspelbare manier vertraagd. De feed-
back mechanismen die afhankelijk zijn van trombine worden weliswaar beïn-
vloed maar dit zorgt niet in een toename van de lag-time. Het zorgt wel voor 
een afname van de remming veroorzaakt door extern toegevoegde TM met on-
geveer 10%. Het is echter erg belangrijk om te benadrukken dat deze conclusies 
enkel betrekking hebben op het bestudeerde substraat (ZGGR-AMC) bij de ge-
bruikte concentratie (416 µM). 
Omdat we de discussie wouden beperken tot een systeem in oplossing, zoals 
Butenas en Mann ook doen, hebben we in deze experimenten gebruik gemaakt 
van gedefibrineerd plasma. Het effect van fibrine (fibrinogeen) wordt verder 
nog besproken in hoofdstuk VII. 
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Een verschuiving van chemisch gecontroleerde naar 
diffusie gecontroleerde trombine generatie 
Met de komst van de CAT-methode werd het mogelijk om trombine generatie te 
meten zowel mét als zonder fibrinogeen. We hebben dit gedaan in plaatjes arm 
plasma en dit bij verschillende temperaturen zoals te zien is in hoofdstuk VII. 
Uit deze experimenten konden we besluiten dat er een verschuiving optreedt 
van chemisch gecontroleerde trombine generatie naar diffusie gecontroleerde 
trombine generatie gedurende de bloedstolling. Tot op heden werd voor waar 
aangenomen dat trombine generatie werd  bepaald door de beginconcentraties 
en reactie-constanten van de betrokken reactiecomponenten. Nochtans, van zo-
dra er een fibrine-netwerk wordt gevormd, hechten phospholipiden-plaatjes 
en/of phospholipiden-deeltjes zich aan dit netwerk en de reactiecomponenten 
kunnen alleen naar en van zulke geïmmobiliseerde netwerken gevoerd worden 
in een stilstaande vloeistof via diffusie door de vloeibare fase. Dit transport via 
diffusie wordt van belang op het moment dat de stolling begint of met andere 
woorden diffusie begint de snelheid van trombine vorming mee te bepalen van-
af het moment dat stolling plaatsvindt. In omstandigheden zonder fibrinogeen of 
in wiskundige simulaties wordt trombine generatie enkel en alleen bepaald door 
de beginsnelheden en reactie-constanten van de reactiecomponenten. Diffusie 
wordt niet in rekening gebracht. In een model waarin prothrombinase geadso-
beerd is aan een macroscopisch oppervlak is diffusie wél snelheidsbepalend 
maar dan onder alle omstandigheden tenzij de reactiecomponenten in extreme 
concentraties aanwezig zijn. Geen van beide benaderingen is juist omdat er een 
verschuiving optreedt van chemische controle naar controle door diffusie rond 
het ogenblik waarop het bloed stolt. Bijgevolg is de beste benadering om de 
trombine generatie in het menselijk lichaam te bepalen, het direct te meten in 
een monster van het geïsoleerde  orgaan d.w.z. in stollend PRP met toevoeging 
van de relevante reactie-componenten van de bloedwand (TF, TM). 
Het effect van verdunning van plasma op de trombine 
generatie 
Een systeem meten betekent niet alleen dat het systeem verstoord wordt (hoofd-
stuk 4), het wordt ook onvermijdelijk verdund aangezien er substraat, calcium, 
een reactiestarter en/of phospholipiden moeten worden aan toegevoegd. In 
hoofdstuk VIII hebben we met behulp van de CAT-methode onderzocht wat de 
invloed is van verdunning op de trombine generatie in PPP. We stelden vast dat 
de ETP eerst toeneemt tot aan de plasma-verdunning 1:6 en dan pas afneemt. 
Dit wordt veroorzaakt door de verdunning van ‘tissue factor pathway inhibitor’ 
(TFPI) en proteine S. Verdunning van deze remmers beïnvloedt de trombine 
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generatie meer dan de verdunning van stollings-bevorderende mechanismen. 
Verdunning onderdrukt proteine S afhankelijke remming en dit veroorzaakt een 
tweede golf van FII-ase-activiteit wat op zijn beurt resulteert in een verlengde 
afbraak-fase. Verdunning van TFPI ontketent het directe extrinsieke reactieme-
chanisme. Beide fenomenen monden uiteindelijk uit in een hogere of verlengde 
trombine-activiteit. Tegelijkertijd worden het intrinsieke reactiemechanisme en 
de ‘Josso-Loop’ beduidend geremd door verdunning. Het intrinsieke reactieme-
chanisme verliest alle activiteit bij verdunningen > 24x terwijl de bijdrage van 
de Josso-Loop bijna volledig verdwijnt als het plasma 1:6 verdund is. Men moet 
bijgevolg erg voorzichtig zijn met het interpreteren van resultaten die verkregen 
zijn in sterk verdund plasma. Dit is vooral belangrijk in omstandigheden waarbij 
de Josso-Loop betrokken is zoals bijvoorbeeld bij het classificeren van hemofi-
lie-patienten. 
Belang voor wetenschap en maatschappij 
Trombine generatie is aan een heropleving bezig sinds algemeen erkend wordt 
dat het een beloftevolle techniek is om het stollings-systeem te typeren. Het 
medisch belang van een algemene functionerings-test van het stollings-systeem 
kan nauwelijks overschat worden aangezien ongeveer de helft van ons zal ster-
ven aan stollings-ziekten. In klinische laboratoria is er een grote behoefte voor 
zulk een test die het mogelijk maakt om patiënten te classificeren met een ver-
hoogd risico op trombose of bloeding en om anti-trombose of anti-bloedings 
therapie op te volgen en te optimaliseren. Het meten van trombine generatie 
lijkt erg beloftevol om aan deze behoefte te voldoen. Het lijkt er op dat het een 
geschikte kandidaat is om de rol van ‘elektro-cardiogram van het stollings-
systeem’ op zich te nemen. Deze vergelijking mag men echter niet te letterlijk 
nemen. De trombine-vormings-capaciteit van bloed is een typische ‘on demand’ 
functie terwijl het ECG een noodzakelijkerwijs continue functie opvolgt. Conti-
nue trombine generatie op een laag niveau bestaat in vivo en kan daarnaast in 
verhoogde mate voorkomen in bepaalde ziekten. Het wordt opgespoord via bij-
producten van de bloedstolling in de bloedsomloop (TAT-complexen, protrom-
bine-fragment 1-2, producten van fibrine-afbraak). Dergelijke producten kunnen 
beschouwd worden als rook-melders die een brandend vuur signaleren. De ETP 
of het potentieel om trombine te genereren moet worden bekeken als een indica-
tor van het risico op vuur oftewel de potentiële trombine-vormende capaciteit 
van het niet-stollende vloeibare orgaan bloed. Nog een verschil is dat niet de 
hele persoon aanwezig hoeft te zijn om trombine generatie te meten, een paar 
ml bloed is voldoende. Het is wel zo dat hoe meer men de fysiologische om-
standigheden wil nabootsen, hoe meer de patient beschikbaar moet zijn voor het 
laboratorium. Trombine generatie in PPP kan perfect gemeten worden in bevro-
ren en vervolgens ontdooide plasma-monsters die dus gemakkelijk kunnen be-
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waard en verzonden worden. Trombine generatie in PRP moet binnen het uur na 
de bloed-afname worden gemeten.  
 
De CAT-methode, zoals we ze in dit proefschrift hebben voorgesteld, was oor-
spronkelijk ontworpen als een geautomatiseerde routine-methode om snel semi-
geautomatiseerde trombine generatie experimenten uit te kunnen voeren in on-
derzoeks-laboratoria met meer mogelijkheden dan de eerder ontwikkelde chro-
mogene techniek of de subsampling-methode. De CAT-methode is echter niet 
alleen een technische innovatie; het is ook een nieuw en beter concept om de 
mechanismen achter hemostase en trombose te onderzoeken omdat het een veel 
groter gedeelte van het fysiologisch mechanisme onderzoekt dan de voorgaande 
testen. Ook troebele media kunnen bestudeerd worden omdat een fluorescerend 
substraat wordt gebruikt als detectie-middel. Als gevolg hiervan worden ook de 
bijdrage van de plaatjes, fibrine, fibrine-plaatjes interacties, en diffusie gecon-
troleerde mechanismen  mee in rekening gebracht. Het is in principe ook moge-
lijk om witte bloedcellen toe te voegen en om experimenten uit te voeren in 
wells die bedekt zijn met endothelium-weefsel. Zolang het niet mogelijk is om 
te meten in volbloed of om trombine te meten in de wond zelf lijkt de CAT-
methode bijgevolg de techniek die het dichtst aanleunt bij de fysiologische om-
standigheden. 
 
In dit proefschrift werden reeds een heleboel onderzoeken gepresenteerd die 
nodig zijn vooraleer klinische studies kunnen worden op touw gezet om te bepa-
len wat de echte waarde is van trombine generatie metingen als klinische test. In 
verschillende laboratoria over heel de wereld en in verschillende onderzoeks-
domeinen worden studies over klinische toepassingen uitgevoerd zoals bvb. 
A. Het classificeren van patiënten met een verhoogd risico op trombose (hyper-
stolbaarheid) of bloeding (hypo-stolbaarheid): hoge of lage trombine generatie 
is een risico-factor op zich, ongeacht de oorzaak. 
B. Het opvolgen en optimaliseren van anti-trombose therapie: het verlagen van 
de trombine generatie capaciteit is waarschijnlijk de essentie van anti-trombose 
therapie, dus het meten van de trombine generatie is mogelijk een universele 
test om anti-stollings therapie op te volgen. 
C. Het opvolgen en optimaliseren van anti-bloedings therapie: het terug verho-
gen van de trombine generatie capaciteit is waarschijnlijk de essentie van anti-
bloedings therapie, dus de effecten van zowel ‘factor VIII-inhibitor bypassing 
therapy (FEIBA)’ en Novoseven kunnen waarschijnlijk worden opgevolgd door 
de trombine generatie te meten. 
D. Het vinden en testen van nieuwe anti-stollingsmiddelen: op basis van de be-
schikbare gegevens kan men gerust aannemen dat een kandidaat medicijn dat de 
trombine generatie met ongeveer 50% remt een anti-stollend effect zal hebben 
en dat het geen bloeding zal veroorzaken. Met de CAT-methode hebben we dus 
een goed middel voor handen om het effect van nieuwe medicijnen te onder-
zoeken in experimenten met menselijk plasma en in klinische onderzoeken. 
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Samengevat, de beschikbare gegevens tot nu toe – die trouwens nog toenemen 
van dag tot dag – zijn veelbelovend. Toekomstig onderzoek zal ongetwijfeld 
ook de beperkingen van deze methode blootleggen maar het lijkt niet overdre-
ven om te verwachten dat het meten van trombine generatie een blijvende en 
waardevolle toevoeging zal blijken aan het instrumentarium van ieder klinisch 
laboratorium. 
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Dankwoord 
Het schrijven van dit dankwoord heeft heel wat voeten in de aarde ge-
had. Ik vind het immers niet gemakkelijk om mijn oprechte gevoelens van 
dankbaarheid te vertalen naar een geschreven tekst. Ik besef maar al te goed dat 
ik heel veel mensen dank verschuldigd ben. Een proefschrift schrijf je niet al-
leen, veel mensen hebben hier mee aan bijgedragen, sommigen een klein steen-
tje, anderen een heel rotsblok. Het behalen van deze doctoraatstitel sluit een 
periode af van 5 jaar en is dan ook een mijlpaal in mijn leven. Er is heel wat 
gebeurd in die 5 jaar: getrouwd, een huis gebouwd en ons gezin uitgebreid met 
een zoon en een dochter. Dit alles kon ik alleen maar combineren met het 
schrijven van een proefschrift dankzij de steun van heel veel mensen in mijn 
omgeving. Daarom wil ik niet alleen degenen bedanken die rechtstreeks hebben 
bijgedragen aan mijn proefschrift maar ook zij die op de een of andere manier 
een steun voor mij zijn geweest tijdens de voorbije 5 jaar.  
Op de eerste plaats ben ik heel veel dank verschuldigd aan mijn eerste 
promotor professor Hemker. Het was en is een hele eer om te mogen samen-
werken met iemand met zo een staat van dienst. Coen - voor deze ene keer mag 
ik je wel tutoyeren - niet alleen op wetenschappelijk vlak heb ik heel wat van je 
opgestoken maar ook van je menselijk inzicht. Na al die jaren aan vergaderings- 
en onderhandelingstafels heb je wel ‘enige’ ervaring opgebouwd en ik vond het 
heel fascinerend om zien hoe je met mensen omgaat. Ook je werkijver werkte 
heel aanstekelijk en ik kon altijd bij je terecht als ik vragen had, zowel op we-
tenchappelijk vlak als op familiaal gebied (bvb. over bepaalde kinderziekten). 
Maar vooral ben ik je heel erg dankbaar dat je me de kans hebt gegeven om te 
promoveren temeer daar het er naar uit ziet dat ik de laatste analist ben die deze 
kans nog zal krijgen.  
Ook jou, beste Hugo, ben ik dankbaar dat je mijn tweede promotor wou 
zijn. We zien elkaar dan wel niet zo vaak maar ik vind het prettig samenwerken 
met jou. Minzaam, vriendelijk en altijd een luisterend oor.  
Rob, ik vond het heel fijn dat je mijn co-promotor wilde zijn. Je bent 
dan misschien niet de grootste prater maar wat je zegt is altijd ‘to the point’. Jij 
bent ongetwijfeld degene waarvan ik het meeste heb opgestoken in het labo en 
ik ben je ontzettend dankbaar dat je me de tijd en ruimte gaf om te werken aan 
mijn proefschrift terwijl jij voor de eiwitzuivering zorgde. Spijtig genoeg is het 
gebruik om een pilsje te drinken op het einde van de dag (’s vrijdags) een beetje 
in verval geraakt. Bij deze beloof ik dan ook dit terug in ere te herstellen nu 
mijn promotie achter de rug is. Als tegenprestatie moet je dan wel nog minstens 
tot je zeventigste blijven doorgaan zoals de traditie binnen Synapse vereist. 
Raed, hartelijk bedankt voor alle hulp bij het realiseren van dit proef-
schrift. Ik heb veel opgestoken van jouw inzicht en de manier waarop je weten-
schappelijke problemen aanpakt. Ik kon altijd bij je terecht met vragen, zowel 
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op wetenschappelijk als op menselijk vlak. Bovendien waardeer ik het erg dat je 
altijd je best doet om zoveel mogelijk tegemoet te komen aan mijn wensen wat 
betreft het nemen van vakantie, thuis-werken e.d. 
Sebastiaan, bedankt dat je mijn para-nimf wou zijn. Bij jou kon ik altijd 
terecht als die on-dingen, die men computers noemt, het weer eens lieten afwe-
ten. Verder kon ik met jou altijd fijn ‘kletsen’ over de actualiteit en andere za-
ken die niets met het werk te maken hebben. 
 Also you, Rafael, thank you very much to read my thesis so carefully 
and to (hopefully) eliminate the last mistakes. But especially I want to thank 
you for your always shining smile, your humour and your sympathy when 
things are going not so well. It makes of you a great colleague and I will miss 
you when you are going back to Venezuela. 
Suzette, jou mag ik natuurlijk niet vergeten. Jij bent het tenslotte die me 
ertoe heeft aangezet om aan deze promotie te beginnen. We hebben dan wel 
maar een paar jaar samen gewerkt, ik was toch onder de indruk van je werkij-
ver, kennis en nauwgezetheid. Bij jou kon ik ook altijd terecht als ik met ‘mui-
zenissen’ zat. Merci beaucoup !  
Riet, Martin, Rob (vd Zande), Trees, bedankt voor alle hulp bij de ad-
ministratieve taken die moesten vervuld worden. Als er vragen waren, kon ik 
altijd bij jullie terecht. Verder was het ook altijd fijn ‘kletsen’ met jullie. 
 Verder gaat mijn dank ook uit naar de leden van de beoordelings-
commissie bestaande uit Prof. dr. P.W. De Leeuw, Prof. dr. M. Hoylaerts, Dr. 
J.C.M. Meijers, Prof. dr. J. Rosing en Prof. dr. J. Waltenberger voor het kritisch 
nalezen van mijn proefschrift. 
Jan van Luxemborg zou ik graag postuum willen bedanken. Hij is de-
gene die me begeleidde tijdens mijn studie aan de Hogeschool Heerlen en ik 
heb hem leren kennen als een erg vriendelijke, behulpzame en joviale kerel. 
Spijtig dat je dit niet meer mag meemaken. 
 
Jos, jou wil ik hier toch ook een speciaal plaatsje geven. Toen we ons 
huis aan het bouwen waren was de ‘deal’ immers dat jij ons als ‘Handige Harry’ 
zou helpen en als tegenprestatie moest ik ervoor zorgen dat ik eerst met succes 
de opleiding tot ingenieur afrondde en vervolgens ook de promotie tot ‘doctor’. 
Ik ben die deal nooit vergeten en die deal plaatste mij soms ook voor mijn ver-
antwoordelijkheid op momenten dat ik het even niet meer zag zitten. Ook jou, 
Lisa, wil ik hierbij niet vergeten. Het jaar dat we aan het bouwen waren en Jos 
al zijn vrije tijd in de bouw stak waardoor er geen plaats meer was voor voetbal, 
was ook voor jou erg zwaar. En ook nu nog kunnen we steeds op jullie rekenen. 
Pa en Ma, heel erg welgemeend bedankt voor alles !  
Joeri en Lore, vake en moeke, pépé zaliger en mémé, ook jullie wil ik 
speciaal bedanken voor alle hulp tijdens en na de bouw van ons huis en vooral 
om er gewoon te zijn voor ons. Wij kunnen niet alleen altijd op jullie rekenen, 
jullie zijn vooral heel fijne mensen met het hart op de juiste plaats. Bedankt ! 
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Ilse, Geert en Kristel, ook jullie erg bedankt voor alle hulp en steun. We 
zien elkaar dan wel niet zo vaak meer sinds we ieder onze eigen weg zijn ge-
gaan maar ik ben ervan overtuigd dat we altijd op elkaar kunnen rekenen als het 
nodig is. Bedankt ! 
Ten slotte mijn mama en papa, aan wie ik zoveel verschuldigd ben en 
die me altijd met raad en daad hebben bijgestaan. Jullie zijn me altijd blijven 
steunen, van kleine dreumes op de kleuterschool tot het behalen van deze docto-
raatstitel. Nu ik zelf vader ben besef ik pas ten volle wat jullie allemaal voor mij 
hebben gedaan. Bedankt ook voor alle hulp tijdens de bouw van ons huis en ook 
nu nog staan jullie altijd klaar voor ons. Weet dat ik jullie graag zie en dat ik 
jullie heel erg dankbaar ben. Mama en papa, heel erg bedankt voor alles ! 
En helemaal op het eind wil ik mijn vrouw en kinderen bedanken. Mijn 
vrouw, die er verschillende avonden alleen voor stond met Lander en Merel 
omdat ik aan het werk was op de computer. Sabrina, bedankt voor je onvoor-
waardelijke steun. Jij was er altijd om me weer op te peppen tijdens de moeilij-
ke momenten. Een huis bouwen, bijstuderen, promoveren en ondertussen 2 kin-
deren ter wereld brengen en opvoeden. Samen lukt het ons wonderwel. Sabke, 
heel erg bedankt voor alle steun, liefde en begrip ! Mijn kinderen, Lander en 
Merel, omdat jullie zulke zonnetjes zijn in huis. Ook al beseffen jullie het nog 
niet, toch hebben jullie ook je steentje bijgedragen gewoon door er te zijn. Sa-
men spelen, ‘in de tuin werken’, de kippen en konijnen eten geven, zwemmen, 
fietsen of ‘naar het bos gaan kijken’... ik geniet er met volle teugen van en het 
zorgde voor de noodzakelijke ontspanning. 
Tot slot bedankt aan al wie me ooit heeft geholpen of me mee heeft ge-
vormd tot wie ik nu ben en die niet apart vermeld staat in dit dankwoord. 
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